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Triglycerides (TG) and cholesterol are the most common lipids in our diet and essential 
for the human body. TG are the main source of energy, and can be stored in white 
adipose tissue (WAT), used for ATP production in skeletal muscle and heart, and used 
for generating heat in brown adipose tissue (BAT). Cholesterol is essential, as a crucial 
component of cellular membranes and as precursor for steroid hormone synthesis. 
Since lipids are hydrophobic, they are transported in the blood as constituents of 
soluble particles called lipoproteins. These lipoproteins are composed of a lipid-rich 
core containing TG and esterified cholesterol, surrounded by a amphiphilic monolayer 
of phospholipids (PL), unesterified free cholesterol and one or more apolipoproteins. 
The latter facilitate formation of the lipoproteins and modulate the activity of proteins 
(i.e. enzymes and transfer factors) involved in lipoprotein remodeling in the circulation. 
Lipoproteins are subdivided into different classes based on their density, namely 
(from lowest to highest density) chylomicrons, very low density lipoproteins (VLDL), 
intermediate density lipoprotein (IDL), low density lipoprotein (LDL) and high density 
lipoprotein (HDL). Both chylomicrons and VLDL are consist mainly of TG and are 
therefore called TG-rich lipoproteins. The metabolism of TG-rich lipoproteins will 




























In the intestine, dietary TG are lipolyzed by pancreatic lipases into 2-monoacylglycerol 
and fatty acids (FA), both of which are subsequently taken up by the intestinal cells 
(enterocytes) where the lipolysis products are re-synthesized into TG.1 Enterocytes 
synthesize apoB that is lipidated in the endoplasmatisch reticulum (ER) by the 
microsomal TG transfer protein (MTP), resulting in the formation of a small 
apoB containing particle. After fusion with larger protein-free lipid droplets, a 
prechylomicron is formed which is transported towards the Golgi and secreted via 
exocytosis.2 Chylomicrons are secreted into the lymph from which they are transported 
via the blood for storage (adipose tissue), or energy supply (skeletal muscle and heart)3 
or heat generation (brown adipose tissue).4
When no food is entering the intestine (during fasting), the liver is the organ that 
ensures a supply of TG by secretion of TG-rich VLDL particles. Assembly of VLDL in 
hepatocytes, the most predominant cell type in the liver, involves a similar pathway as 
chylomicron synthesis including MTP-mediated transfer of TG to apoB and fusion of 
the generated particle with other lipid droplets, resulting in the formation of mature 
VLDL that is released into the circulation.5, 6 The assembly of VLDL is highly dependent 
on the availability of TG within the hepatocyte. The main direct sources for VLDL-TG 
are 1) plasma-derived FA that are released by the adipose tissue mainly in the fasted 
state and are esterified in the hepatocyte into TG, 2) cytosolic TG that previously 
accumulated in the hepatocyte and 3) de novo synthesized FA that is used for de novo 
synthesis of TG within hepatocytes. FA synthase (FAS) and stearyl-CoA desaturase-1 
(SCD-1) represent the most important genes involved in the de novo synthesis of FA 
and TG, respectively.
In the circulation, TG that are derived from chylomicrons and VLDL are lipolyzed 
by capillary-bound lipoprotein lipase (LPL) into glycerol and FA,, the latter being 
subsequently taken up by underlying tissues including WAT, skeletal muscle, heart, and 
BAT. In the postprandial state (after a meal), LPL expression is highest in WAT, thereby 
directing most of the chylomicron-derived TG into adipose tissue for storage.7, 8 In 
the fasted state, LPL expression relatively increases in skeletal muscle as compared to 
WAT thereby ensuring VLDL-derived FA as energy source.9 LPL activity in heart is less 
regulated by the feeding status10 and regulation of LPL in BAT is currently unknown. 
Through hydrolysis of TG, and concomitant uptake of FA by the peripheral tissues, 
the TG-rich lipoproteins reduce in size and become residual CM remnants and VLDL 
remnants (i.e. IDL and LDL). These are taken up by the liver through specific receptors 
such as the LDL receptor and LDLr-related protein (LRP). 11 
obesiTy and associaTed meTabolic disTUrbances 
When energy intake exceeds energy expenditure (i.e. positive energy balance), TG 
is stored in the body as WAT. A prolonged positive energy balance will thus lead to 
overweight and obesity. In fact, world-wide obesity is reaching epidemic proportions 
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due to a sedentary lifestyle combined with a caloric-rich diet. The adipose tissue has 
the largest capacity to store energy in the form of TG, by increasing both adipocyte 
hypertrophy (increase in cell size) as well as hyperplasia (increase in cell number). 
However, since expandability of adipose tissue is limited, excess TG is redirected 
towards non-adipose tissues such as skeletal muscle and liver, both of which are able 
to store TG to a more limited extent.12 In fact, obesity is frequently accompanied by 
excess fat accumulation (steatosis) in liver13 and muscle,14 which has been linked 
to the development of metabolic disturbances such as insulin resistance, ultimately 
resulting in the onset of type 2 diabetes.15-17 In addition to insulin resistance, the 
excess TG availability leads to an increased circulation of TG in the plasma which 
is called hypertriglyceridemia and an important risk factor for the development of 
atherosclerosis and, ultimaltely, cardiovascular diseases (CVD). 
Obviously, obesity and associated metabolic disorders including insulin resistance 
and atherosclerosis could at least partly be prevented by reducing food intake and 
increasing regular physical activity levels. Unfortunately, these lifestyle changes have 
proven to be very difficult to accomplish which urges the development of therapeutic 
strategies combating obesity and its associated disorders.
meTabolic inflammaTion
Inflammatory pathways have evolved as important mediators that may link obesity to 
metabolic disturbances. Obesity is accompanied by low-grade systemic inflammation, 
which is characterized by increased presence of cytokines and other markers of 
inflammation in the circulation.18, 19 
Both white adipose tissue and the liver are largely involved in the onset and 
development of metabolic inflammation. The expansion of the adipose tissue during 
development of obesity coincides with the influx of macrophages and secretion of pro-
inflammatory cytokines in adipose tissue of obese mice and humans.20, 21 The initial 
trigger for macrophage infiltration in adipose tissue is suggested to be the secretion of 
pro-inflammatory cytokines by adipocytes upon expansion22 that attract and activate 
infiltrating macrophages, as adipocyte size is correlated to the amount of macrophage 
infiltration in adipose tissue.21 In addition to adipose tissue, HFD and obesity also 
induce inflammation in liver, as reflected by increased markers of hepatic inflammation 
(SAA and CRP) in obese subjects and increased hepatic NF-κB activity in mice fed a 
HFD.23, 24
The obesity-associated low-grade inflammation appears to be causally involved in 
the onset and development of metabolic disturbances such as insulin resistance and 
atherosclerosis. Pro-inflammatory cytokines such as IL-1β and TNFα that are secreted 
by the liver and adipose tissue can directly induce insulin resistance by interfering with 
insulin signaling pathways25, 26 and induce formation of atherosclerotic plaques.27, 28 
The transcription and activation of these pro-inflammatory cytokines is regulated 




caspase-1. NF-κB is a transcription factor that regulates expression of several pro-
inflammatory cytokines including IL-1β and TNFα.29 The NLRP3 inflammasome 
caspase-1 is a protein-complex that is crucial for activation of the pro-inflammatory 
IL-1β. The exact role of NF-κB and the NLRP3 inflammasome in metabolic inflammation 
in adipose tissue and liver remains to be determined, as well as its contribution to 
metabolic disturbances. This may reveal new potential therapeutic targets in the 
treatment of obesity-associated insulin resistance and atherosclerosis. 
oUTline of The Thesis
Albeit that metabolic inflammation plays a key role in the development of insulin 
resistance and atherosclerosis, no current therapies exist that target inflammation in 
the treatment of these metabolic diseases. Better understanding of the interaction 
between inflammatory pathways and metabolic disturbances will help to develop new 
strategies to treat patients at risk for type 2 diabetes and CVD. The research described in 
this thesis was performed to gain more insight into the effect of various inflammatory 
pathways on the development of hyperlipidemia, insulin resistance and atherosclerosis. 
The first part of this thesis focuses on the relation between inflammation and 
hyperlipidemia, which are both risk factors for the development of atherosclerosis. In 
chapter 2, current knowledge on the role of lipids and inflammatory processes in the 
development of atherosclerosis is described, as well as the interaction between lipid 
metabolism and inflammation that may aggravate the development of atherosclerosis. 
The effects of lipid-lowering drugs on inflammatory processes, as well as the effects of 
the anti-inflammatory drugs on lipid metabolism are discussed. In chapter 3, the role 
of the anti-inflammatory drug aspirin on lipid metabolism was evaluated. Specifically, 
the mechanism by which aspirin reduces plasma lipid levels was investigated in the 
hypertriglyceridemic APOC1 mouse model, by studying the effects of aspirin on 
VLDL-triglyceride metabolism. 
The liver is an organ that plays an important role in triglyceride metabolism as well as 
inflammation. The aim of the study described in chapter 4 was to specifically determine 
the effect of hepatic NF-κB activity on the development of hypertriglyceridemia, by 
evaluating whether transgenic activation of IKK-β only in the hepatocytes of E3L mice 
affected VLDL-triglyceride metabolism directly. Whether the hepatic NF-κB activity 
affects the development of atherosclerosis was subsequently explored in chapter 5. 
Toll-like receptor 4 (TLR4) is a receptor of the immune system that activates NF-κB 
signaling. Endotoxin, a component of Gram-negative bacteria and a well known 
ligand for TLR4, can induce hyperlipidemia during infection by increasing hepatic 
VLDL-TG production. Upon high-fat feeding, saturated FA are believed to activate 
TLR4/ NF-κB signaling in the liver, suggesting that TLR4 might be an important link 
between obesity-induced hepatic inflammation and hyperlipidemia. Therfore, the aim 
of chapter 6 was to investigated whether absence of TLR4 could reduce VLDL-TG 
production in high-fat fed mice.
14
The second part of this thesis describes studies exploring the role of the 
inflammasome-mediated caspase-1 activity in obesity and insulin resistance. The 
inflammasome complex is another part of the innate immune system that activates 
caspase-1 that is responsible for the activation of the pro-inflammatory cytokines IL-18 
and IL-1ß. These two pro-inflammatory cytokines have been shown to be involved 
the development of obesity and insulin resistance. In chapter 7, we questioned 
whether absence of components of the inflammasome complex would affect HFD-
induced obesity, adipose tissue inflammation and insulin resistance. Since absence 
of inflammasome-mediated caspase-1 markedly reduced HFD-induced obesity and 
insulin resistance, the mechanism by which absence of caspase-1 reduces adipose tissue 
mass was investigated in chapter 8, by evaluating TG-rich lipoprotein metabolism in 
caspase-1 deficient and wild-type mice. 
Finally, the results from these studies and its implications are discussed in chapter 9. 
references
1. Hussain MM. A proposed model for the assembly of chylomicrons. Atherosclerosis 2000;148:1-15.
2. Mansbach CM, Gorelick F. Development and physiological regulation of intestinal lipid absorption. II. Dietary 
lipid absorption, complex lipid synthesis, and the intracellular packaging and secretion of chylomicrons. Am J 
Physiol Gastrointest Liver Physiol 2007;293:G645-G650.
3. Mu H, Porsgaard T. The metabolism of structured triacylglycerols. Prog Lipid Res 2005;44:430-448.
4. Bartelt A, Bruns OT, Reimer R, Hohenberg H, Ittrich H, Peldschus K, Kaul MG, Tromsdorf UI, Weller H, 
Waurisch C, Eychmuller A, Gordts PL, Rinninger F, Bruegelmann K, Freund B, Nielsen P, Merkel M, Heeren J. 
Brown adipose tissue activity controls triglyceride clearance. Nat Med 2011;17:200-205.
5. Xiao C, Hsieh J, Adeli K, Lewis GF. Gut-liver interaction in triglyceride-rich lipoprotein metabolism. Am J 
Physiol Endocrinol Metab 2011;301:E429-E446.
6. Shelness GS, Sellers JA. Very-low-density lipoprotein assembly and secretion. Curr Opin Lipidol 2001;12:151-157.
7. Olivecrona T, Bergo M, Hultin M, Olivecrona G. Nutritional regulation of lipoprotein lipase. Can J Cardiol 
1995;11 Suppl G:73G-78G.
8. Zechner R. The tissue-specific expression of lipoprotein lipase: implications for energy and lipoprotein 
metabolism. Curr Opin Lipidol 1997;8:77-88.
9. Ruge T, Wu G, Olivecrona T, Olivecrona G. Nutritional regulation of lipoprotein lipase in mice. Int J Biochem 
Cell Biol 2004;36:320-329.
10. Goldberg IJ, Eckel RH, Abumrad NA. Regulation of fatty acid uptake into tissues: lipoprotein lipase- and CD36-
mediated pathways. J Lipid Res 2009;50 Suppl:S86-S90.
11. Ginsberg HN. New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. 
Circulation 2002;106:2137-2142.
12. Slawik M, Vidal-Puig AJ. Adipose tissue expandability and the metabolic syndrome. Genes Nutr 2007;2:41-45.
13. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006;43:S99-S112.
14. Malenfant P, Joanisse DR, Theriault R, Goodpaster BH, Kelley DE, Simoneau JA. Fat content in individual 
muscle fibers of lean and obese subjects. Int J Obes Relat Metab Disord 2001;25:1316-1321.
15. Virkamaki A, Korsheninnikova E, Seppala-Lindroos A, Vehkavaara S, Goto T, Halavaara J, Hakkinen AM, Yki-
Jarvinen H. Intramyocellular lipid is associated with resistance to in vivo insulin actions on glucose uptake, 
antilipolysis, and early insulin signaling pathways in human skeletal muscle. Diabetes 2001;50:2337-2343.
16. Sakurai M, Takamura T, Ota T, Ando H, Akahori H, Kaji K, Sasaki M, Nakanuma Y, Miura K, Kaneko S. Liver 
steatosis, but not fibrosis, is associated with insulin resistance in nonalcoholic fatty liver disease. J Gastroenterol 
2007;42:312-317.
17. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J, Sovijarvi A, Halavaara J, Yki-
Jarvinen H. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production 




18. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight 
and obese adults. JAMA 1999;282:2131-2135.
19. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor 
necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995;95:2409-2415.
20. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, Jr. Obesity is associated with 
macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-1808.
21. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic 
inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 
2003;112:1821-1830.
22. Skurk T, berti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and adipokine expression 
and secretion. J Clin Endocrinol Metab 2007;92:1023-1033.
23. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE. Local and systemic insulin resistance 
resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005;11:183-190.
24. Peng Y, Rideout D, Rakita S, Lee J, Murr M. Diet-induced obesity associated with steatosis, oxidative stress, and 
inflammation in liver. Surg Obes Relat Dis 2011.
25. Lagathu C, Yvan-Charvet L, Bastard JP, Maachi M, Quignard-Boulange A, Capeau J, Caron M. Long-term 
treatment with interleukin-1beta induces insulin resistance in murine and human adipocytes. Diabetologia 
2006;49:2162-2173.
26. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in 
obesity-linked insulin resistance. Science 1993;259:87-91.
27. Merhi-Soussi F, Kwak BR, Magne D, Chadjichristos C, Berti M, Pelli G, James RW, Mach F, Gabay C. Interleukin-1 
plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. 
Cardiovasc Res 2005;66:583-593.
28. Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. 
Cardiovasc Res 2008;79:360-376.
29. de Winther MP, Kanters E, Kraal G, Hofker MH. Nuclear factor kappaB signaling in atherogenesis. Arterioscler 
Thromb Vasc Biol 2005;25:904-914.
16
2inTerplay beTween lipid meTabolism and inflammaTion – Two TarGeTs in The TreaTmenT of aTherosclerosisJanna a. van diepen*, Jimmy f.p. berbée*, louis m. havekes, patrick c.n. rensen*These authors contributed equally to the manuscript
Submitted
absTracT
Hyperlipidemia and inflammation are well known risk factors for the development of 
atherosclerosis and both have been shown to play a causal role in the progression of 
atherosclerotic plaques. In recent years, a strong interplay between lipid metabolism 
and inflammation has been discovered, which can explain why lipid-lowering drugs 
and anti-inflammatory drugs reduce atherosclerosis beyond expectations based on 
their primary mode of action. In this review, we summarize the off-target effects of 
lipid-lowering drugs (i.e. statins, fibrates, niacin and ezetimibe) on inflammatory 
processes and those of inflammation-lowering drugs (i.e. salicylates, anti-TNF and 
IL-1ra) on lipid metabolism, and discuss the added value of these off-target effects in 
the use of these drug classes for the treatment of atherosclerosis.
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1. inTrodUcTion
Both hyperlipidemia and inflammation are well known risk factors for the development 
of atherosclerosis and have been shown to play a causal role in the progression of 
atherosclerotic plaques.1 In the current review, we will describe the role of lipids and 
inflammation in the development of atherosclerosis and the interaction between lipid 
metabolism and inflammation that influences the development of atherosclerosis. We 
will discuss the current knowledge about the off-target effects of lipid-lowering drugs 
on inflammatory processes, as well as the off-target effects of anti-inflammatory drugs 
on lipid metabolism, whereby the mechanisms underlying these effects have been 
mainly derived from experimental studies.  
2. lipids and aTherosclerosis
The prevalence of hyperlipidemia and cardiovascular disease (CVD) increases as a 
consequence of increased nutrient intake in the western societies, where the average 
diet contains a high percentage fat and cholesterol.2 Hyperlipidemia is an important 
risk factor for the development of atherosclerosis and is characterized by increased 
plasma cholesterol and triglyceride (TG) levels. These lipids are carried by ‘atherogenic’ 
lipoproteins (chylomicrons, VLDL, their remnant lipoproteins and LDL) that can enter 
the arterial wall and accumulate inside, thereby causing lipid deposition and initiating 
early atherosclerosis.3 LDL is prone to oxidative modifications by for example reactive 
oxygen species (ROS) resulting in oxidized LDL (oxLDL) that can induce endothelial 
cell activation in the vessel wall.4 OxLDL can also be taken up by macrophage scavenger 
receptors such as scavenger receptor A (SRA) or CD36, turning macrophages into 
foam cells, thereby contributing to the formation of the so called ‘foamy atherosclerotic 
plaques’.5 Hyperlipidemia is frequently accompanied by decreased plasma levels of HDL, 
which is then called “dyslipidemia”. HDL is considered to be atheroprotective mainly 
by increasing reverse cholesterol transport, a process whereby HDL acts as cholesterol 
acceptor and transports cholesterol from atherosclerotic lesions back to the liver for 
excretion into the bile.6 Therefore, lipid-lowering therapy is the main treatment strategy 
for combating atherosclerosis, while HDL-raising is an evolving additional strategy.
3. inflammaTion and aTherosclerosis
Atherosclerosis is increasingly being considered as an inflammatory disease, since 
inflammatory processes play a key role in various stages of plaque development. These 
include the activation of endothelial cells (ECs) leading to expression of adhesion 
molecules such as intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion 
molecule (VCAM)-1 that attract inflammatory cells (e.g. neutrophils, T-cells and 
monocytes) into the early atherosclerotic lesion. Within the plaque, smooth muscle 
cells (SMCs) and ECs secrete proinflammatory mediators that stimulate monocyte 
differentiation into macrophages. These macrophages further develop into foam 
lipid meTabolism, inflammaTion and aTherosclerosis
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cells upon uptake of oxLDL and locally amplify the inflammatory response, thereby 
attracting more immune cells and inducing migration of SMCs into the plaque.7-9 
Nuclear factor-kappaB (NF-κB) is a transcription factor that plays a key role in 
the development of atherosclerosis. NF-κB is expressed by multiple cell types in the 
atherosclerotic plaque such as ECs, SMCs and immune cells, in which it regulates 
expression of adhesion molecules (e.g. ICAM-1 and VCAM-1), chemokines (e.g. 
macrophage chemoattractant protein (MCP)-1), and proinflammatory cytokines (e.g. 
TNFα, IFN-γ, IL-1ß and IL-6), all of which play an important role during the various 
stages of plaque formation.10, 11 In addition, NF-κB regulates the expression of several 
factors involved in apoptosis and cell proliferation.10
The inflammatory stimuli that contribute to the progression of atherosclerosis can 
have a local origin, as described above, or a non-vascular origin. Non-vascular sources 
of inflammation that are risk factors for atherosclerosis include chronic infection, 
inflammatory diseases (e.g. rheumatoid arthritis (RA)) and diet-induced inflammation, 
of which the latter will be described in paragraph 4.1.
4. inTeracTion beTween lipids and inflammaTion
Although hyperlipidemia and inflammation are individual risk factors for the 
development of atherosclerosis, interaction between lipid metabolism and inflammatory 
pathways has been reported in multiple organs with different pathways involved, which 
will be described below.
4.1 lipids affect inflammation
Diet-induced inflammation is a form of low-grade chronic inflammation that is caused 
by a nutrient overload, although the exact mechanisms underlying the development 
of this so called ’metabolic’ inflammation are still under investigation. Cholesterol 
feeding elevates circulating markers of inflammation such as C-reactive protein 
(CRP) and serum amyloid A (SAA) in lean subjects.12 In addition, obese humans are 
characterized by systemic inflammation as reflected by increased circulating CRP and 
cytokine levels.13, 14
Mechanistic studies in animals show that diets high in (saturated) fatty acids (FA) 
and/or cholesterol are accompanied by inflammatory processes in adipose tissue15 and 
liver.16, 17 Upon expansion of the adipose tissue, resident and infiltrating macrophages 
start to secrete inflammatory mediators (e.g. cytokines) that induce a low-grade 
systemic inflammation.15, 18 In liver, high-fat feeding increases hepatic NF-κB activity 
and expression of proinflammatory cytokines.19 A high cholesterol diet even more 
potently induces hepatic inflammation as reflected by increased macrophage content 
and expression of MCP-1, CD68 and proinflammatory cytokines as well as increased 
plasma SAA and E-selectin levels.16, 17
The exact mechanism(s) by which FA and cholesterol induce local inflammatory 
responses are not fully clear. Part of the mechanism may involve the increased translocation 
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of LPS from the gut into the circulation upon HFD feeding, thereby causing ‘metabolic 
endotoxemia’.20, 21 In addition, saturated FA are also believed to directly increase NF-κB 
signaling via activation of Toll-like receptors (TLRs).22, 23 Studies in hyperlipidemic 
mouse models suggest that dietary cholesterol induces hepatic inflammation via a 
different mechanism. Dietary cholesterol increases circulating levels of (V)LDL and 
TG-rich remnants, which can be modified by oxidation and taken up by Kupffer cells via 
scavenger receptors thereby triggering an inflammatory response in the liver.24 
The activation of local, non-vascular, inflammatory pathways by FA and cholesterol 
may aggravate the development of atherosclerosis, most likely via increased circulation 
of proinflammatory mediators. We recently showed that transgenic activation of 
hepatic NF-κB signaling contributes to the formation of atherosclerotic lesions.25 In 
addition, increase in plasma SAA levels after cholesterol feeding has been shown to 
associate with atherosclerosis independent of plasma lipid levels.26   
 Besides induction of hepatic and adipose tissue inflammation, FA and cholesterol 
can similarly and simultaneously induce vascular inflammation.27 Comparable to 
Kupffer cells in the liver, infiltrated monocytes in the vessel wall can take up modified 
oxLDL that activates or amplifies local inflammatory pathways such as the NF-κB 
pathway. Ex vivo studies have additionally shown that circulating monocytes can be 
activated by TG-rich lipoprotein remnants, most likely  by direct interaction between 
TG-rich lipoproteins and monocytes and uptake of FA,28 which might contribute to 
endothelial activation and monocyte adhesion to the vascular wall.
Interestingly, the cholesterol-induced hepatic and vascular inflammation appears 
reversible by reducing the cholesterol content of the diet, as reflected by a decreased 
hepatic and aortic NF-κB activity, decreased plasma SAA levels and a reduction in 
macrophage content in the atherosclerotic plaque.29 Vascular inflammation may also 
be reduced by HDL that possesses anti-inflammatory capacities and reduces VCAM-1 
and ICAM-1 expression in the aortic wall of cholesterol-fed rabbits.30 However, since 
the potential of HDL as an anti-atherogenic therapy has already extensively been 
reviewed by others,31, 32 it is not discussed in the current review.
4.2 inflammatory mediators affect lipid metabolism
Although many studies focused on the effects of lipids on inflammatory pathways, 
only few studies specifically investigated the effects of metabolic inflammation on 
lipid metabolism. Interestingly, observations in patients with acute inflammation 
reveal that bacterial and viral infection is accompanied by hypertriglyceridemia.33, 34 
Most of the current knowledge on the mechanistic relation between inflammation 
and lipid metabolism comes from rodent and in vitro studies that investigated the 
effect of infection and acute inflammation on lipids and lipoprotein metabolism, 
which has been extensively reviewed.35, 36 Changes in circulating lipoproteins during 
inflammation play a vital role in host defense during infection, however, similar 
changes in lipoproteins upon prolonged chronic inflammation will contribute to the 
development of atherosclerosis.
lipid meTabolism, inflammaTion and aTherosclerosis
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Lipopolysaccharide (LPS; or ‘endotoxin’) administration in rats induces a 
hyperlipidemic response, which is caused primarily by an increase of VLDL-TG.37 
Similarly, administration of the proatherogenic cytokines TNFα, IL-1ß or IL-6, increased 
plasma VLDL-TG levels,35, 38 thereby inducing an atherogenic lipoprotein profile. The 
increased plasma VLDL-TG is mainly caused by increased VLDL-TG production, as 
related to an increased hepatic lipogenesis39, 40 but also attributed by reduced VLDL-TG 
clearance via inhibition of lipoprotein lipase (LPL) activity.37, 41 Although inflammation 
clearly increases plasma TG levels in humans and animal models, the effects on plasma 
cholesterol levels are less clear and differ between species.35 While in humans both LPS 
injection42 and infection43, 44 reduces plasma cholesterol levels, due to a reduction in 
LDL and mainly HDL levels, in mice, LPS injection increases total cholesterol levels45 
and infection has no effect on plasma cholesterol levels.46 In addition to increasing 
VLDL-TG and reducing HDL-C, infection and inflammation can contribute to a 
proatherogenic lipid profile by increasing oxidation of LDL.47
It remains to be established whether low-grade systemic inflammation, observed 
in atherosclerosis, has similar effects on lipid metabolism as high-grade acute 
inflammation, evoked by high doses of LPS and cytokines. We recently showed that 
genetic activation of NF-κB activity specifically in hepatocytes, at levels comparable 
to those induced by metabolic inflammation, increased VLDL-TG production48 and 
aggravated atherosclerosis,25 suggesting that metabolic inflammation can have similar 
adverse effects on lipoprotein metabolism as acute inflammation. Future experimental 
studies in rodents with a relatively mild tissue-specific increase of specific inflammatory 
molecules could be useful for further delineating the direct effects of metabolically 
relevant inflammatory pathways on lipid metabolism.
4.3 interaction of inflammation and lipid metabolism in the progression of atherosclerosis
Taken together, it is evident that lipids, such as (saturated) FA and cholesterol, can 
induce inflammatory processes. Vice versa, acute inflammatory stimuli, such as LPS 
and cytokines as well as low-grade hepatic NF-κB activity, can induce proatherogenic 
changes in lipoprotein metabolism. Therefore, the effect of lipids on inflammation 
could likely explain the exponential rather than linear relationship between plasma 
cholesterol levels and severity of atherosclerosis that is observed in animal models.16 
On the other hand, this suggests that patients who use lipid-lowering drugs such as 
statins, fibrates and niacin that are currently used for the treatment of atherosclerosis 
will benefit from the off-target effects of these drugs with respect to reducing 
inflammation. Indeed, recent data provide evidence that these lipid-lowering drugs 
reduce atherosclerosis beyond their lipid-lowering activities, at least partly by reducing 
inflammatory signaling pathways. 
In the remainder of this review, we will summarize current knowledge on the 
effects of lipid-lowering drugs on inflammatory processes (either directly or indirectly) 
and those of inflammation-lowering drugs on lipid metabolism, and discuss the added 
value of these off-target effects in the treatment of atherosclerosis. 
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5. effecT of lipid-lowerinG drUGs on inflammaTion 
Lipid-lowering drugs are principally prescribed to reduce hyperlipidemia and thus 
atherosclerosis, thereby reducing the risk of cardiovascular events. Interestingly, 
most of these lipid-lowering drugs are able to reduce atherosclerosis beyond their 
lipid-lowering capacities. Experimental studies in rodents have revealed that several 
targets of lipid-lowering drugs, such as nuclear receptors or key regulators of lipid 
metabolism, do interact with inflammatory pathways and thereby reduce inflammation. 
This is suggested to be the mechanism by which lipid-lowering drugs have additional 
beneficial ‘pleiotropic’ effects on atherosclerosis and other CVD as seen in clinical 
trials. The mechanisms by which the currently used lipid-lowering strategies reduce 
inflammatory parameters are discussed below and summarized in table 1.
5.1 statins
Statins are the most widely used lipid-lowering drugs that reduce LDL-cholesterol 
levels by competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase, the rate-limiting step in cholesterol biosynthesis. The inhibition of 
cholesterol synthesis induces compensatory hepatic expression of the LDL receptor 
(LDLr) and decrease in hepatic VLDL-production, thereby reducing plasma (V)LDL-
cholesterol and -TG levels.49 In addition, statins modestly increase plasma HDL levels 
by reducing hepatic expression as well as plasma concentration and activity of CETP.50 
Statins very effectively reduce atherosclerosis and cardiovascular events in 
hypercholesterolemic subjects. Interestingly, the reduction in cardiovascular events in 
clinical trials can not be explained solely by the reduction in cholesterol levels.51, 52 In 
addition to lowering lipids, statins have anti-inflammatory effects that contribute to 
their atheroprotective properties. Results from large clinical trials showed that statins 
reduce systemic markers of inflammation such as CRP and SAA.53 
Statins may reduce inflammation secondary to reducing plasma cholesterol, since 
plasma cholesterol levels are related to tissue-specific inflammation17 and a reduction in 
plasma cholesterol per se reduces markers of systemic inflammation such as SAA, hepatic 
NF-κB activity and macrophage content in the plaque,29, 54 as discussed in paragraph 4.1. 
However, statistical analysis suggested that the reduction in plasma CRP levels upon 
statin treatment occurs partly independent of LDL-cholesterol levels.55, 56 This finding 
has been strengthened by experimental studies in rodents where statins exert anti-
inflammatory activity independent57 or even in the absence58, 59 of the lipid-lowering 
effects of statins. Mechanistic studies in the hyperlipidemic APOE*3-Leiden mouse 
model that responds to statins in lowering cholesterol similar to humans, revealed that 
statin treatment induced additional anti-inflammatory activities in liver and vasculature 
compared to a similar reduction in cholesterol levels by low-cholesterol feeding.60
The mechanisms by which statins reduce inflammation independent of lipid-
lowering have mainly been investigated in vitro, which has been summarized by 
Schonbeck et al.61 Statins appear to reduce multiple inflammatory pathways which can 
be attributed by secondary effects that are caused by HMG-CoA reductase inhibition. 
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HMG-CoA reductase controls the mevalonate pathway that not only results in 
synthesis of cholesterol, but also of isoprenoids that are required for the function of 
small GTPases (e.g. Rho, Rac, Rab, Ras, Rheb) that affect multiple signaling pathways.62 
Incubation of cultured ECs, SMCs and monocytes/macrophages with statins indeed 
revealed that statins directly reduce many different inflammatory pathways. Statins 
downregulated inflammatory-modulating transcription factors such as NF-κB and 
activator protein (AP)-163 and reduced expression of MCP-164 and proinflammatory 
cytokines such as IL-1ß, IL-6 and TNFα.61, 65 In addition, statins reduce expression 
of adhesion molecules in primary human monocytes66 and reduce monocyte-EC 
interactions in vitro.67 Besides being powerful inhibitors of cholesterol synthesis, statins 
thus also appear powerful direct inhibitors of inflammatory pathways.
It remains to be established whether statins reduce all of these inflammatory 
pathways in humans, as relatively high concentrations of statins have been used for 
these mechanistic experiments in vitro. Importantly, in vivo animal studies revealed that 
a high dosage of statin is an important determinant for its anti-inflammatory effects. 
High-dose statin treatment in mice reduced vascular monocyte adhesion and reduced 
the expression of inflammatory markers in both the liver (i.e. SAA and fibrinogen) as well 
as in the vessel wall (i.e. VCAM-1, MCP-1 and TNFα),60 while low-dose statin treatment 
only reduced vascular monocyte adhesion and VCAM-1 expression.68 Interestingly, 
monocytes from statin-treated hypercholesterolemic patients showed a dose-dependent 
reduction in the expression of adhesion molecules66 and a study in patients with acute 
myocardial infarction (that activates the inflammatory response) confirmed that statin 
treatment dose-dependently reduced circulating CRP and TNFα levels.69
It is interesting that inhibition of HMG-CoA reductase by statins has direct 
inhibitory effects on cholesterol synthesis as well as inflammatory pathways. The fact 
that both cholesterol and isoprenoids are synthesized from the same precursors by the 
mevalonate pathway emphasizes the close relation between lipid and inflammatory 
pathways and clarifies why statins reduce atherosclerosis to a higher extent than 
expected based on their lipid-lowering ability.
5.2 fibrates
Fibrates are the first line of drugs that are currently used for the treatment of 
hypertriglyceridemia. Fibrates are synthetic ligands for peroxisome proliferator-
activated receptor α (PPARα), the nuclear receptor that activates genes involved in lipid 
metabolism upon activation. PPARα activation potently reduces plasma TG levels as 
a result of increased VLDL-TG clearance. This increased clearance is due to enhanced 
LPL activity by 1) upregulation of LPL expression and 2) upregulation of apolipoprotein 
AV (apoAV) and downregulation of apoCIII expression.70, 71 Plasma VLDL and LDL 
levels may further be reduced by upregulation of hepatic LDLr expression.72 Fibrates 
additionally increase HDL-cholesterol levels by hepatic upregulation of apoAI, 
leading to an increased HDL production, as well as downregulating both hepatic 
expression as well as plasma concentration and activity of CETP, that further increases 
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HDL-cholesterol.73 Altogether, fibrates reduce plasma VLDL-TG and LDL-cholesterol 
levels and increases HDL-cholesterol levels, contributing to an anti-atherogenic lipid 
profile.
Indeed, fibrates have shown to reduce atherosclerosis and CVD in hyperlipidemic 
rodent models74 and in dyslipidemic patients at risk for CVD.75, 76 Interestingly, similar 
to statin treatment, fibrate treatment reduced atherosclerosis in patients to a greater 
extent than expected based on solely its lipid-lowering effects.77 Kooistra et al.78 showed 
in hyperlipidemic APOE*3-Leiden mice that fenofibrate reduces atherosclerosis 
beyond plasma cholesterol-lowering alone. This could, at least partly, be ascribed to 
the anti-inflammatory activities of fibrates. Indeed, not only in animal models, but also 
in dyslipidemic patients, fibrate treatment reduces inflammatory markers such as CRP 
and IL-6.79, 80
The reduction in systemic inflammation upon fibrate treatment may be secondary to 
local changes in lipid metabolism that affect inflammatory pathways. PPARα activation 
increases FA oxidation in adipose tissue, thereby reducing adipocyte hypertrophy, and 
increases adipocyte differentiation81, processes that have been associated with reduced 
macrophage activation and gene expression of inflammatory markers in adipose 
tissue.82 Similarly, activation of PPARα increases hepatic FA oxidation, thereby reducing 
hepatic steatosis and lipid peroxidation, that prevents the development of hepatic 
inflammation.83 In line with this, fibrates reduce hepatic markers of inflammation and 
the macrophage content of the liver.84, 85
Although fibrates may (partly) reduce systemic inflammation secondary to local 
changes in lipid metabolism, many studies reveal that the main mechanism by which 
fibrates reduce inflammation is probably the direct inhibitory action of PPARα on 
NF-κB signaling. Activation of PPARα reduces inflammatory signaling via direct 
physical interaction, and thereby inhibition, of NF-κB79 as well as by indirect inhibition 
of NF-κB via induction of IkB expression.86 In the liver, this may explain why PPARα 
activation suppresses hepatic inflammatory gene expression independent of its effects 
on hepatic lipid content.87 Altogether, fibrates thus reduce systemic inflammation, 
either via local changes in lipid metabolism in adipocytes and hepatocytes or via direct 
interaction of PPARα with NF-κB in peripheral tissues.
Besides adipocytes and hepatocytes, PPARα is expressed in multiple cell types 
involved in atherosclerosis development such as ECs, SMCs, and monocytes/
macrophages, and co-localizes with these cells in atherosclerotic lesions.88 It is therefore 
conceivable that most of the anti-inflammatory effects of fibrates in the arterial wall 
are mediated by direct inhibition of NF-κB by PPARα. Reduced NF-κB activity in the 
plaque directly reduces expression of VCAM-1 and ICAM-1,89 thereby diminishing 
recruitment and infiltration of inflammatory macrophages to the plaques.78 The PPARα 
mediated reduction in vascular NF-κB activity therefore likely contributes to the 
atherosclerosis-reducing effect of fibrates.
The direct interaction between two key transcription factors in the regulation of 
lipid- and inflammatory pathways, PPARα and NF-κB respectively, reveals another 
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close intracellular interaction between lipid metabolism and inflammation and explains 
why fibrates reduce atherosclerosis beyond expectations.
5.3 niacin
Niacin (nicotinic acid or vitamin B3) has been used as a lipid-lowering drug for 
many years, although the G protein-coupled receptor (GPR) 109A that is responsible 
for its effects has only been elucidated a decade ago.90-92 By activating GPR109A in 
adipocytes, niacin reduces the activity of hormone sensitive lipase (HSL) that acutely 
reduces the free FA (FFA) flux from adipose tissue to the liver. As hepatic VLDL-TG 
production is highly dependent on the influx of FFA from the circulation, this is 
commonly proposed as the main mechanism by which niacin reduces plasma (V)
LDL levels. In addition, niacin reduces diacylglycerol acyltransferase-2 (DGAT2) 
activity in hepatocytes, thereby decreasing TG synthesis and apoB secretion 93. 
Besides lowering (V)LDL, niacin is the most effective drug currently on the market 
to raise plasma HDL levels94 and therefore gains increasing interest despite its 
adverse side effects (i.e. flushing and gastrointestinal disorders). The raise in plasma 
HDL levels upon niacin treatment is dependent on the presence of CETP and can 
be attributed to a reduced hepatic expression and plasma concentration and activity 
of CETP.95, 96 This effect on CETP may be secondary to the reduction in hepatic TG 
and cholesterol content that has been observed upon niacin treatment.96 Niacin thus 
effectively reduces the proatherogenic plasma lipid profile by decreasing (V)LDL and 
increasing HDL levels.
Niacin reduces atherosclerosis in patients97, 98 and in various mouse models.99-101 
In addition to lowering lipids, niacin has anti-inflammatory effects that are likely to 
contribute to its atheroprotective properties. Similar to statin and fibrate treatment, 
niacin reduces plasma CRP levels in patients at risk for CVDs.102
Part of the anti-inflammatory effects of niacin may be secondary to the improved 
lipoprotein profile. Niacin reduces plasma (V)LDL that is prone for oxidative 
modulation, which likely reduces hepatic and vascular uptake of oxLDL by 
macrophages as described in paragraph 4.1. Niacin may also reduce inflammation 
secondary to the raise in plasma HDL levels. Some studies suggest that niacin does 
not only increase HDL levels, but also modifies HDL composition, resulting in an 
improved anti-inflammatory and anti-oxidative capacity of HDL,103 although results 
are not consistent.104 
The reduction in plasma (V)LDL and increase in plasma HDL levels might contribute 
to the niacin-mediated reduction in systemic inflammation. However, studies in 
rabbits and apoE-deficient mice show that niacin reduces vascular inflammation also 
independent of changes in plasma lipid levels.100, 105 In these studies, niacin reduced 
vascular VCAM-1, MCP-1 and TNFα expression and reduces macrophage and 
neutrophil infiltration into the plaque. This suggests that niacin has anti-inflammatory 
effects directly in the vasculature, which is supported by in vitro studies that reveal that 
niacin reduces TNFα-induced NF-κB activation, expression of VCAM-1 and MCP-1 
in ECs as well as monocyte adhesion to ECs.106 In addition to direct anti-inflammatory 
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effects in the vascular wall, niacin reduces secretion of proinflammatory cytokines by 
adipocytes in vitro,94 that may contribute to the reduction in systemic inflammation 
upon niacin treatment in vivo.
Most of the anti-inflammatory effects of niacin are suggested to be mediated 
via the GPR109A that is not only expressed in adipocytes, but also in immune cells 
including macrophages.107 In addition, some anti-inflammatory effects of niacin might 
be independent of the GPR109A, since in vitro studies revealed that in the absence of 
the GPR109A niacin reduces ROS production in ECs and inhibits EC-mediated LDL 
oxidation.106 Whether these GPR109A independent effects occur in vivo remains 
uncertain, since LDLr-deficient mice receiving bone marrow cells derived from 
GPR109A-deficient mice did not benefit from the vascular anti-inflammatory effects of 
niacin.101
The fact that niacin reduces plasma lipid levels and inhibits inflammatory signaling 
through, at least partly, the GPR109A, emphasizes another close link between 
intracellular lipid and inflammatory pathways. Moreover, it shows that niacin, despite 
primarily being a lipid-lowering drug, has strong anti-inflammatory effects that 
contribute to the reduction in atherosclerosis.
5.4 ezetimibe
Statins, fibrates and niacin are the current available drugs to treat patients with 
hyperlipidemia at risk for CVDs. Ezetimibe is approved as a lipid-lowering drug that may 
be used in combination with statins, but the outcomes of the first large clinical trials are 
still awaited.108 Ezetimibe inhibits the activity of the Niemann-Pick C1 Like 1 (NPC1L1) 
transporter that is critical for intestinal cholesterol absorption.109, 110 By doing so, 
ezetimibe reduces cholesterol absorption, thereby effectively reducing plasma cholesterol 
levels in hypercholesterolemic monkeys and mice.111, 112 Human studies also show that 
ezetimibe effectively reduces LDL-cholesterol levels,113 even on top of weight loss114 or 
in combination with statins,115 thereby thus further reducing the proatherogenic plasma 
lipoprotein profile. Ezetimibe indeed has shown to effectively reduce atherosclerosis in 
preclinical animal models, as recently reviewed by Davis et al.112, 116
Similar to the other lipid-lowering drugs, ezetimibe treatment attenuates systemic 
inflammation in human subjects (i.e.  serum CRP levels)114 as well as vascular 
inflammation in mice (e.g. aortic IL-6 and eNOS expression),117, 118 which may 
contribute to the reduction in atherosclerosis upon ezetimibe treatment. The reduction 
in inflammation upon ezetimibe treatment may be secondary to the reduction in 
hepatic and plasma cholesterol levels, since this has been associated with reduced 
hepatic and vascular inflammation.16, 29 Whether ezetimibe additionally possesses 
direct anti-inflammatory effects independent of the reduction in plasma and hepatic 
cholesterol levels, such as seen for statins, fibrates and niacin, is so far not known. One 
may hypothesize, since ezetimibe reduces not only intestinal cholesterol absorption, 
but to a minor extent also (saturated) FA absorption,119 that ezetimibe additionally 
reduces intestinal LPS absorption. However, whether this really occurs and whether it 
is clinically relevant remains to be determined. 
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6. effecT of inflammaTion-lowerinG drUGs on lipid meTabolism
Although inflammation clearly plays a role in the development of atherosclerosis, 
only few current human therapies primarily target inflammatory pathways in the 
treatment of atherosclerosis. The last decade, many papers have revealed that in animal 
studies, diminished activation of inflammatory pathways have marked effects on 
atherosclerosis.120-123 Currently, anti-inflammatory therapies are under development for 
the treatment of atherosclerosis as recently reviewed by Charo et al.124 Anti-inflammatory 
drugs may directly lower atherosclerosis, via inhibition of inflammatory mediators 
that contribute to atherosclerosis. In addition, anti-inflammatory drugs may reduce 
atherosclerosis by improving the atherogenic plasma lipid profile, since proinflammatory 
mediators induce a proatherogenic lipid profile as discussed in paragraph 4.2. However, 
since anti-inflammatory drugs are not the main drugs currently used for atherosclerosis 
treatment, less research has focused on the effects of anti-inflammatory drugs on lipid 
Table 1: Therapeutic actions of lipid-lowering drugs and their effects on inflammation.
Drug Therapeutic action Effects on lipid metabolism Effects on inflammation
Statin HMG-CoA red. inhibitor ↓ cholesterol synthesis ↓ mevalonate pathway (isoprenoids)
↓ plasma (V)LDL-cholesterol ↓ NF-κB and AP-1
↓ inflammatory mediators
(e.g. cytokines, adhesion molecules)
Fibrate PPARα activator ↑ plasma VLDL-TG clearance ↓ NF-κB
↓ plasma TG ↓ inflammatory mediators
↓ plasma (V)LDL-cholesterol (e.g. cytokines, adhesion molecules)
↑ plasma HDL-cholesterol
Niacin GPR109A agonist ↓ HSL activity ↓ activity immune cells via GPR109A
↓ FFA flux to liver ↓ NF-κB
↓ VLDL-productie ↓ inflammatory mediators
↓ plasma (V)LDL-cholesterol (e.g. cytokines, chemokines)
↑ plasma HDL-cholesterol
Ezetimibe NPC1L1 inhibitor ↓ intestinal cholesterol absorption
↓ plasma (V)LDL-cholesterol ↓ inflammatory mediators
 (e.g. cytokines, acute-phase proteins)
Primary actions are depicted in bold. AP-1, activator protein-1; GPR109A, G protein-coupled receptor 109A; 
HMG-CoA red., 3-hydroxy-3-methylglutaryl coenzyme A reductase; HSL, hormone-sensitive lipase; NF-κB, 
nuclear factor-kappaB; NPC1L1, Niemann-Pick C1 Like Protein 1; PPARα, peroxisome proliferator-activated 
receptor α.
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metabolism. The studies that are available involve mainly pre-clinical studies (animal 
models) and are described below and summarized in table 2.
6.1 salicylates (salicylate/aspirin/salsalate)
Aspirin (acetyl salicylic acid) is a salicylate drug belonging to the NSAIDs (non-
steroidal anti-inflammatory drugs) and is frequently used for prevention and treatment 
of CVD, due to its anti-platelet aggregating and anti-inflammatory activity. Aspirin is 
primarily known as a cyclooxygenase-1 (COX-1) inhibitor, thereby reducing synthesis 
of prostaglandins, which are involved among others in the regulation of hemostasis, 
platelet function, and macrophage differentiation.125 Low-dose aspirin reduces 
vascular inflammation in mice126 and plasma proinflammatory cytokine levels in 
patients at risk for CVD.127 However, the anti-inflammatory effects of aspirin are most 
pronounced at high-dose aspirin treatment, when it also inhibits the activity of NF-
κB.128 As discussed above, NF-κB is a transcription factor crucially involved in many 
aspects of inflammation10 and is activated in the atherosclerotic lesion.129 Although 
the anti-platelet aggregating effects of aspirin contribute to the reduction in CVD, the 
fact that aspirin treatment reduces CVD mostly in patients with high inflammatory 
status indicates that the anti-inflammatory effects of aspirin strongly contribute to the 
reduction in CVD upon treatment.130
Although salicylate treatment reduces systemic inflammation, this is not the only 
way by which salicylate treatment prevents CVD. Treatment of hyperlipidemic APOE*3-
Leiden mice with salicylate not only reduced hepatic and aortic NF-κB activity, but 
also markedly reduced plasma cholesterol levels,29 demonstrating additional effects on 
lipid metabolism. Actually, since long it is known that high dose aspirin and salicylate 
treatment can reduce plasma FFA and TG levels,131, 132 which was suggested to be 
caused by inhibition of lipogenesis133 as well as inhibition of FA release from adipose 
tissue.134 Recent mechanistic studies from our group in rodents showed that aspirin 
and salicylate treatment reduce plasma VLDL-TG and VLDL-cholesterol levels in 
atherosclerotic mouse models,29, 135, 136 due to a reduction in VLDL-TG production.135 
The mechanism by which aspirin reduces hepatic VLDL-TG production could either 
be directly via its inhibitory effects on hepatic NF-κB, since hepatic NF-κB activity is 
positively associated with VLDL-TG production,48 or indirectly via a drop in plasma 
FFA levels, thereby reducing the FA incorporation into VLDL-TG.135 
These observations show that the anti-inflammatory salicylate drugs do not only 
reduce atherosclerosis by reducing inflammation, but additionally by inducing an 
anti-atherogenic lipid profile. However, although high-dose aspirin treatment has the 
most pronounced anti-inflammatory effects, caution should be taken regarding high-
dose aspirin treatment, as this may increase the risk of gastrointestinal side effects.125 
Anti-inflammatory drugs that similarly reduce inflammation, plasma lipid levels and 
atherosclerosis, that do not have these side effects may need to be developed. In fact, 
salsalate is regarded as a safer alternative and is now used for clinical trials in type 2 
diabetic patients. Recently, high-dose salsalate treatment has shown to reduce plasma 
TG levels in diabetic patients.137




The experience with salicylate treatment suggests that other anti-inflammatory agents 
may also be efficient in preventing CVDs, not only by reducing inflammatory processes, 
but also by reducing pro-atherogenic lipid profiles. Partly due to side effects of high-dose 
aspirin treatment, more attention is paid to develop new anti-inflammatory therapies.124 
We now discuss strategies to reduce signaling of the proinflammatory cytokines TNFα 
and IL-1ß, both of which have been shown to be involved in the development of 
atherosclerosis and affect lipid metabolism directly, as discussed in paragraph 4.2.
TNFα is a critical mediator of inflammation with an important role in the 
development of atherosclerosis. Anti-TNF therapy has been used for the treatment of 
chronic inflammatory rheumatoid arthritis (RA) and reduces cardiovascular events 
in these patients.138 This reduction in cardiovascular events is most likely caused by 
attenuation of chronic inflammation, since it does not affect or even increase plasma 
total cholesterol, TG, LDL and HDL levels in RA patients.139 Most experimental 
data are derived from genetic models showing that disrupted TNFα signaling is 
associated with reduced atherosclerosis development without affecting plasma lipid 
levels.140 A single experimental report studied the effect of TNFα antagonism related 
to atherosclerosis in apoE-deficient mice and found no effect on plasma lipid levels 
and a tendency towards reduced atherosclerosis development.122 Others evaluated 
the potency of anti-TNF treatment in metabolic diseases such as obesity and showed 
increased insulin sensitivity in insulin-resistant patients141 and mice,142 although results 
are not consistent.143 Whether TNFα antagonism is able to reduce plasma lipid levels in 
hyperlipidemic patients needs to be evaluated in future studies.
IL-1β is a proinflammatory cytokine that mediates inflammation and is 
counterbalanced by IL-1 receptor antagonist (IL-1ra) via competitive binding to the 
IL-1 receptor (IL-1R). Genetic studies have revealed a link between IL-1β activity 
and atherosclerosis by showing that polymorphisms known to increase the IL-1β:IL-
1ra ratio are associated with increased incidence of CVDs.144, 145 In animal models, 
IL-1ß activity has causally been linked to the development of atherosclerosis.146 
As IL-1ß expression is elevated in the atherosclerotic plaque and secreted by ECs, 
SMCs and macrophages147, IL-1ß may increase atherosclerosis by direct activation 
of inflammatory pathways in the plaque. Indeed, IL-1ra administration reduced 
atherosclerosis without changes in plasma lipid levels in apoE-deficient mice.122 
However, IL-1ß administration to rats causes hyperlipidemia,148 suggesting that 
IL-1ra treatment may also be able to modulate plasma lipid levels. Absence of IL-1ra 
increases plasma cholesterol levels and reduces HDL levels in apoE-deficient mice,149 
which is amplified by a high-cholesterol diet.150 In addition, a recent study showed that 
an IL-1ß polymorphism associated with increased IL-1ß activity, increases fasting and 
postprandial plasma lipids.151 This raises the question whether IL-1ra administration 
may be able to reduce atherosclerosis by reducing plasma lipid levels, in addition 
to decreasing inflammation. The effects of IL-1ra administration on lipoprotein 
metabolism has not been studied in great detail. However, so far, subcutaneous 
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IL-1ra administration in mice,122 in patients with RA152 or in human subjects with the 
metabolic syndrome153 did not influence plasma lipid levels.
Although data of anti-cytokine therapy in relation to lipid metabolism and 
atherosclerosis are scarce, the findings so far suggest that cytokine inhibition effectively 
reduces inflammation, but has no clear effect on plasma lipid levels. Possibly, inhibition 
of individual mediators of inflammation, like cytokines, simply lacks sufficient impact 
on pathways of lipid and lipoprotein metabolism. Cytokine inhibition reduces 
atherosclerosis in RA patients, and most likely also reduces atherosclerosis in other 
patients with a clearly enhanced chronic inflammatory state (e.g. inflammatory bowel 
disease), but the effect in for example hyperlipidemic or type 2 diabetic patients 
remains to be established and may be limited due to the lower inflammatory state of 
these patients.
Table 2: Therapeutic actions of inflammation-lowering drugs and their effects on lipid 
metabolism.
Drug Therapeutic action Effects on inflammation Effects on lipid metabolism
Salicylates COX-1 inhibitor ↓ prostaglandin synthesis ↓ VLDL production
↓ platelet aggregation ↓ plasma cholesterol
↓ NF-κB (high dose) ↓ plasma FFA
↓ plasma TG
Anti-TNF TNFα inhibitor ↓ TNFα signaling No consistent effects
IL-1ra IL-1R antagonist ↓ IL-1ß signaling No effect on plasma lipids
Primary actions are depicted in bold. COX-1, cyclo-oxygenase-1; FFA, free fatty acid; IL-1β, interleukin-1 
beta; IL-1ra, interleukin-1 receptor antagonist; NF-κB, nuclear factor-kappa B; TG, triglyceride; TNFα, 
Tumor necrosis factor -alpha.
7. conclUdinG remarks
The last decade it has become clear that plasma lipid levels and plasma inflammatory 
mediators are not only independent risk factors for the development of atherosclerosis, 
but interaction exist between lipid and inflammatory pathways, thereby aggravating 
the development of atherosclerosis. Vice versa, the interaction between lipids and 
inflammatory mediators has shown to be beneficial in the treatment of atherosclerosis, 
since lipid-lowering drugs not only reduce plasma lipid levels, but also reduce 
levels of inflammatory mediators which further increase their efficiency in reducing 
atherosclerosis and CVDs. 
It is interesting to note that various classes of lipid-lowering drugs all reveal anti-
inflammatory properties. Part of the anti-inflammatory effects may be mediated by 
a similar mechanism, related to the reduction in (V)LDL and lipoprotein remnants. 
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In addition, however, they evoke (at least part of) their anti-inflammatory effects 
independent of lipid-lowering through different mechanisms: 1) statins interfere 
with multiple inflammatory pathways via inhibition of the mevalonate pathway, 2) 
fibrates inhibit the inflammatory NF-κB pathway through direct inhibitory actions 
of their target nuclear receptor PPARα on NF-κB activity, and 3) niacin may reduce 
inflammation directly via the GPR109A receptor on immune cells. Whether ezetimibe 
has direct anti-inflammatory effects is unknown, but it could possibly reduce intestinal 
endotoxin absorption. The fact these drugs all affect inflammatory pathways via 
different interactions in various cell types emphasizes that lipid- and inflammatory 
pathways are interrelated at multiple levels and in multiple tissues.
The effect of lipid-lowering therapies on inflammatory pathways has intensively 
been studied. In contrast, the effect of anti-inflammatory therapies on lipid metabolism 
has not been investigated to a great extent, although anti-inflammatory therapies are 
now under (pre-clinical) development for the treatment of atherosclerosis. So far, 
high-dose salicylate drugs such as aspirin have shown to reduce plasma cholesterol 
and TG levels, thereby contributing to the reduction in atherosclerosis in animal 
models. Cytokine inhibition effectively reduces inflammation, but the impact of this 
strategy appears too limited to also beneficially affect lipid pathways. Future studies 
may focus on the effects of new anti-inflammatory drugs with a broad spectrum on 
lipid metabolism. This will contribute to the understanding of the efficiency of these 
drugs in the treatment of atherosclerosis.
Further knowledge on the interaction between inflammation and lipid metabolism 
may improve treatment of patients at risk for CVD. Since CVD patients are very 
heterogeneous with respect to plasma lipid levels and inflammatory status, the 
exact contributions of lipids and inflammatory pathways to the development of 
atherosclerosis may vary between patients and need to be evaluated in subsets of 
clinical patients. Treatment strategies should subsequently be based on the type 
of patient at risk for CVD. Patients with an enhanced inflammatory status (e.g. RA, 
inflammatory bowel disease and chronic obstructive pulmonary disease patients) may 
benefit from lipid-lowering therapies with the strongest anti-inflammatory effects, or 
possibly anti-inflammatory therapy only. In fact, statins have been investigated for 
their efficacy in chronic inflammatory diseases such as RA.154 Patients at risk for CVD 
with increased plasma lipid levels may benefit most from lipid-lowering strategies only, 
which will likely reduce (metabolic) inflammation as a consequence. Treatment with 
both a lipid-lowering drug in combination with an inflammation-lowering drug may 
also have an additional therapeutic value and should be focus of future investigation. 
Understanding the mechanisms by which lipid-lowering and anti-inflammatory 
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absTracT
Systemic inflammation is strongly involved in the pathophysiology of the metabolic 
syndrome, a cluster of metabolic risk factors including hypertriglyceridemia. 
Aspirin treatment lowers inflammation via inhibition of NF-κB activity, but also 
reduces hypertriglyceridemia in humans. The aim of this study was to investigate the 
mechanism by which aspirin improves hypertriglyceridemia. Human apolipoprotein 
CI (apoCI)-expressing mice (APOC1 mice), an animal model with elevated plasma 
triglyceride (TG) levels, as well as normolipidemic wild-type (WT) mice were fed a 
high-fat diet (HFD) and treated with aspirin. Aspirin treatment reduced hepatic NF-κB 
activity in HFD-fed APOC1 and WT mice and in addition, aspirin decreased plasma 
TG levels (-32%; p<0.05) in hypertriglyceridemic APOC1 mice. This TG-lowering 
effect could not be explained by enhanced VLDL-TG clearance, but aspirin selectively 
reduced hepatic production of VLDL-TG in both APOC1 (-28%; p<0.05) and WT mice 
(-33%; p<0.05) without affecting VLDL-apoB production. Aspirin did not alter hepatic 
expression of genes involved in FA oxidation, lipogenesis and VLDL production, but 
decreased the incorporation of plasma-derived FA by the liver into VLDL-TG (-24%; 
p<0.05), which was independent of hepatic expression of genes involved in FA uptake 
and transport. We conclude that aspirin improves hypertriglyceridemia by decreasing 
VLDL-TG production without affecting VLDL particle production. Therefore, the 




The metabolic syndrome is a clustering of metabolic risk factors, including steatosis, 
insulin resistance and hyperlipidemia, predisposing to the early onset of atherosclerosis 
and cardiovascular morbidity and mortality. It is well established that the metabolic 
syndrome is associated with increased systemic inflammation.1 Moreover, 
accumulating evidence suggests a strong involvement of systemic inflammation in 
the pathogenesis of components of the metabolic syndrome.2 Hypertriglyceridemia, 
one of the components of the metabolic syndrome and an important risk factor for 
the development of cardiovascular disease, is strongly associated with increased 
inflammation.3 Early studies show that sepsis, infection and inflammation are 
accompanied by hypertriglyceridemia.4-6 More recent studies show that administration 
of LPS induces hypertriglyceridemia.7,8 In addition, multiple cytokines, such as IL-6 
and TNF-α, increase serum triglyceride (TG) levels.9,10 Inhibition of inflammation 
might therefore be an attractive therapeutic target in patients with HFD-induced 
hypertriglyceridemia.
Non-steroidal anti-inflammatory drugs (NSAID) such as aspirin are known to 
inhibit the enzyme cyclooxygenase (COX). In addition, high doses of aspirin lower 
activation of inflammatory pathways by inhibition of the NF-κB pathway,11,12 which 
plays a crucial role in the inflammation-mediated pathogenesis of the metabolic 
syndrome.2 Interestingly, aspirin treatment diminishes hypertriglyceridemia in both 
obese rodents13 and patients with type 2 diabetes mellitus.14 However, the mechanism 
underlying this TG-lowering effect still has to be elucidated.
We previously found that human apolipoprotein CI (apoCI)-expressing (APOC1) 
mice have increased plasma TG, by a diminished clearance of VLDL particles through 
apoCI-mediated inhibition of lipoprotein lipase (LPL),15 which is aggravated by high-fat 
diet (HFD) feeding (unpublished observation by I.O.C.M. Vroegrijk et al). Therefore, 
we reasoned that the HFD-fed APOC1 transgenic mouse is an appropriate model to 
study the effectiveness of treatments targeting HFD-induced hypertriglyceridemia. 
The aim of this study was to investigate the mechanism by which aspirin reverses 
HFD-induced hypertriglyceridemia. Therefore, we studied the effect of aspirin on 
VLDL-TG metabolism in vivo in HFD-fed hypertriglyceridemic APOC1 mice as well 
as in C57Bl/6 wild-type (WT) mice, to extend any findings towards the mouse model 
that is most widely used for evaluation of treatments for the metabolic syndrome. Our 
results show that a high dose of aspirin improves hypertriglyceridemia as a consequence 
of a clear reduction of hepatic VLDL-TG production, mediated by a diminished hepatic 
incorporation of plasma-derived FA into VLDL-TG.
maTerials and meThods
animals, diet and aspirin treatment
Transgenic APOC1 mice with hemizygous expression of the human APOC1 gene were 
generated as previously described and backcrossed at least 10 times to the C57Bl/6 
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background. The APOC1 mouse model develops hypertriglyceridemia mainly due 
to a diminished clearance of VLDL particles through apoCI-mediated inhibition 
of lipoprotein lipase (LPL).16,17 Male APOC1 mice and WT mice (also on a C57Bl/6 
background) were housed under standard conditions with a 12-hour light-dark cycle. 
At the age of 10–12 weeks, mice received a HFD (45 energy% derived from palm oil; 
D12451, Research Diet Services, Wijk bij Duurstede, The Netherlands) for a period 
of 6 weeks. Aspirin treatment (120 mg/kg/day in drinking water; pH 6.4) was given 
during the last 4 weeks on HFD and mice were subsequently used for experiments 
after an overnight fast at 9:00 am. Control mice received the same drinking water of pH 
6.4 without the addition of aspirin. Mice were allowed free access to food and water. 
Animal experiments were approved by the institutional ethical committee on animal 
care and experimentation.
liver nf-κb activation
Since the most common form of NF-κB is the p50/p65 heterodimer,18 the activity of both 
the p50 and p65 subunits in liver tissue was determined using electrophoretic mobility 
shift assay (EMSA).19 Shortly, tissues were homogenized in ice-cold Passive Lysis Buffer 
(Promega, Madison, WI) and centrifuged (14,000 rpm; 20 min; 4ºC). Protein content of 
the supernatant was determined using the BCA protein assay kit (Pierce, Rockford, IL). 
For the EMSA, the gel shift assay system was purchased from Promega. The probe was 
end-labeled using T4 polynucleotide kinase and [32P]ATP and purified on a Microspin 
G-25 column (GE Healthcare, Piscataway, NJ). For each sample, 50 µg protein was 
incubated with labelled probe and binding buffer (Promega) for 20 min at RT. Specific 
competition was done by adding unlabeled NF-kB binding probe to the reaction. The 
mixtures were run on 4.5% polyacrylamide gel electrophoresis in 0.5x Tris/Borate/
EDTA (TBE) buffer. The gel was vacuum-dried and exposed to radiographic film.
plasma parameters 
Blood was collected from the tail vein into chilled paraoxon (Sigma, St Louis, MO)-
coated capillaries to prevent ongoing lipolysis.20 Capillaries were placed on ice, 
centrifuged and plasma was assayed for TG, total cholesterol (TC) and phospholipids 
(PL) using commercially available enzymatic kits from Roche Molecular Biochemicals 
(Indianapolis, IN) in 96-wells plates (Greiner Bio-One). Free fatty acids (FFA) were 
measured using NEFA-C kit from Wako Diagnostics (Instruchemie, Delfzijl, the 
Netherlands). ß-hydroxybutyrate (ß-HB) was determined using the enzymatic ß-HB 
Assay kit from BioVision (Mountain View, CA, USA)
liver lipids
Lipids were extracted from livers according to a modified protocol from Bligh and 
Dyer.21 Shortly, a small piece of liver was homogenized in ice-cold methanol. After 
centrifugation, lipids were extracted by addition of 1800 µL CH3OH:CHCl3 (3:1 v/v) 
to 45 µL homogenate. The CHCl3 phase was dried and dissolved in 2% Triton X-100. 
Hepatic TG and TC concentrations were measured using commercial kits as described 
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earlier. Liver lipids were expressed per mg protein, which was determined using the 
BCA protein assay kit (Pierce).
Generation of Vldl-like emulsion particles
VLDL-like TG-rich emulsion particles were prepared and characterized as described 
previously.22,23 Lipids (100 mg) at a weight ratio of triolein: egg yolk phosphatidylcholine: 
lysophosphatidylcholine: cholesteryl oleate: cholesterol of 70: 22.7: 2.3: 3.0: 2.0, 
supplemented with 200 µCi of glycerol tri[9,10(n)-3H]oleate ([3H]TO) were sonicated at 
10 µm output using a Soniprep 150 (MSE Scientific Instruments, Crawley, UK). Density 
gradient ultracentrifugation was used to obtain 80 nm-sized emulsion particles, which 
were used for subsequent experiments. TG content of the emulsions was measured as 
described above. Emulsions were stored at 4°C under argon and used within 7 days.
in vivo clearance of Vldl-like emulsion particles
To study in vivo clearance of the VLDL-like emulsion particles, overnight fasted 
mice were anesthetized by intraperitoneal injection of acepromazine (6.25 mg/kg 
Neurotranq, Alfasan International BV, Weesp, The Netherlands), midazolam (6.25 mg/
kg Dormicum, Roche Diagnostics, Mijdrecht, The Netherlands), and fentanyl (0.31 
mg/kg Janssen Pharmaceuticals, Tilburg, The Netherlands). Mice were injected (t=0) 
via the tail vein with 200 µL of [3H]TO-labeled emulsion particles at a dose of 100 
µg of TG per mouse. Blood samples were taken from the tail vein at 1, 2, 5, 10 and 
15 minutes after injection and plasma 3H-activity was counted. Plasma volumes were 
calculated as 0.04706 x body weight (grams) as determined from 125I-BSA clearance 
studies as described previously.24 After taking the last blood sample, the liver, heart, 
spleen, muscle and white adipose tissue (i.e. gonadal, subcutaneous and visceral) were 
collected. Organs were dissolved overnight at 60°C in Tissue Solubilizer (Amersham 
Biosciences, Rosendaal, The Netherlands) and 3H-activity was counted. Uptake of [3H]
TO-derived radioactivity by the organs was calculated from the 3H activity in each 
organ divided by plasma-specific activity of [3H]TG and expressed per mg wet tissue 
weight.
hepatic Vldl-TG and Vldl-apob production
To measure VLDL production in vivo, mice were fasted overnight as described above. 
Mice were injected intravenously with Tran35S label (150 µCi/mouse; MP Biomedicals, 
Eindhoven, The Netherlands) to label newly produced apoB. After 30 minutes, at 
t=0 min, Triton WR-1339 (Sigma-Aldrich) was injected intravenously (0.5 mg/g 
body weight, 10% solution in PBS) to block serum VLDL clearance. Blood samples 
were drawn before (t=0) and 15, 30, 60 and 90 min after injection and used for 
determination of plasma TG concentration as described above. After 120 min, mice 
were exsanguinated via the retro-orbital plexus. VLDL was isolated from serum after 
density gradient ultracentrifugation at d<1.006 g/mL by aspiration25 and counted for 
incorporated 35S-activity.
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hepatic gene expression analysis
Total RNA was extracted from liver tissues using the Nucleospin RNA II kit (Macherey-
Nagel, Düren, Germany) according to the instructions of the manufacturer. The quality of 
each mRNA sample was examined by lab-on-a-chip technology using Experion Stdsens 
analysis kit (Biorad, Hercules, CA). 1 µg of total RNA was reverse-transcribed with iScript 
cDNA synthesis kit (Bio-Rad) and obtained cDNA was purified with Nucleospin Extract 
II kit (Macherey-Nagel). Real-Time PCR was carried out on the IQ5 PCR machine 
(Biorad) using the Sensimix SYBR Green RT-PCR mix (Quantace, London, UK). mRNA 
levels were normalized to mRNA levels of cyclophilin (Cyclo) and glyceraldehyde-3-
phosphate dehydrogenase (Gapdh). Primer sequences are listed in table 1. 
Table 1. Primers used for quantitative real-time PCR analysis.
















Acox1, acyl-Coenzyme A oxidase 1, palmitoyl; Apob, apolipoprotein B; Cd36, fatty acid translocase; Cpt1a, 
carnitine palmitoyltransferase 1a; Dgat1, diglyceride acyltransferase 1; Fabp1, fatty acid binding protein 1; 
Fasn, fatty acid synthase; Mttp, microsomal triglyceride transfer protein; Ppara, peroxisome proliferative 
activated receptor alpha; Slc27a2, fatty acid transport protein 2; Slc27a4, fatty acid transport protein 4; 
Slc27a5, fatty acid transport protein 5; Srebf1, sterol-regulatory element binding protein.
contribution of plasma fa to Vldl-TG production
To measure the contribution of plasma derived FA to the VLDL-TG production in 
vivo, mice were fasted overnight as described above. Mice received a continuous i.v. 
infusion of 3H-labeled FA ([9,10(n)-3H] palmitic acid in PBS with 2% bovine serum 
albumin) at a rate of 100µL/h (1.6 µCi/h). After 2 hours of 3H-labeled FA infusion a 
blood sample was taken (t=0 min), and Triton WR-1339 (Sigma-Aldrich) was injected 
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intravenously (0.5 mg/g body weight, 10% solution in PBS) to block serum VLDL 
clearance. Additional blood samples were drawn 15, 30, 60 and 90 min after injection 
and used for determination of 3H activity in the TG fraction. Lipids were extracted 
by adding 10 µL plasma to 3.25 mL extraction fluid (heptane/methanol/chloroform; 
100:128:137 (v/v/v)). 3H-TG were subsequently separated from 3H-FA; 1mL potassium 
carbonate (0.1M K2CO3, pH 10.5) was added followed by vortexing and centrifugation 
(3600 rpm; 15 min), leading to an upper alkaline-methanol-aqueous phase containing 
saponified 3H-FA and a lower chloroform-organic phase containing 3H-TG.26 A fraction 
(0.5 mL) of the total aqueous phase (2.45 mL) was counted for 3H in scintillation fluid. 
The amount of 3H-TG in each sample was calculated by distracting total 3H-FA activity 
from total 3H activity. 
statistical analysis
Data are presented as means ± SD. Statistical differences were calculated using the 
Mann-Whitney test for two independent samples with SPSS 16.0 (SPSS Inc, Chicago, 
IL). P<0.05 was regarded statistically significant.
resUlTs
aspirin reduces hepatic nf-κb activation
To verify that aspirin inhibits hepatic NF-κB activity, the activities of the NF-κB 
subunits p50 and p65 were measured in livers of APOC1 and WT mice fed a HFD and 
treated with or without aspirin using a gel shift assay (Fig. 1). Aspirin indeed reduced 
the activity of both p50 (-69%; P<0.05) and p65 (-48%; P<0.05) in APOC1 mice (Fig. 
1A) and the activity of p50 in WT mice (-72%; P<0.05), while the reduction in the 
activity of p65 did not reach statistical significance (P=0.13) (Fig. 1B).
Figure 1. Aspirin reduces hepatic NF-κB activation. APOC1 and WT mice were fed a HFD 
for 6 weeks and treated without or with aspirin. Mice were sacrificed after an overnight fast and 
hepatic NF-κB activity was measured by electrophoretic mobility shift assay in liver tissue of 
APOC1 (A) and WT (B) mice treated without (open bars) or with (closed bars) aspirin. Activities 
of subunits p50 and p65 were measured. Values are means ± SD (n=3-4). *P<0.05
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aspirin lowers plasma triglyceride and cholesterol levels in hfd-fed APOC1 mice
To examine whether aspirin could reduce hypertriglyceridemia in APOC1 mice, 
hyperlipidemic APOC1 mice were fed a HFD for 6 weeks and treated with or without 
aspirin and plasma lipids were determined (Fig. 2). Treatment of mice with aspirin 
reduced plasma TG levels by -32% (3.94 ± 0.15 to 2.67 ± 0.59 mmol/L; P<0.05; Fig. 2A) 
and plasma TC levels by -33% (4.09 ± 0.52 to 2.76 ± 0.90 mmol/L; P<0.05; Fig. 2B). 
Aspirin treatment did not affect plasma PL levels (Fig. 2C) and FFA levels (Fig. 2D). The 
reduction in plasma TG and TC levels was not caused by a reduction in bodyweight, 
since aspirin did not affect bodyweight in APOC1 mice (control: 30.5 ± 2.1 g; aspirin: 
28.9 ± 3.0 g). In WT mice fed a HFD for 6 weeks, aspirin did not affect plasma TG, 
TC, PL or FFA levels (Fig. 2E-H). In addition, aspirin did not affect bodyweight in WT 
mice (control: 30.3 ± 2.1 g; aspirin: 30.8 ± 1.9 g)
aspirin attenuates Vldl-like emulsion particle-TG clearance in hfd-fed APOC1, but not wT mice
A reduction in fasted plasma TG levels can be explained by an increase in VLDL-TG 
clearance and/or a decrease in hepatic VLDL-TG production. To determine whether 
aspirin enhances the clearance of VLDL-TG, the plasma clearance and organ distribution 
of [3H]-TO-labeled TG-rich VLDL-like emulsion particles was evaluated in aspirin 
and control treated hypertriglyceridemic APOC1 mice (Fig. 3). Unexpectedly, aspirin 
inhibited, rather than enhanced, serum clearance of [3H]TO (t ½ = 15.9 ± 6.6 vs 5.6 ± 2.6 
min) (Fig. 3A) in APOC1 mice. This reduction in [3H]TO clearance upon aspirin was 
reflected by reduced uptake of [3H]TO-derived radioactivity by the liver by -60% (123 
± 1 vs 308 ± 75 nmol/g; P<0.05), by skeletal muscle by -66%  (11 ± 2 vs 31 ± 15 nmol/g; 
P<0.05) and by white adipose tissue (WAT), which reached statistical significance for 
gonadal WAT (12 ± 3 vs 44 ± 22 nmol/g; P<0.05) (Fig. 3B). Apparently, aspirin reduces 
rather than enhances TG clearance in APOC1 mice and can, therefore, not explain the 
aspirin-induced reduction in VLDL-TG. In WT mice fed a HFD for 6 weeks, aspirin 
did not affect plasma clearance of [3H]TO (Fig. 3C) or organ specific uptake of [3H]
TO-derived radioactivity (Fig. 3D) in WT mice. Apparently, the decreasing effect of 
aspirin on TG clearance may be specific for APOC1 mice.
aspirin lowers Vldl-TG production in hfd-fed APOC1 and wT mice
Because the decrease in plasma TG levels in APOC1 mice upon aspirin treatment was 
not caused by increased TG clearance, we investigated whether the decreased TG levels 
could be explained by diminished hepatic VLDL-TG production in APOC1 mice. The 
rate of hepatic VLDL-TG production was measured by determining plasma TG levels 
after intravenous Triton WR1339 injection (Fig 4). We found a reduction in hepatic 
VLDL-TG secretion rate in APOC1 mice treated with aspirin by -28% (3.42 ± 0.53 
vs 4.95 ± 1.11 mM/h; P<0.05) (Fig. 4A), whereas aspirin did not affect the rate of 
VLDL-apoB production (Fig. 4B). Interestingly, similar to our observation in APOC1 
mice, aspirin did reduce the hepatic VLDL-TG secretion rate in HFD-fed WT mice by 
-33% (2.79 ± 0.47 mM/h vs 4.19 ± 0.48 mM/h; P<0.05; Fig. 4C), whereas VLDL-apoB 
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Figure 2. Aspirin lowers plasma triglyceride and cholesterol levels in HFD-fed APOC1 mice. 
Plasma triglycerides (TG) (A&E), total cholesterol (TC) (B&F), phospholipids (PL) (C&G) 
and free fatty acid (FFA) (D&H) levels were measured in plasma of overnight-fasted HFD-fed 
APOC1 and WT mice treated without or with aspirin. Values are means ± SD (n=4-5). *P<0.05.
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production rate was also not affected (Fig. 4D). Apparently, aspirin generally reduces the 
VLDL-TG production in HFD-fed mice, independent of the genotype. Furthermore, 
since each VLDL particle contains a single apoB molecule, this observation shows that 
aspirin treatment inhibits hepatic VLDL-TG production, without affecting the rate of 
VLDL particle production.
aspirin does not affect liver lipid levels in hfd-fed APOC1 and wT mice
To determine whether the attenuation in hepatic VLDL-TG production was the result 
of decreased lipid substrate availability in the liver, the effect of aspirin on hepatic lipid 
content was measured (Fig. 5). However, aspirin did not affect liver TG levels (Fig. 5A) 
Figure 3. Aspirin attenuates TG clearance of VLDL-like emulsion particles in HFD-fed 
APOC1, but not WT mice. HFD-fed APOC1 and WT mice that were treated without or with 
aspirin were fasted overnight and injected with [3H]TO-labeled VLDL-like emulsion particles. 
Blood was collected at the indicated time points and radioactivity was measured in plasma of 
APOC1 (A) and WT (C) mice treated without (open circles) or with (closed circles) aspirin. 
Uptake of [3H]TO-derived activity by various organs was determined, and total FA uptake was 
calculated from the specific activity of TG in plasma, and expressed as nmol FA per mg wet tissue 
weight in APOC1 (B) and WT (D) mice. Values are means ± SD (n=4). *P<0.05. WAT, white 
adipose tissue; intest, intestinal; sc, subcutaneous; gon, gonadal.
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and TC levels (Fig. 5B) in APOC1 mice. Also, aspirin did not affect liver TG (Fig. 5C) 
or TC (Fig. 5D) levels in WT mice.
aspirin treatment does not affect hepatic expression of genes involved in fa oxidation, 
lipogenesis or Vldl production
Since changes in hepatic gene expression could underlie the reduction in VLDL-TG 
production, we determined the effect of aspirin on expression of genes involved in 
FA oxidation, lipogenesis and VLDL production (Table 2). In both APOC1 and WT 
mice, aspirin did not affect expression of peroxisome proliferative activated receptor 
alpha (Ppara), a transcription factor that regulates genes involved in FA oxidation and 
ketogenesis, nor did it affect its target genes acyl-Coenzyme A oxidase 1 (Acox1) and 
carnitine palmitoyltransferase 1a (Cpt1a). In line with these results, aspirin did not 
Figure 4. Aspirin decreases VLDL-TG production in HFD-fed APOC1 and WT mice. APOC1 
and WT mice were fed a HFD and treated without or with aspirin. Overnight fasted mice were 
injected with Trans35S and TritonWR1339 and blood samples were drawn at the indicated time 
points. TG concentrations were determined in APOC1 (A) and WT (C) mice treated without 
(open circles) or with (closed circles) aspirin and plotted as the increase in plasma TG relative to 
t=0 (A). After 120 min, VLDL was isolated by ultracentrifugation, 35S-activity was counted and 
the production rate of newly synthesized VLDL-35S-apoB was determined for APOC1 (B) and 
WT (D). Values are means ± SD (n=5). *P<0.05.
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increase plasma ß-HB levels in WT mice (data not shown), which is a plasma marker 
for hepatic FA oxidation and ketogenesis. This implies that the reduced VLDL-TG 
production upon aspirin treatment is not caused by increased hepatic FA oxidation. 
We additionally determined the effect of aspirin on expression of genes involved in 
lipogenesis. In both APOC1 and WT mice, aspirin did not affect expression of sterol 
regulatory element binding protein 1c (Srebp-1c), which regulates genes required for 
de novo lipogenesis, nor did it affect acyl:diacylglycerol transferase 1 (Dgat1), which 
catalyzes the final and only committed step in TG synthesis, or FA synthase (Fas), which 
plays a key role in FA synthesis. These data suggests that aspirin does not affect genetic 
regulation of de novo lipogenesis. In addition, even though aspirin induced an increase 
of VLDL-TG secretion, aspirin did not affect hepatic gene expression of microsomal 
TG transfer protein (Mttp) which is involved in the assembly and secretion of VLDL. 
Furthermore, aspirin does not affect hepatic gene expression of apoB (Apob) in APOC1 
mice, which is in line with the observation that aspirin does not affect VLDL-apoB 
secretion in vivo. However, despite the fact that aspirin did not affect VLDL-apoB 
secretion in WT mice, gene expression of Apob was increased in WT mice.
Figure 5. Aspirin does not affect liver lipids in HFD-fed APOC1 and WT mice. Livers were 
collected from overnight-fasted HFD-fed APOC1 and WT mice treated without or with aspirin. 
Lipids were extracted and triglyceride (TG, A&C) and total cholesterol (TC, B&D) concentrations 
were measured and expressed per mg protein. Values are means ± SD (n=6).
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aspirin treatment decreases the contribution of plasma-derived fa to the Vldl-TG  production
Because the decrease in VLDL-TG production was not caused by a reduced hepatic 
lipid content or decreased expression of genes involved in de novo lipogenesis that could 
reduce lipid availability for VLDL-TG secretion, we investigated whether the decreased 
VLDL-TG production could be explained by a diminished contribution of plasma 
derived FA for VLDL-TG secretion in WT mice (Fig. 6). The contribution of plasma 
derived FA was measured by determining plasma 3H-TG levels after continuous 3H-FA 
infusion and intravenous Triton WR1339 injection. We found that aspirin reduced 
hepatic 3H-TG secretion rate in WT mice by -24% (3.1 ± 0.4 vs 2.4 ± 0.7 x 103 dpm/h; 
P<0.05), which suggests that aspirin reduces VLDL-TG production by reducing the 
incorporation of plasma-derived FA into VLDL-TG. This reduction is not caused by 
a reduced hepatic expression of genes involved in hepatic FA uptake and transport 
(Table 2), since aspirin did not affect liver-type FA binding protein (Fabp1), FA 
transport proteins 2, 4 and 5 (Slc27a2, Slc27a4, Slc27a5) and even increased expression 
of FA translocase (Cd36) in APOC1, but not WT, mice. These data imply that aspirin 
reduced the VLDL-TG production independent of changes in hepatic expression of 
genes involved in FA uptake and transport.
discUssion
Treatment of obese rodents and patients with type 2 diabetes with high dose aspirin 
reduces hypertriglyceridemia.13,14 However, so far, the mechanistic basis for the relation 
between aspirin intake and reduced plasma TG levels has been poorly understood. 
In the present study we focused on the effects of aspirin on VLDL-TG metabolism 
in HFD-induced obese hyperlipidemic APOC1 mice and additionally evaluated the 
effects of aspirin on VLDL-TG metabolism in HFD-fed normolipidemic WT mice. Our 
results document that aspirin treatment improves hypertriglyceridemia by reducing the 
hepatic production of VLDL-TG as a result of an attenuated hepatic incorporation of 
plasma derived FA into VLDL-TG, rather than from increased clearance of VLDL-TG 
from the circulation.
Figure 6. Aspirin reduces the contribution of 
plasma derived FA to the VLDL-TG production. 
WT mice were fed a HFD and treated without or 
with aspirin. Overnight fasted mice received a 
continuous i.v. infusion of 3H-labeled FA ([9,10(n)-
3H] palmitic acid for 2 h, followed by an i.v. injection 
of TritonWR1339. Blood samples were drawn at 
the indicated time points and 3H activity in the TG 
fraction was determined in mice treated without 
(open circles) or with (closed circles) aspirin and 
plotted as the increase in plasma 3H-TG relative to 
t=0. Values are means ± SD (n=7). *P<0.05.
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In the present study, aspirin treatment decreased plasma TG and TC levels in 
HFD fed APOC1 mice that display hypertriglyceridemia. This improvement in 
hyperlipidemia is in accordance with earlier studies, showing reduced serum TG 
concentrations upon aspirin or salicylate treatment in patients with type 2 diabetes 
mellitus14 and in diabetic rats.13 
Our data show that aspirin treatment attenuated the clearance of VLDL-like TG-rich 
particles in APOC1 mice. Therefore, the decrease in plasma TG levels by aspirin can 
not be explained by increased TG clearance. Earlier studies report that high dose LPS 
injections reduce the clearance of TG-rich lipoproteins by inhibition of the LPL activity, 
mediated by cytokines.6,27 If indeed inflammation inhibits clearance of TG, inhibition 
Table 2. Aspirin generally does not affect hepatic expression of genes involved in FA uptake 
and transport, FA oxidation, lipogenesis or VLDL secretion.
    Gene Protein
APOC1 WT
Control Aspirin p-value Control Aspirin p-value
FA uptake and transport
   Fabp1 FABP1 1.00 ± 0.37 0.73 ± 0.35 0.22 1.00 ± 0.41 0.61 ± 0.25 0.14
   Slc27a2 FATPa2 1.00 ± 0.45 1.23 ± 0.49 0.46 1.00 ± 0.33 0.74 ± 0.16 0.14
   Slc27a4 FATPa4 1.00 ± 0.35 1.74 ± 0.51 0.13 1.00 ± 0.44 1.01 ± 0.47 0.77
   Slc27a5 FATPa5 1.00 ± 0.17 1.20 ± 0.39 0.18 1.00 ± 0.40 0.96 ± 0.31 0.62
   Cd36 CD36 1.00 ± 0.58 1.75 ± 0.40 0.05 1.00 ± 0.80 0.45 ± 0.22 0.23
FA oxidation
   Ppara PPARα 1.00 ± 0.29 1.12 ± 0.46 0.62 1.00 ± 0.37 0.72 ± 0.18 0.18
   Acox1 ACO 1.00 ± 0.42 1.55 ± 0.55 0.14 1.00 ± 0.36 0.59 ± 0.12 0.09
   Cpt1a CPT1a 1.00 ± 0.55 1.36 ± 0.43 0.22 1.00 ± 0.10 0.96 ± 0.11 0.46
Lipogenesis
   Dgat1 DGAT1 1.00 ± 0.37 1.20 ± 0.11 0.29 1.00 ± 0.42 1.06 ± 0.53 0.85
   Fasn FAS 1.00 ± 0.42 1.05 ± 1.09 0.81 1.00 ± 0.40 0.97 ± 0.27 0.90
   Srebf1 SREBP-1c 1.00 ± 0.40 1.22 ± 0.53 0.41 1.00 ± 0.53 0.85 ± 0.68 0.72
VLDL secretion
   Apob ApoB 1.00 ± 0.46 1.20 ± 0.26 0.73 1.00 ± 0.32 1.59 ± 0.31* 0.03
   Mttp MTP 1.00 ± 0.37 0.87 ± 0.21 0.56 1.00 ± 0.39 1.21 ± 0.12 0.34
Livers were isolated from overnight fasted APOC1 and WT mice fed a HFD and treated without or with 
aspirin. mRNA was isolated and mRNA expression of the indicated genes was quantified by RT-PCR. Genes 
are grouped as genes involved in FA uptake and transport, FA oxidation, lipogenesis and VLDL production. 
Data are calculated as fold difference as compared to the control group. Values are means ± SD (n=4-5). 
*P<0.05 compared to control group. Acox1, acyl-Coenzyme A oxidase 1, palmitoyl; Apob, apolipoprotein 
B; Cd36, fatty acid translocase; Cpt1a, carnitine palmitoyltransferase 1a, liver; Dgat1, diglyceride acyltrans-
ferase 1; Fabp1, fatty acid binding protein 1, liver; Fasn, fatty acid synthase; Mttp, microsomal triglyceride 
transfer protein; Ppara, peroxisome proliferative activated receptor alpha; Slc27a2, fatty acid transport 
protein 2; Slc27a4, fatty acid transport protein 4; Slc27a5, fatty acid transport protein 5; Srebpf1, sterol-
regulatory element binding protein.
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of inflammation by aspirin is expected to increase TG-rich lipoprotein clearance, which 
is in contrast to our observation in APOC1 mice. It should be noted that aspirin, in 
addition to inhibition of inflammation via NF-κB, also inhibits prostaglandin synthesis, 
which has been demonstrated to restore the LPS-induced inhibition of LPL.28 Moreover, 
an early report has shown that aspirin treatment inhibits post-heparin LPL activity in 
humans.29 It would be interesting to elucidate the mechanism by which aspirin reduces 
the VLDL-TG clearance, however this is beyond the scope of the current manuscript 
as it does not explain the reduction in hypertriglyceridemia that we observe. Moreover, 
the observation may be a specific feature of the APOC1 transgenic mouse model, since 
we did not observe such an effect in WT mice.
Aspirin very effectively reduced hepatic secretion of VLDL-TG in APOC1 mice, 
explaining the reduction in hypertriglyceridemia upon aspirin treatment. In addition, 
aspirin equally reduced hepatic secretion of VLDL-TG in WT mice, indicating 
that the effects of aspirin on the VLDL-TG production do not exclusively occur in 
hypertriglyceridemic mouse models such as the APOC1 mouse. To our knowledge, 
we show for the first time that a decrease in inflammation corresponds with a drop 
in VLDL-TG production. The reduction of VLDL-TG secretion in our study is not 
paralleled by a reduction in apoB secretion in both APOC1 and WT mice, suggesting 
that aspirin reduces the lipidation of VLDL particles rather than reducing the number 
of particles that are secreted by the liver. In contrast to our data on apoB secretion, 
a recent study by Tsai et al30 observed that suppression of IKK with BMS345541 
decreased apoB secretion in vitro in primary hamster hepatocytes and HepG2 cells. 
Even though differences between species might explain these conflicting findings, both 
these published in vitro studies and our present in vivo study point towards a link 
between the IKK/NF-κB pathway and the regulation of VLDL production. Moreover, 
we have recently shown that activation of the hepatic IKK/NF-κB pathway increases 
VLDL-TG production,31 supporting the hypothesis that the effects of aspirin on 
the VLDL-TG production are mediated via a reduction in hepatic NF-κB activity. 
Nevertheless, activation of hepatic IKK/NF-κB increases hepatic Fas expression,31 
while aspirin in the current study did not change hepatic expression of Fas, neither 
did it change expression of other genes involved in TG synthesis, such as Dgat1 and 
Srepb-1c, suggesting that aspirin more likely lowers VLDL-TG production by other 
mechanisms than via its effects on hepatic NF-κB activity.  
A reduction in hepatic lipid availability by increased lipid oxidation could underlie 
the mechanism by which aspirin reduces hepatic VLDL-TG production. However, 
aspirin did not affect expression of genes involved in FA oxidation nor plasma levels 
of ß-HB, a marker of hepatic FA oxidation and ketogenesis. Similarly, aspirin did 
not affect expression of genes involved in de novo lipogenesis or VLDL production, 
suggesting that aspirin does not reduce VLDL-TG production by changing expression 
of genes involved in hepatic lipid metabolism. 
It has been suggested that the decrease in plasma TG concentration that occurs upon 
aspirin treatment might be secondary to the fall in plasma FFA levels.32 A reduction in 
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FFA delivery to the liver could result in a reduced availability of FA for the release of 
VLDL-TG by the liver.33 Indeed, although aspirin did not change plasma FFA levels, 
it changed the turnover of FA as reflected by a -24% reduction in the incorporation of 
plasma derived FA into VLDL-TG, showing that aspirin in fact lowers the availability 
of plasma derived FA for VLDL-TG production. This reduction of FA incorporation 
into VLDL-TG upon aspirin treatment was not caused by a reduced hepatic expression 
of FA transporter proteins, suggesting that aspirin reduces the FA incorporation via 
another mechanism. It is possible that aspirin reduces posttranscriptional processing of 
FA transporters independent of mRNA expression, since expression of FA transporters 
does not always correlate with changes in protein content or the rate of FA transport.34 
Alternatively, aspirin might increase FA uptake and transport via simple diffusion, 
since FA uptake has been described independent of any FA transporter.34 
The decrease of FA turnover that we observed could be secondary to an increased 
insulin sensitivity of adipose tissue, thereby decreasing FA mobilization to plasma. 
Indeed, high dose salicylates, such as aspirin have shown to increase insulin sensitivity13 
and the reduction in VLDL-TG production in our study is similarly accompanied 
by an increased insulin sensitivity (unpublished observation). However, the aspirin-
induced reduction in FA utilization and subsequent VLDL-TG secretion in our study 
were determined under fasting conditions, when the role of insulin is marginal. In 
fasting conditions, the lipolytic activity of adipocytes is stimulated by catecholamines. 
Interestingly, aspirin has been reported to reduce catecholamine-stimulated lipolysis, 
which is therefore a more likely explanation for our findings.35,36 In addition, it has been 
shown that aspirin reduces release of FA from adipose tissue directly via inhibition 
of TNF-α induced lipolysis.37 We therefore propose that the fact that aspirin reduces 
plasma derived FA utilization by the liver, is likely caused via direct inhibition of 
intracellular lipolysis in adipose tissue, which reduces plasma FA availability. Adipose 
tissue lipolysis might be further inhibited in the fed state by an increased sensitivity 
for insulin.
In conclusion, our data show that aspirin inhibits NF-κB and decreases HFD-
induced hypertriglyceridemia by reducing hepatic VLDL-TG secretion rather than 
by accelerating the tissue distribution of VLDL-TG. The reduction in VLDL-TG is 
not caused by a decreased steatosis, increased FA oxidation or changes in de novo 
lipogenesis, but by an attenuation of hepatic incorporation of plasma derived FA into 
VLDL-TG. In scope of our findings, aspirin could potentially be a new therapeutic 
drug in the treatment of hypertriglyceridemia. However, chronic high-dose aspirin is 
associated with risk for bleeding. Salsalate on the other hand is a non-steroidal anti-
inflammatory drug with similar structure that is regarded as a safer alternative. High-
dose salsalate treatment has recently shown to reduce TG levels in diabetic patients 
similar to high-dose aspirin treatment,38 and could therefore potentially be a new drug 
for the treatment of hypertriglyceridemia.
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absTracT
Low-grade inflammation in different tissues, including activation of the nuclear 
factor κB (NF-κB) pathway in liver, is involved in metabolic disorders such as 
type 2 diabetes and cardiovascular diseases (CVD). In this study we investigated 
the relation between chronic hepatocyte-specific overexpression of IKK-β and 
hypertriglyceridemia, an important risk factor for CVD, by evaluating whether 
activation of IKK-β only in the hepatocyte affects VLDL-triglyceride (TG) 
metabolism directly. Transgenic overexpression of constitutively active human IkB 
kinase (IKK-β) specifically in hepatocytes of hyperlipidemic APOE*3-Leiden mice 
clearly induced hypertriglyceridemia. Mechanistic in vivo studies revealed that 
the hypertriglyceridemia was caused by increased hepatic VLDL-TG production, 
rather than a change in plasma VLDL-TG clearance. Studies in primary hepatocytes 
showed that IKK-β overexpression also enhances TG secretion in vitro, indicating a 
direct relation between IKK-β activation and TG production within the hepatocyte. 
Hepatic lipid analysis and hepatic gene expression analysis of pathways involved in 
lipid metabolism suggested that hepatocyte specific IKK-β overexpression increases 
VLDL production not by increased steatosis or decreased FA oxidation, but most likely 
by ChREBP-mediated upregulation of Fas expression. These findings implicate that 
specific activation of inflammatory pathways exclusively within hepatocytes induces 
hypertriglyceridemia. Furthermore, we identify the hepatocytic IKK-β pathway as a 
possible target to treat hypertriglyceridemia.
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inTrodUcTion
Obesity is associated with diseases such as dyslipidemia, type 2 diabetes and 
cardiovascular disease (CVD). The accumulation of lipids in numerous tissues is 
accompanied by increased inflammatory processes, such as macrophage infiltration 
and production of inflammatory mediators in white adipose tissue. In liver, fat 
accumulation increases the activity of the pro-inflammatory nuclear factor κB 
(NF-κB), and liver-specific activation of NF-κB induces metabolic disturbances.1,2 
Hypertriglyceridemia is caused by accumulation of VLDL particles in the 
plasma as a consequence of changes in lipid metabolism that are associated with 
obesity. Proinflammatory cytokines can cause hypertriglyceridemia3 and, conversely, 
suppression of inflammation may reduce hypertriglyceridemia4 suggesting a direct 
causal role for inflammatory pathways in the development of hypertriglyceridemia. 
In fact, administration of lipopolysaccharide (LPS), an inflammatory component of 
the outer membrane of Gram-negative bacteria, increases plasma triglyceride (TG) 
levels.5 However, many inflammatory mediators affect multiple tissues, such as muscle, 
adipose tissue and liver and, moreover, they can act on multiple cell types including 
macrophages. The specific contribution of hepatocytes in the relation between 
inflammation and TG metabolism has never been studied. 
In the current study we, therefore, aimed to investigate whether activation of the 
inflammatory NF-κB pathway exclusively in hepatocytes affects VLDL-TG metabolism 
and, as a consequence, causes hypertriglyceridemia. To this end, we used hepatocyte-
specific transgenic IKK-β (LIKK) mice, which have been described before.1 LIKK mice 
have an albumin promoter to drive expression of constitutively active human IκB 
kinase β (IKK-β), which activates the NF-κB pathway selectively in hepatocytes. To 
study the effects of the hepatocyte-specific inflammation on VLDL-TG metabolism, 
we crossbred the LIKK mouse with the transgenic APOE*3-Leiden (E3L) mouse that 
expresses human APOE*3-Leiden (a mutant form of APOE3) and human APOC1,6 
both of which attenuate the clearance of apoE-containing TG-rich lipoproteins. 
Therefore, the E3L mouse shows increased plasma TG and cholesterol levels and is 
a well-established model of human-like lipoprotein metabolism.7 By using the E3L.
LIKK mouse, we were able to study the effects of the inflammatory NF-κB pathway 
in the hepatocyte on TG-rich lipoprotein metabolism directly. Our results show that 
activation of NF-κB in hepatocytes of E3L mice induces hypertriglyceridemia by 
enhancing VLDL-TG production directly within hepatocytes.
maTerials and meThods
animals
LIKK mice, which express constitutively active human IKK-β selectively in hepatocytes 
under control of the albumin promoter1 were crossbred with E3L mice,6 expressing 
both human APOE*3-Leiden and human APOC1, in our animal facility to obtain 
heterozygous E3L.LIKK mice on a C57Bl/6J background. Male E3L.LIKK and E3L 
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littermates were housed under standard conditions with a 12-hour light-dark cycle 
and were fed a standard mouse chow diet with free access to water. Experiments 
were performed in 14-week old animals after an overnight fast. All experiments were 
approved by the institutional ethical committee on animal care and experimentation.
western blot analysis
Tissues were homogenized by Ultraturrax (22,000 rpm; 2x5 sec) in an ice-cold buffer 
(pH 7.4) containing 30 mM Tris.HCl, 150 mM NaCl, 10 mM NaF, 1 mM EDTA, 
1 mM Na3VO4, 0.5% (v/v) Triton X-100, 1% (v/v) SDS and protease inhibitors 
(Complete, Roche, Mijdrecht, The Netherlands) at a 1:6 (w/v) ratio. Homogenates were 
centrifuged (16,000 rpm; 15 min, 4°C) and the protein content of the supernatant was 
determined using the BCA protein assay kit (Pierce, Rockford, IL). Proteins (20-50 
µg) were separated by 7-10% SDS-PAGE followed by transfer to a polyvinylidene 
fluoride (PVDF) membrane. Membranes were blocked for 1 h at room temperature 
in Tris-buffered saline with Tween-20 (TBST) with 5% non-fat dry milk followed by 
an overnight incubation with the following antibodies: p-Ser536 NF-κB p65 (#3031), 
NF-κB p65 (#3034), p-Ser32/36 IκBα (#9246), IκBα (#9242) (all from Cell Signalling), 
MTP (#612022) (BD Biosciences, Erembodegem, Belgium) and DGAT1 (#54037) 
(Abcam, Cambridge, UK). Blots were then incubated with a horseradish peroxidase 
(HRP)-conjugated secondary antibodies for 1 h at room temperature. Bands were 
visualized by enhanced chemiluminescence (ECL) and quantified using Image J (NIH).
plasma lipids and lipoprotein profiles
Blood was collected from the tail vein into chilled paraoxon (Sigma, St Louis, MO)-
coated capillaries to prevent ongoing lipolysis.8 Capillaries were placed on ice, 
centrifuged and plasma was assayed for TG, total cholesterol (TC), and phospholipids 
(PL) using commercially available enzymatic kits from Roche Molecular Biochemicals 
(Indianapolis, IN). Free fatty acids (FFA) were measured using NEFA-C kit from 
Wako Diagnostics (Instruchemie, Delfzijl, the Netherlands). For the determination of 
lipid distribution over plasma lipoproteins, 50 µL of pooled plasma was used for fast 
performance liquid chromatography (FPLC). Plasma was injected onto a Superose 6 
column (Äkta System; Amersham Pharmacia Biotech, Piscataway, NJ), and eluted at 
a constant flow rate of 50 µL/min with PBS pH 7.4. TG and TC were measured as 
described above in collected fractions of 50 µL. 
liver lipids
Lipids were extracted from livers according to a modified protocol from Bligh and 
Dyer.9 Briefly, a small piece of liver was homogenized in ice-cold methanol. After 
centrifugation, lipids were extracted by addition of 1800 µL CH3OH:CHCl3 (3:1 v/v) 
to 45 µL homogenate. The CHCl3 phase was dried and dissolved in 2% Triton X-100. 
Hepatic TG and TC concentrations were measured using commercial kits as described 
earlier. Liver lipids were expressed per mg protein, which was determined using the 
BCA protein assay kit.
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fa composition of liver TG
Liver samples (100 mg) were homogenized with 0.5 mL saline. Subsequently, 5 mL of 
chloroform: methanol (2: 1 by volume) was added containing butylated hydroxytoluene 
(BHT). In addition, an internal TG standard was added before extraction. Liver lipids 
were extracted according to the method of Folch et al.10 Total TG were separated by 
spotting lipid extracts onto silica gel 60 (Merk) thin-layer chromatography plates 
and running in hexane: diethyl ether: acetic acid (85: 15: 1, v/v/v). Lipid bands were 
visualized under UV light after spraying with 0.1% ANS (8-anilino-1-naphthalene 
sulfonic acid), and identified using commercial standards. TG bands were scraped 
into glass tubes and methylated at 80°C with 1.5% H2SO4 in methanol for 2 h. TG-
derived FA were eluted into hexane. Separation and quantification of the FA methyl 
esters (FAMEs) from liver TG was achieved using gas chromatography, on an Agilent 
6890 GC (Agilent Technologies, UK) fitted with a 30 m x 0.53 mm (film thickness 1 
µm) capillary column (RTX-Wax). Individual FA peaks were identified by a reference 
containing known FAMEs. FA compositions (mol%) were then determined.
Generation of Vldl-like emulsion particles
VLDL-like TG-rich emulsion particles were prepared and characterized as described 
previously.11,12 Lipids (100 mg) at a weight ratio of triolein: egg yolk phosphatidylcholine: 
lysophosphatidylcholine: cholesteryl oleate: cholesterol of 70: 22.7: 2.3: 3.0: 2.0, 
supplemented with 200 µCi of glycerol tri[9,10(n)-3H]oleate ([3H]TO) were sonicated at 
10 µm output using a Soniprep 150 (MSE Scientific Instruments, Crawley, UK). Density 
gradient ultracentrifugation was used to obtain 80 nm-sized emulsion particles, which 
were used for subsequent experiments. TG content of the emulsions was measured as 
described above. Emulsions were stored at 4°C under argon and used within 7 days.
In vivo clearance of Vldl-like emulsion particles
To study the in vivo clearance of the VLDL-like emulsion particles, overnight fasted 
mice were anesthetized by intraperitoneal injection of acepromazine (6.25 mg/kg 
Neurotranq, Alfasan International BV, Weesp, The Netherlands), midazolam (6.25 mg/
kg Dormicum, Roche Diagnostics, Mijdrecht, The Netherlands), and fentanyl (0.31 
mg/kg Janssen Pharmaceuticals, Tilburg, The Netherlands). Mice were injected (t=0) 
via the tail vein with 200 µL of [3H]TO-labeled emulsion particles at a dose of 100 µg of 
TG per mouse. Blood samples were taken from the tail vein at 1, 2, 5, 10 and 15 minutes 
after injection and plasma 3H-activity was counted. Plasma volumes were calculated as 
0.04706 x body weight (g) as determined from 125I-BSA clearance studies as described 
previously.13 After taking the last blood sample, the liver, heart, spleen, muscle and 
white adipose tissue (i.e. gonadal, subcutaneous and visceral) were collected. Organs 
were dissolved overnight at 60°C in Tissue Solubilizer (Amersham Biosciences, 
Rosendaal, The Netherlands) and 3H-activity was counted. Uptake of [3H]TO-derived 
radioactivity by the organs was calculated from the 3H activity in each organ divided by 
plasma-specific activity of [3H]TG and expressed per mg wet tissue weight.
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In vivo hepatic Vldl-TG and Vldl-apob production
To measure VLDL production in vivo, mice were fasted overnight and anesthetized 
as described above. Mice were injected intravenously with Tran35S label (150 µCi/
mouse; MP Biomedicals, Eindhoven, The Netherlands) to label newly produced 
apolipoprotein B (apoB). After 30 minutes, at t=0 min, Triton WR-1339 (Sigma-
Aldrich) was injected intravenously (0.5 mg/g body weight, 10% solution in PBS) to 
block serum VLDL clearance. Blood samples were drawn before (t=0) and 15, 30, 60 
and 90 min after injection and used for determination of plasma TG concentration 
as described above. After 120 min, mice were exsanguinated via the retro-orbital 
plexus and euthanized by cervical dislocation. VLDL was isolated from serum after 
density gradient ultracentrifugation at d<1.006 g/mL by aspiration14 and counted for 
incorporated 35S-activity. 
isolation of primary mouse hepatocytes.
Primary hepatocytes were isolated from mouse livers according to the method of Berry 
and Friend15 modified by Groen et al.16 Briefly, the portal vein was cannulated and liver 
was first perfused with a calcium-free Krebs/bicarbonate buffer, saturated with 95% 
O2 and 5% CO2 at a flow rate of 5 mL/min. Subsequently, perfusion of the liver was 
continued with calcium-containing Krebs/bicarbonate buffer with 0.0125% collagenase 
(Roche, Penzberg, Germany) during 10-15 min until cellular dissociation was 
observed. Cells were gently released and centrifuged four times at 50g for 1 min at 4°C 
to remove non-parenchymal cells from pelleted hepatocytes. Isolated hepatocytes were 
washed and suspended in complete Williams’ E medium containing insulin (Actrapid), 
fetal calf serum, dexamethasone and penicillin/streptomycin (P/S). Hepatocytes were 
isolated with similar yields from livers of E3L.LIKK and E3L mice, 70-80% viable, 
as assessed by trypan blue dye exclusion, and 99% free of non-parenchymal cells by 
visual inspection. No differences with respect to viability were observed between cells 
isolated from E3L.LIKK and E3L mice. Cells were seeded into 12-well dishes (Greiner 
Bio-One), pre-coated with collagen at a density of 1.0x106 viable cells/well in 2 mL 
complete Williams’ E medium. After a 2 h adherence period, non-attached cells were 
removed from the cultures by careful washing.
 In vitro measurement of TG secretion by hepatocytes
TG secretion in vitro was measured as described previously.17 After an overnight 
incubation, cells were washed 2 times and incubated 4 h in fetal calf serum-free and 
hormone-free (SF-HF) Williams’ E medium. To measure rates of secretion of TG, cells 
were subsequently incubated in SF-HF medium containing 4.4 µCi of [3H]glycerol 
(Amersham; UK) with or without 0.75 mM oleate (C18:1) complexed with BSA to 
stimulate lipogenesis. After 1, 2, 4 or 20 h incubation, medium was collected and 
cells were washed three times and harvested in 2 mL PBS. Lipids were extracted from 
medium according to a modified protocol from Bligh and Dyer.9,17 The lipids were dried 
under nitrogen, dissolved into chloroform with 2 mM tripalmitin added as a carrier 
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and subjected to TLC (Silica gel 60, Merck, Belgium) using hexane: diethylether: acetic 
acid (80/20/1; v/v/v) as mobile phase. Lipid spots were visualized using iodine vapor, 
and tripalmitin-positive spots were scraped off, dissolved in 0.5 M acetic acid, and 
assayed for radioactivity by scintillation counting. Protein content of the cells was 
determined using the BCA protein assay kit as described earlier. Data are expressed as 
dpm/mg protein.
hepatic gene expression analysis
Total RNA was extracted from liver tissues using the Nucleospin RNA II kit (Macherey-
Nagel, Düren, Germany) according to manufacturer’s instructions. RNA quality of 
each sample was examined by lab-on-a-chip technology using Experion Std Sens 
analysis kit (Biorad, Hercules, CA, USA). One µg of total RNA was reverse-transcribed 
with iScript cDNA synthesis kit (Bio-Rad) and the obtained cDNA was purified with 
Nucleospin Extract II kit (Macherey-Nagel). Real-Time PCR was carried out on the 
IQ5 PCR machine (Biorad) using the Sensimix SYBR Green RT-PCR mix (Quantace, 
London, UK). mRNA levels were normalized to mRNA levels of cyclophilin (Cyclo) 
and glyceraldehyde-3-phosphate dehydrogenase (Gapdh). Primer sequences are listed 
in Supplemental Table S1. 
statistical analysis
Data are presented as means ± SD. Statistical differences were calculated using the 
Mann-Whitney test for two independent samples with SPSS 16.0 (SPSS Inc, Chicago, 
IL). P<0.05 was regarded statistically significant.
resUlTs
likk increases liver nf-kb signalling in e3l mice
To verify that LIKK expression in E3L mice increases hepatic NF-κB signalling, livers 
from E3L and E3L.LIKK mice were assayed for the presence of phosphorylated over total 
NF-κB and IκBα using Western blot (Fig. 1). Indeed, expression of LIKK increased the 
ratio of pNF-κB Ser536 over NF-κB (1.6 ± 0.4 fold; P<0.05) (Fig. 1A, B) as well as that of 
pIκBα Ser32/36 over IκBα (1.9±0.6 fold; P<0.05) (Fig. 1C, D). The increased ratio of pIκBα 
Ser32/36 over IκBα was mainly caused by a decrease of total IκBα (0.8±0.1 fold; P<0.05), 
indicating increased IκBα ubiquitination and degradation by the proteasome, which 
reflects activation of the NF-κB pathway. These data are in line with the increased NF-κB 
signalling previously observed in LIKK mice as compared to wild-type (WT) mice.1
likk induces hypertriglyceridemia in e3l mice
To determine whether the hepatocyte-specific inflammation affects plasma lipid levels, 
TG, TC, PL and FFA levels were measured in plasma of E3L and E3L.LIKK mice 
(Fig. 2). LIKK expression in E3L mice increased TG by +39% (2.90±0.52 vs 2.09±0.28 
mmol/L; P<0.05; Fig. 2A), TC by +18% (2.24±0.25 vs 1.90±0.28 mmol/L; P<0.05; 
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Fig. 2B), and PL by +22% (2.12±0.18 vs 1.74±0.27 mmol/L; P<0.05; Fig. 2C). LIKK did 
not affect plasma FFA levels (Fig. 2D). Lipoprotein profiling showed that the LIKK-
induced increase in plasma TG could be explained by a rise in VLDL-TG (+42%) 
(Fig. 2E). Likewise, the increase in TC was mainly  reflected by an increase in VLDL-C 
(+54%), LDL-C (+34%) and HDL-C (+25%) (Fig. 2F).
likk does not affect clearance of Vldl-like emulsion particle-TG in e3l mice
Hypertriglyceridemia is caused by a decrease in VLDL-TG clearance and/or an increase 
in hepatic VLDL-TG production. To investigate whether LIKK inhibits the clearance 
of VLDL-TG, the plasma clearance and organ distribution of [3H]TO-labeled TG-rich 
VLDL-like emulsion particles was evaluated in E3L.LIKK versus E3L mice (Fig. 3). 
LIKK did not affect the plasma half-life of [3H]TO (Fig. 3A), nor the uptake of [3H]
TO-derived fatty acids (FA) by the various organs (Fig. 3B), indicating that LIKK does 
not increase plasma TG levels by decreasing TG clearance.
likk increases Vldl-TG production in e3l mice
As no difference was observed in TG clearance between E3L.LIKK and E3L mice, 
it is likely that the LIKK-induced increase in plasma TG levels can be explained by 
Figure 1. LIKK increases hepatic NF-κB signaling in E3L mice. E3L and E3L.LIKK mice 
were fed a chow diet and sacrificed at the age of 14 weeks after an overnight fast. NF-κB 
signaling was measured in liver tissue by phosphorylation of NF-κB (A,C) and IκB (B,D). 
Representative Western blots of phosphorylated NF-κB (NF-κB Ser536) and total NF-κB (A) 
and phosphorylated IκBα (pIκBα Ser32/36) and total IκBα (B) are shown for 3 mice per group. 
Ratios of phosphorylated proteins over total proteins were quantified (B,D). Values are means ± 
SD (n=5-7). *P<0.05.
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Figure 2. LIKK induces hyperlipidemia in E3L mice. Plasma triglycerides (TG) (A), total 
cholesterol (TC) (B), phospholipids (PL) (C) and free fatty acid (FFA) (D) levels were measured 
in plasma of overnight fasted E3L and E3L.LIKK mice. Values are means ± SD (n=5-7). *P<0.05. 
Plasma was collected, pooled per group, and subjected to FPLC to separate lipoproteins. 
Distribution of TG (E) and TC (F) over lipoproteins was determined.
an increase of VLDL-TG production. The rate of hepatic VLDL-TG production was 
measured by determining plasma TG levels after intravenous Triton WR1339 injection 
(Fig. 4). Indeed, LIKK strongly increased the accumulation of plasma TG at all time 
points (Fig. 4A). The VLDL-TG production rate, as determined from the slope of 
the curve from all individual mice, was increased by +48% (3.90 ± 1.01 vs 2.64 ± 
0.82 mM/h, P<0.05) (Fig. 4B), whereas the rate of VLDL-apoB production did not 
hepaTic inflammaTion enhances Vldl-TG prodUcTion
4
67
change significantly (P=0.52) (Fig. 4C). Since each VLDL particle contains a single 
apoB molecule, LIKK apparently increases plasma TG levels by enhancing VLDL-TG 
production without affecting VLDL particle production.
likk does not affect liver lipid levels
To investigate whether the increase in hepatic VLDL-TG production was the result of 
increased lipid substrate availability in the liver, the effect of LIKK on the hepatic lipid 
content was investigated (Fig. 5). However, E3L and E3L.LIKK mice did not differ with 
respect to liver TG levels (Fig. 5A) and TC levels (Fig. 5B). LIKK did not influence the 
FA composition of hepatic TG, apart from a mild increase in the relative abundance of 
linoleic acid (18:2 n-6) by +19% (P<0.05) (Suppl. Fig. S1).
 likk directly increases TG secretion in hepatocytes from e3l mice
To evaluate whether IKK-ß overexpression in hepatocytes directly increases VLDL-TG 
production, we next studied TG secretion from isolated hepatocytes of E3L and E3L.
LIKK mice in vitro. We used [3H]glycerol as precursor for TG synthesis, by measuring 
the accumulation of [3H]TG in the medium (Fig. 6). In the absence of oleate, the [3H]
TG secretion was low, but LIKK significantly increased the [3H]TG secretion after 20 h 
of incubation as compared to the [3H]TG secretion from control E3L hepatocytes (2.3-
fold; P<0.05) (Fig. 6A). In the presence of oleate, as a substrate for TG synthesis, [3H]
Figure 3. LIKK does not affect clearance of VLDL-like emulsion particle-TG in E3L mice. 
E3L and E3L.LIKK mice that were fasted overnight were injected with [3H]TO-labeled 
VLDL-like emulsion particles. Blood was collected at the indicated time points and radioactivity 
was measured in plasma (A) of E3L mice (open circles) and E3L.LIKK mice (closed circles). 
Uptake of [3H]TO-derived activity by various organs was determined, and total FA uptake was 
calculated from the specific activity of TG in plasma, and expressed as nmol FA per mg wet 
tissue weight (B). Values are means ± SD (n=8). WAT, white adipose tissue; visc, visceral; sc, 
subcutaneous; gon, gonadal.
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TG secretion was markedly increased, and LIKK caused an additional increase in [3H]
TG secretion, reaching significance after 20 h of incubation (1.9-fold at 20 h; P<0.05) 
(Fig. 6B).
likk increases hepatic expression of fatty acid synthase, but does not affect protein levels or 
expression of genes involved in Vldl production
To obtain further insight into the mechanism underlying the effects of IKK-ß 
overexpression on VLDL-TG production, we evaluated the hepatic expression of genes 
involved in VLDL secretion, lipogenesis, FA oxidation, cholesterol metabolism, bile 
acid metabolism, lipid droplets and nuclear receptors in livers of E3L and E3L.LIKK 
mice (Table 1). Even though LIKK induced an increase of VLDL-TG production in vivo 
and in vitro, LIKK did not affect hepatic gene expression or protein level (Suppl. Fig. 
S2A,B) of microsomal TG transfer protein (Mttp), which is involved in the assembly 
and secretion of VLDL. In addition, LIKK did not affect apoB (Apob) expression, in 
line with the observation that LIKK did not increase VLDL-apoB secretion in vivo. 
Also, LIKK did not affect expression of sterol regulatory element binding protein 1c 
Figure 4. LIKK increases VLDL-TG 
production in E3L mice. E3L and E3L.LIKK 
mice were fasted overnight and injected with 
Trans35S (t=-30 min) and Triton WR1339 
(t=0) and blood samples were drawn at the 
indicated time points. TG concentrations were 
determined in plasma of E3L mice (open circles) 
and E3L.LIKK mice (closed circles), and plotted 
as the increase in plasma TG relative to t=0 (A). 
The rate of TG production was calculated from 
the slopes of the curves from the individual 
mice (B). After 120 min, VLDL was isolated by 
ultracentrifugation, 35S-activity was counted, 
and the production rate of newly synthesized 
VLDL-35S-apoB was determined (C). Values 
are means ± SD (n=5-8). *P<0.05.
hepaTic inflammaTion enhances Vldl-TG prodUcTion
4
69
Figure 5. LIKK does not affect liver lipid content in E3L mice. Livers were obtained from 
overnight fasted E3L and E3L.LIKK mice and lipids were extracted. Triglycerides (TG, A) and 
total cholesterol (TC, B) concentrations were measured and expressed per mg protein. Values are 
means ± SD (n=5-7). *P<0.05.
Figure 6. LIKK increases TG secretion in hepatocytes from E3L mice. Hepatocytes were 
isolated from E3L (open circles) and E3L.LIKK mice (closed circles), cultured overnight, and 
incubated without or with oleate complexed with bovine serum albumin. [3H]Glycerol was 
added to quantify newly synthesized triacylglycerols. Medium was collected at the indicated 
time points, [3H]TG was measured and expressed as dpm per mg cell protein. Values are means 
± SD of 3-6 mice per group, in vitro experiments were performed in triplicate (n=3-6). *P<0.05.
(Srebp-1c), which regulates genes required for de novo lipogenesis, nor did it affect 
expression or protein levels (Suppl. Fig. S2A,C) of acyl:diacylglycerol transferase 1 
(Dgat1), which catalyzes the final and only committed step in TG synthesis. 
In addition, LIKK did not largely affect clusters of genes involved in FA oxidation 
(acyl-Coenzyme A oxidase 1 (Acox1) and carnitine palmitoyltransferase 1a (Cpt1a), 
cholesterol metabolism (ATP-binding cassette sub-family G member 5 (Abcg5), 
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ATP-binding cassette sub-family G member 8 (Abcg8) and HMG-CoA reductase 
(Hmgcr) or bile acid metabolism (cholesterol 7 alpha hydroxylase (Cyp7a1) and sterol 12 
alpha-hydrolase (Cyp8b1)), apart from a 1.9-fold increase in cholesterol 27 hydroxylase 
(Cyp27a1) expression. Additionally, LIKK did not affect clusters of genes involved in lipid 
droplet formation (perilipin 2 (Plin2), fat-specific protein FSP27 (Cidec) and cell death 
activator CIDE-A (Cidea)),or expression of nuclear receptors (peroxisome proliferator 
activated receptor alpha (Ppara), PPAR-gamma coactivator 1-beta (Ppargc1) and liver 
X receptor alpha (Nr1h3)), apart from a 1.6-fold increase in expression of perilipin 
5 (Plin5) and farnesoid X activated receptor (Nr1h4) respectively. 
However, LIKK did increase expression of FA synthase (Fas), which plays a key role 
in FA synthesis, by 2.4-fold, and of liver-type pyruvate kinase (Pklr) by 1.7-fold, both 
of which are target genes of ChREBP. Taken together, these data suggest that LIKK 
increases VLDL-TG production by ChREBP-mediated upregulation of Fas expression, 
suggesting an increase in de novo lipogenesis.
discUssion
Obesity leads to an increase in inflammatory processes in numerous organs 
including the liver.18 In the current study, we questioned whether increased 
activation of inflammatory pathways in the liver, specifically in hepatocytes, induces 
hypertriglyceridemia. Indeed, we show that chronic activation of the inflammatory 
NF-κB pathway specifically in hepatocytes increases plasma TG, which was caused 
by an increased VLDL-TG production rather than a decreased clearance of VLDL-
TG. Furthermore, we provide evidence that the increased TG production induced by 
hepatocyte-specific IKKβ overexpression is a direct effect of the transgene expression 
in the hepatocyte.
The strong relation between inflammation and hypertriglyceridemia has largely 
been derived from the observed increase in plasma TG during acute infection, which 
is believed to contribute to the host defense.19 However, although similar inflammatory 
pathways are involved, metabolic inflammation is clearly different from acute 
inflammation with respect to its cause, intensity and duration. The inflammation that 
is observed in obesity, is a chronic and low-grade inflammation that is caused by a 
metabolic overload, rather than a pathogen.20 The NF-κB activity in the liver of E3L.
LIKK mice in this study is about 1.5-fold higher compared to control E3L mice, which 
is similar to hepatic NF-κB activation levels seen after HFD feeding and in obesity.1 
The present study shows that this low-grade activation of hepatocyte-specific IKK-β 
induces an increase in plasma TG levels in E3L mice, a model for human-like lipoprotein 
metabolism, which was due to an increase in plasma VLDL-TG levels. Additional 
investigation of VLDL-TG metabolism revealed that the increased VLDL-TG levels 
were not caused by decreased clearance of TG from VLDL-like particles, but rather 
by increased hepatic production of VLDL-TG. These findings are in line with a study 
showing that injection of a low dose of LPS increases secretion of VLDL-TG, without 
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Table 1. Effect of LIKK on hepatic expression of genes involved in lipid metabolism in E3L mice.
Gene Protein E3L E3L.LIKK Change
VLDL secretion
Apob ApoB 1.00 ± 0.35 1.01 ± 0.34 n.s.
Mttp MTP 1.00 ± 0.46 1.34 ± 0.36 n.s.
Lipogenesis
Srebp-1c SREBP1c 1.00 ± 0.39 1.10 ± 0.74 n.s.
Dgat1 DGAT1 1.00 ± 0.32 1.21 ± 0.41 n.s.
Fas FAS 1.00 ± 0.52 2.43 ± 1.07** +143%
FA oxidation
Acox1 ACO 1.00 ± 0.70 1.13 ± 0.20 n.s.
Cpt1a CPT1a 1.00 ± 0.58 0.95 ± 023 n.s.
Glucose metabolism
Pklr L-PK 1.00 ± 0.48 1.72 ± 0.80* +72%
Cholesterol metabolism
Abcg5 ABCG5 1.00 ± 0.22 1.05 ± 0.31 n.s.
Abcg8 ABCG6 1.00 ± 0.16 0.93 ± 0.16 n.s.
Hmgcr HMG-CoA 1.00 ± 0.19 0.98 ± 0.08 n.s.
Bile acid metabolism
Cyp7a1 CYP7A1 1.00 ± 0.59 1.19 ± 0.55 n.s.
Cyp8b1 CYP8B1 1.00 ± 0.60 1.21 ± 0.27 n.s.
Cyp27a1 CYP27A1 1.00 ± 0.41 1.85 ± 0.51** +85%
Lipid droplets
Plin2 PLIN2/ADRP 1.00 ± 0.98 1.04 ± 0.33 n.s.
Plin5 PLIN5/PAT-1 1.00 ± 0.72 1.64 ± 0.55* +64%
Cidec CIDE-3/FSP27 1.00 ± 0.98 1.05 ± 0.42 n.s.
Cidea CIDEA 1.00 ± 0.65 0.85 ± 0.59 n.s.
Transcription factors
Ppara PPARα 1.00 ± 0.28 0.89 ± 0.16 n.s.
Ppargc1b PGC-1β 1.00 ± 0.63 0.77 ± 0.26 n.s.
Nr1h3 LXRα 1.00 ± 0.35 1.09 ± 0.09 n.s.
Nr1h4 FXR 1.00 ± 0.50 1.58 ± 0.43* +58%
Livers were isolated from overnight fasted E3L and E3L.LIKK mice. mRNA was isolated and mRNA expres-
sion of the indicated genes was quantified by RT-PCR. Data are calculated as fold difference as compared to 
the control group. Values are means ± SD (n=8). *P<0.05 and  **P<0.01 compared to the control group. n.s., 
not significant. Abcg5, ATP-binding cassette sub-family G member 5 ; Abcg8, ATP-binding cassette sub-
family G member 8; Acox1, acyl-Coenzyme A oxidase 1; Apob, apolipoprotein B; Cidea, cell death activator 
CIDE-A; Cidec, fat-specific protein FSP27; Cpt1a, carnitine palmitoyltransferase 1a; Cyp27a1, cholesterol 
27 hydroxylase; Cyp7a1, cholesterol 7 alpha hydroxylase; Cyp8b1, sterol 12 alpha-hydrolase; Dgat1, diglyc-
eride acyltransferase 1; Fas, fatty acid synthase; Hmgcr, HMG-CoA reductase; Mttp, microsomal triglycer-
ide transfer protein; Nr1h3, liver X receptor alpha; Nr1h4, farnesoid X activated receptor; Pklr, liver-type 
pyruvate kinase; Plin2, perilipin 2; Plin5, perilipin 5; Ppara, peroxisome proliferator activated receptor 
alpha; Ppargc1b, PPAR-gamma coactivator 1-beta; Srebp-1c, sterol-regulatory element binding protein.
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affecting its clearance.5 However, LPS associates with macrophages rather than with 
hepatocytes,21 which hampers interpretation which cell type is primarily responsible 
for the increase in VLDL-TG secretion. In addition to LPS, individual cytokines, that 
activate various cell types, increase VLDL-TG production.3,22 Since both LPS and 
cytokines can activate NF-κB signalling, our findings could suggest that the increase in 
VLDL secretion caused by LPS and cytokines in these earlier studies has been mediated, 
at least in part, via direct or indirect activation of NF-κB in the hepatocytes. In the 
present study, even though LIKK clearly increased VLDL-TG secretion, there were 
no significant effects of LIKK on apoB production or hepatic Apob gene expression. 
This suggests that NF-κB activation increases the intracellular lipidation of apoB, but 
not the number of VLDL-particles secreted. This is in contrast with a study of Tsai 
et al,23 showing that adenoviral-mediated overexpression of IKK did increase apoB 
secretion in HepG2 cells. This discrepancy could possibly be explained by the level of 
IKK overexpression, which was higher with adenoviral-mediated IKK overexpression 
in their in vitro HepG2 model than with transgenic overexpression in our in vivo 
study. It is thus reasonable to postulate that low grade NF-κB activity mainly increases 
lipidation of the VLDL particles, whereas a higher degree of NF-κB activation could in 
addition increase the number of secreted VLDL-particles.
It is interesting to speculate about the mechanism why hepatocyte-specific NF-κB 
activation increases VLDL-TG secretion, as many different factors could theoretically 
be involved. For example, IKK-β overexpression can cause insulin resistance,1 
which could result in an inability of insulin to suppress VLDL-TG production.24 
Furthermore, Kupffer cells have been suggested to play an important role in hepatic 
lipid metabolism.25 Additionally, Kupffer cell products could possibly suppress 
lipid oxidation in hepatocytes via NF-κB mediated suppression of PPARα activity.26 
Furthermore, although plasma FFA levels were unaltered by LIKK, liver-directed FA 
flux may have been influenced, resulting in altered substrate availability for VLDL-TG 
production. Therefore, to evaluate the effect of IKK-β overexpression in hepatocytes on 
VLDL-TG production in absence of these potentially confounding factors, we studied 
the effect of IKK-β in hepatocytes on TG production in vitro. In fact, IKK-β expression 
in hepatocytes per se appeared to directly increase VLDL-TG production. Although 
additional factors may contribute to the effect of LIKK on VLDL-TG production in 
vivo, a direct effect of IKK-β overexpression in hepatocytes thus at least contributes to 
this phenomenon.
PPAR-α, LXR and FXR have shown to be activated during inflammation and 
interact with inflammatory processes27,28 and could possibly underlie the mechanism 
by which hepatocyte-specific NF-κB activation increases VLDL-TG secretion directly 
within the hepatocyte. However, no change was observed in expression of hepatic 
PPAR-α and LXR or expression of their target genes. NF-κB activation did increase 
FXR expression, but FXR activation has been linked to a lower VLDL-TG secretion,29 
making a causal relationship between FXR activation and the increase in VLDL-TG 
secretion unlikely. Apparently, chronic hepatocyte-specific activation of NF-κB by 
hepaTic inflammaTion enhances Vldl-TG prodUcTion
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IKK-β overexpression does not induce identical changes in lipogenic pathways that 
are seen in acute inflammation, however, it clearly increases VLDL-TG production 
and induces hypertriglyceridemia. Increased hepatic lipid availability, by increased 
lipogenesis and/or decreased lipid oxidation, could also underlie the mechanism by 
which hepatocyte-specific NF-κB increases VLDL-TG secretion. Acute inflammation 
has been shown to increase hepatic lipogenesis as measured by incorporation of 3H2O 
into FA in vivo.5,30,31 In our study we measured expression of genes involved in hepatic 
FA oxidation and de novo lipogenesis. Despite the fact that LIKK did not decrease the 
expression of genes involved in FA oxidation, LIKK clearly increased expression of 
Fas, which is a key enzyme in the regulation of FA synthesis. Although upregulation of 
Fas could be mediated by the transcription factors LXR, Srebp-1c and ChREBP,32,33 the 
observed upregulation of Pklr as a main ChREBP target gene suggests that LIKK most 
likely activates ChREBP, thereby increasing Fas expression. The fact that activation of 
NF-κB has been linked to local disturbances in glucose metabolism that could activate 
ChREBP would underscore this observation.1,34,35 It is thus conceivable that increased 
ChREBP mediated Fas expression increases hepatic lipogenesis and thereby increases 
lipid availability for VLDL-TG production.36 In fact, activation of lipogenesis results in 
large, but not more, VLDL particles, which is consistent with our findings37. The fact 
that we did not observe an increase in the hepatic TG content or FA oxidation that 
could have been expected by increased Fas expression,38 can be explained by efficient 
incorporation of newly synthesized TG into nascent VLDL resulting in the increased 
hepatic VLDL-TG secretion. 
In conclusion, we show that activation of hepatocyte-specific NF-κB through 
overexpression of IKK-ß increases TG levels in E3L mice by stimulation of VLDL-TG 
secretion, directly within the hepatocyte, without effects on VLDL-TG clearance. The 
stimulation of VLDL-TG secretion is not driven by increased steatosis or decreased FA 
oxidation, but most likely by ChREBP mediated upregulation of Fas expression.
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Supplemental Table S1. Primers used for quantatitive real-time PCR analysis.

























Abcg5, ATP-binding cassette sub-family G member 5 ; Abcg8, ATP-binding cassette sub-family G member 
8; Acox1, acyl-Coenzyme A oxidase 1; Apob, apolipoprotein B; Cidea, cell death activator CIDE-A; Cidec, 
fat-specific protein FSP27; Cpt1a, carnitine palmitoyltransferase 1a; Cyp27a1, cholesterol 27 hydroxylase; 
Cyp7a1, cholesterol 7 alpha hydroxylase; Cyp8b1, sterol 12 alpha-hydrolase; Dgat1, diglyceride acyltrans-
ferase 1; Fasn, fatty acid synthase; Hmgcr, HMG-CoA reductase; Mttp, microsomal triglyceride transfer 
protein; Nr1h3, liver X receptor alpha; Nr1h4, farnesoid X activated receptor; Pklr, liver-type pyruvate 
kinase; Plin2, perilipin 2; Plin5, perilipin 5; Ppara, peroxisome proliferator activated receptor alpha; 
Ppargc1b, PPAR-gamma coactivator 1-beta; Srebp-1c, sterol-regulatory element binding protein.




Supplemental Figure S1. Effect of LIKK on fatty acid composition of hepatic triglycerides in 
E3L mice.
Livers were obtained from overnight fasted E3L and E3L.LIKK mice and lipids were extracted. 
TG were isolated by thin-layer chromatography followed by fatty acid separation and 
quantification using gas chromatography. Fatty acid composition was then determined (in 
Mol%). Values are means ± SD (n=5-7).
Supplemental Figure S1. Effect of LIKK on fatty acid composition of hepatic triglycerides 
in E3L mice.. Livers were obtained from overnight fasted E3L and E3L.LIKK mice and lipids 
were extracted. TG were isolated by thin-layer chromatography followed by fatty acid separation 
and quantification using gas chromatography. Fatty acid composition was then determined (in 
Mol%). Values are means ± SD (n=5-7).
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Supplemental Figure S2. LIKK does not affect hepatic MTP and DGAT1 protein levels. 
E3L and E3L.LIKK mice were fed a chow diet and sacrificed at the age of 14 weeks after an 
overnight fast. MTP and DGAT1 levels were measured in liver tissue by Western blots and Actin 
was used as an internal control. Representative Western blots are shown for 3 mice per group 
(A).  Ratios of MTP (B) and DGAT1 (C) proteins over Actin levels were quantified. Values are 






Supplemental Figure S2. LIKK does not affect hepatic MTP and DGAT1 protein levels. E3L 
and E3L.LIKK mice were fed a chow diet and sacrificed at the age of 14 weeks after an overnight 
fast. MTP and DGAT1 levels were measured in liver tissue by Western blots and Actin was used 
as an internal control. Representative Western blots are shown for 3 mice per group (A).  Ratios 
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absTracT
The liver is the key organ involved in systemic inflammation, but the relation between 
hepatic inflammation and atherogenesis is poorly understood. Since nuclear factor-kB 
(NF-kB) is a central regulator of inflammatory processes, we hypothesized that chronically 
enhanced hepatic NF-kB activation, through hepatocyte-specific expression of IκB 
kinase-β (IKKb) (LIKK), will aggravate atherosclerosis development in APOE*3-Leiden 
(E3L) mice. E3L.LIKK and E3L control littermates were fed a Western-type diet for 24 
weeks. E3L.LIKK mice showed a 2.3-fold increased atherosclerotic lesion area and more 
advanced atherosclerosis in the aortic root with less segments without atherosclerotic 
lesions (11 vs. 42%), and more segments with mild (63% vs. 44%) and severe (26% vs. 14 
%) lesions. Expression of LIKK did not affect basal levels of inflammatory parameters, but 
plasma cytokine levels tended to be higher in E3L.LIKK mice after lipopolysaccharide 
(LPS) administration. E3L.LIKK mice showed transiently increased plasma cholesterol 
levels, confined to (V)LDL. This transient character resulted in a mild (+17%) increased 
cumulative plasma cholesterol exposure. We conclude that selective activation of NF-kB 
in hepatocytes considerably promotes atherosclerosis development which is (at least 
partly) explained by an increased sensitivity to proinflammatory triggers and transiently 
increased plasma cholesterol levels.
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inTrodUcTion
Increased inflammation, in addition to disturbances in lipid metabolism, is the other 
main contributor to the development of atherosclerosis [1]. Nuclear factor-kB (NF-kB) 
has been identified as the most important transcription factor in the regulation of 
inflammatory processes during atherosclerosis development [2]. In unstimulated cells, 
NF-kB p65/p50 dimer is kept inactive by its inhibitory protein: inhibitor of kB (IkB). 
A wide range of extracellular stimuli, including cytokines, microbial components, and 
also free fatty acids, induce activation of the IkB kinase complex, which consists of two 
kinases (IKKa and -b) and a regulatory subunit, NEMO/IKKg. This complex mediates 
the phosphorylation of IkB, resulting in its ubiquitination and degradation, leaving the 
NF-kB dimer free to translocate to the nucleus and activate its target genes [2].
While general inhibition of the NF-kB pathway by pharmacological agents reduces 
atherosclerosis development in mice [3,4], the relative contribution of NF-kB may differ 
at cellular- or tissue-specific level. Suppression of the NF-kB pathway in endothelial cells 
by ablation of NEMO/IKKg has been shown to decrease atherosclerosis development 
[5]. In murine bone marrow transplantation models, inhibition of the NF-kB pathway 
at distinct levels in hematopoietic cells can have different outcomes, i.e. deficiency of 
the NF-kB p50 subunit resulted in smaller atherosclerotic lesions [6], whereas deletion 
of IKKb increased atherosclerosis development [7]. Surprisingly, the role of the NF-kB 
pathway in hepatocytes on atherosclerosis development has not been investigated 
thus far.
The liver plays a central role in both lipid metabolism [8] and inflammation [9]. 
Disturbances in lipid metabolism and increased inflammation are the two main risk 
factors for atherogenesis [1]. Hepatocytes form the largest population of cells in the liver 
and execute most of its important functions. During inflammation, acute phase proteins 
are mainly synthesized by the hepatocytes [10]. Interestingly, hepatocyte-specific 
deficiency of gp130, a receptor component of IL-6 signaling which signals independent 
of the NF-kB pathway, decreases atherosclerosis in apoe-/- mice [11], suggesting that 
reduced hepatic inflammation is associated with less atherosclerosis development.
Despite ample evidence implicating the involvement of NF-kB in atherogenesis, 
the hepatocyte-specific role of NF-κB in atherosclerosis has not been investigated 
directly. Therefore, in this study we aimed to investigate whether chronic activation 
of hepatocyte-specific NF-kB aggravates atherosclerosis development. We used 
transgenic mice with hepatocyte-specific expression of human IKKb (Liver-specific 
IKKb or LIKK mice), resulting in an increase of active NF-kB [12], crossbred with 
atherosclerosis-prone APOE*3-Leiden (E3L) mice. E3L mice exhibit a human-like 
lipoprotein distribution on a cholesterol-rich diet due to transgenic expression of a 
human mutant of the APOE3 gene, and are therefore susceptible to atherosclerosis 
development [13]. Collectively, our results show that hepatocyte-specific NF-kB 
activation markedly aggravates atherosclerosis development in E3L mice.




animals and study design
Transgenic LIKK mice expressing constitutively active human IKKb in the hepatocytes 
by an albumin promoter [12] were crossbred with E3L mice to generate heterozygous 
E3L.LIKK and control E3L littermates, as described before [14]. Mice were housed 
under standard conditions with a 12-hour light/dark cycle and had free access to food 
and water. Female mice of 10-12 weeks of age were fed a Western-type diet containing 
15% (w/w) cacao butter supplemented with 0.25% (w/w) cholesterol (Hope Farms, 
Woerden, The Netherlands). Food intake and body weight were measured weekly. 
Unless indicated otherwise, blood was drawn every 4 weeks after 4 hours of fasting in 
EDTA-containing tubes by tail bleeding, and plasma was isolated by centrifugation. 
All animal experiments were approved by the Institutional Ethical Committee on 
Animal Care and Experimentation of the Leiden University Medical Center (Leiden, 
The Netherlands).
mrna expression analysis 
Total RNA from livers of E3L and E3L.LIKK mice was isolated using an RNA isolation 
kit according to manufacturer’s specifications, including a 15 min. DNAse I treatment 
(Macherey-Nagel, Düren, Germany). Quality control of the isolated RNA was checked 
with the lab-on-a-chip technology using Experion Stdsens analysis kit (Bio-Rad, Hercules, 
CA). One µg of total RNA was converted to cDNA with iScript cDNA Synthesis kit (Bio-
Rad) and purified with Nucleospin Extract II kit (Macherey-Nagel, Düren, Germany). 
Real time PCR (RT-PCR) was carried out on an iQ5 Single-Color real-time PCR detection 
system (Bio-Rad) using the Sensimix SYBR Green RT-PCR mix (Quantace, London, 
UK). Expression levels were normalized using hypoxanthine-guanine phosphoribosyl 
transferase (Hprt), cyclophilin (Cyclo) and glyceraldehyde 3-phosphate dehydrogenase 
(Gapdh). Primer sequences are listed in Supplemental Table 1. 
western blot analysis
Liver tissue was homogenized by Ultraturrax (22,000 rpm; 2x5 sec) in an ice-cold 
buffer (pH 7.4) containing 30 mM Tris.HCl, 150 mM NaCl, 10 mM NaF, 1 mM 
EDTA, 1 mM Na3VO4, 0.5% (v/v) Triton X-100, 1% (v/v) SDS and protease inhibitors 
(Complete, Roche, Mijdrecht, The Netherlands) at a 1:6 (w/v) ratio. Homogenates were 
centrifuged (16,000 rpm; 15 min., 4°C) and the protein content of the supernatant was 
determined using the BCA protein assay kit (Pierce, Rockford, IL). Proteins (20-50 µg) 
were separated by 7-10% SDS-PAGE followed by transfer to a polyvinylidene fluoride 
membrane. Membranes were blocked for 1 hour at room temperature in Tris-buffered 
saline with Tween-20 with 5% non-fat dry milk followed by an overnight incubation 
with either IKKb (ab32135, Abcam, Cambridge, UK), tubulin, pSer536 NF-κB p65 or 
NF-κB p65 antibodies (#2148, #3031, #3034, resp., Cell Signaling, Danvers, MA). Blots 
were then incubated with horseradish peroxidase-conjugated secondary antibodies for 
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1 hour at room temperature. Bands were visualized by enhanced chemiluminescence 
and quantified using Image J software (NIH, USA).
plasma inflammatory markers
Plasma levels of serum amyloid A (SAA) were determined using the murine Phase 
Serum Amyloid A Assay kit (Tridelta, County Kildare, Ireland) according to 
manufacturer’s instructions. Plasma levels of inflammatory cytokines and chemokines 
(IFNg, IL-12 p70, IL-1b, IL-6, TNFa and IL-10) were measured using a multiplex 
murine inflammatory cytokine profile immunoassay from Meso Scale Discovery 
(MSD) on a MSD 2400 plate reader according to the manufacturer’s protocol (MSD, 
Gaithersburg, MD). 
lipopolysaccharide stimulation
Mice were injected i.v. with Salmonella minnesota Re595 lipopolysaccharide (LPS) 
(Sigma-Aldrich, St. Louis, MO) (50 mg/kg body weight). Blood was collected 90 
min. after injection in heparin-coated capillaries. Plasma was assayed for cytokines as 
described above.
facs staining of leukocyte subpopulations in peripheral blood
Nonfasted, whole blood was drawn in EDTA-containing tubes by tail bleeding and 
incubated with antibodies against Ly6C-FITC (kindly provided by Dr P.J. Leenen, 
Erasmus University, Rotterdam, The Netherlands), Ly6G-PE, CD115-biotin and 
CD11b-APC (all from Pharmingen, Alphen a/d Rijn, The Netherlands). In between all 
steps, cells were washed with PBS containing 1% BSA and 0.05% Na-azide.
Binding of anti-CD115-biotin was detected with streptavidin conjugated with 
PerCP-Cy5.5 (Pharmingen, Alphen a/d Rijn, The Netherlands). Red blood cells were 
lysed with shock-buffer, cells were fixed with 1% paraformaldehyde and measured with 
an LSRII (Becton Dickinson, Erembodegem, Belgium).
To obtain leukocyte profiles, the following gating strategy was applied: debris was 
gated out in a forward (FSC)/side scatter (SSC) plot and leukocytes minus debris 
were divided according to their CD11b expression (myeloid lineage: CD11b-pos; 
lymphoid lineage: CD11b-neg). CD11b-pos cells were then selected and using Ly6G 
expression and SSC, cells were divided in neutrophilic granulocytes (Ly6G-hi/SSC-
hi), eosinophilic granulocytes (Ly6G-neg/SSC-hi) and a non-granulocyte population 
(Ly6G-neg/SSC-low). The non-granulocyte population was then selected and using 
their CD11b and CD115 expression, monocytes (CD11b-pos/CD115-pos) and NK 
cells (CD11b-med/CD115-neg) were identified. Next, the monocyte population was 
selected and using Ly6C expression and FSC, classical monocytes (Ly6C-hi/FSC-
low), non-classical monocytes (Ly6C-low/FSC-low) and intermediate monocytes 
(Ly6C-med/FSC-low) were identified. Going back to the lymphoid lineage (CD11b-
neg cell population), using Ly6C-expression, lymphocytes (Ly6C-low/FSC-low) and 
lymphoblasts (Ly6-ly6C-med/FSC-hi) were identified.
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plasma lipids, lipoprotein profile, hepatic Vldl-TG production and liver lipids analysis
Plasma total cholesterol (TC), triglycerides (TG) and phospholipids (PL) levels were 
determined using enzymatic kits from Roche Molecular Biochemicals (Woerden, 
The Netherlands) according to the manufacturer’s protocols. We used the following 
formula to calculate the cumulative plasma TC levels over 24 weeks of Western-type 
diet feeding which equals the area under the curve for the plasma TC in time: 4*TCt=0 
+ 0.5*4*(TCt=4 – TCt=0) + 4*TCt=4 + 0.5*4*(TCt=8 – TCt=4)  + 4*TCt=8 + 0.5*4*(TCt=12 
– TCt=8) + 4*TCt=12 + 0.5*4*(TCt=16 – TCt=12) + 4*TCt=16 + 0.5*4*(TCt=20 – TCt=16) + 
4*TCt=20 + 0.5*4*(TCt=24 – TCt=20). The correlation between cumulative plasma 
TC level and atherosclerotic lesion area was assessed for both E3L and E3L.LIKK 
mice. For the determination of lipid distribution over plasma lipoproteins, pooled 
plasma per group was size-fractionated using an ÄKTA fast performance liquid 
chromatography (FPLC) system (Pharmacia, Roosendaal, The Netherlands). Each 
sample was injected onto a Superose 6 HR3.2/30 column and eluted at a constant 
flow rate of 50 µL/min in PBS, pH 7.4. Fractions of 50 µL were collected and assayed 
for TC as described above. 
Mice were fasted for 4 hours prior to the start of the  hepatic VLDL-TG production 
experiment, and, subsequently, sedated with 6.25 mg/kg acepromazine (Alfasan), 6.25 
mg/kg midazolam (Roche), and 0.3125 mg/kg fentanyl (Janssen-Cilag). At timepoint 
zero, blood was taken via tail bleeding and mice were i.v. injected with 100 μL PBS 
containing 100 μCi Trans35S label to measure de novo total apolipoprotein B (apoB) 
synthesis. After 30 min., the animals received 500 mg of tyloxapol (Triton WR-1339, 
Sigma-Aldrich) per kg body weight as a 10% (w/w) solution in sterile saline, to prevent 
systemic lipolysis of newly secreted hepatic VLDL-TG. Additional blood samples were 
taken at regular timepoints after tyloxapol injection and used for determination of 
plasma TG concentration. At timepoint 120 min., the animals were sacrificed and 
blood was collected by orbital puncture for isolation of VLDL by density gradient 
ultracentrifugation. 35S-labeled total apoB content was measured in the VLDL fraction 
after precipitation with isopropanol.
Lipids from liver tissue were extracted according to a protocol adapted from Bligh 
and Dyer. Hepatic TG, PL concentrations were determined using the enzymatic kits 
as described previously. TC, free cholesterol (FC) and cholesteryl ester (CE) content 
were assessed with a cholesterol/cholesteryl ester quantitation enzymatic kit according 
to manufacturer’s specifications (Biovision Research Products, Mountain View, CA). 
Liver lipids were expressed per mg protein, which was measured using the BCA protein 
assay kit (Pierce, Rockford, IL). 
atherosclerosis quantification
Mice were euthanized by carbon dioxide inhalation after 24 weeks of diet. Hearts were 
isolated and fixed in 4% paraformaldehyde, dehydrated and embedded in paraffin, and 
were cross-sectioned (5 µm) throughout the entire aortic root area. Of each mouse, 
4 sections with 50-µm intervals were used for quantification of atherosclerotic lesion 
84
area. Characterization of lesion severity was performed separately in each of the 3 
segments between the aortic valves in the 4 sections.
Sections were stained with hematoxylin-phloxine-saffron (HPS). Atherosclerotic 
lesions were categorized for severity by one blinded observer, according to the 
guidelines of the American Heart Association, adapted for mice. Various types of 
lesions were distinguished: type 0 (no lesions) (Supplemental Fig. 8A), type I to III 
(early fatty streak-like lesions containing foam cells) (Supplemental Fig. 8B-D), and 
type IV to V (advanced lesions containing foam cells in the media, presence of fibrosis, 
cholesterol clefts, mineralization, and/or necrosis) (Supplemental Fig. 8E-F). 
Immunohistochemistry for determination of adhering monocytes and 
macrophage-, and smooth muscle cell content in the lesions was performed as described 
previously. The sections were incubated overnight with antibody M18 (1:100, Santa 
Cruz Biotechnology, Santa Cruz, Calif) and, subsequently, with biotinylated rabbit 
anti-goat conjugate(1:400, Brunschwig chemie, Amsterdam, The Netherlands) for 
quantification of MCP-1. AIA 31240 rabbit antiserum (1:1000, Accurate Chemical 
and Scientific, Westbury, NY) in combination with biotinylated donkey anti-rabbit 
conjugate (1:3000, Amersham Pharmacia Biotech) were used for quantification of both 
the number of monocytes adhering to the endothelium as well as the macrophage area. 
Antibody M0851 (1:800, Dako, Carpinteria, CA) and biotinylated horse anti-mouse 
conjugate (1:400, Vector Laboratories, Burlingame, CA) were used to quantify smooth 
muscle actin. Immunostaining was amplified using Vector Laboratories Elite ABC 
kit (Vector Laboratories, Burlingame, CA) and the immunoperoxidase complex was 
visualized with Nova Red (Vector Laboratories, Burlingame, CA). Counterstaining was 
performed with Mayer’s haematoxylin. Sirius red was used to stain for collagen in the 
lesions (Chroma, Stuttgart, Germany).
Total lesion size, MCP-1-, macrophage-, smooth muscle cell-, and collagen content 
were quantified using Cell^D image analysis software (Olympus Soft Imaging Solutions, 
Münster, Germany).
statistical analysis
Data are presented as means ±SEM. SPSS 17.0 for Windows (SPSS, Chicago, Ill) was 
used for statistical analysis. Statistical differences were assessed with the Mann-Whitney 
U test. For lesion typing, differences were determined by the c2 test. To assess the 
correlation between cumulative cholesterol exposure and atherosclerotic lesion area, the 
Pearson correlation test was performed after log transformation of the atherosclerotic 
lesion area. Differences at P<0.05 were regarded as statistically significant. 
resUlTs
likk causes low-grade inflammation
The overall appearance of E3L and E3L.LIKK mice was similar. To assess whether 
expression of LIKK affects body weight gain, we measured food intake and body weight 
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weekly. Both were not different between E3L.LIKK and E3L control mice (Supplemental 
Fig. 1A-B). The liver- and spleen weight and histological morphology of the liver were 
also comparable between E3L.LIKK and E3L mice (data not shown). To gain more 
insight in the effects of LIKK on inflammation, we determined whether LIKK expression 
increased the inflammatory state of the liver and systemic inflammatory markers in 
E3L.LIKK mice on a Western-type diet. We confirmed previous findings [14] showing 
that the enhanced expression of hepatocyte-specific human IKKb (Supplemental 
Fig. 2A) resulted in a 1.4-fold increased hepatic NF-kB activation, displayed by an 
enhanced expression the phosphorylated p65 subunit (pNF-kBSer536) (Supplemental 
Fig. 2B). IKKb kinase phosphorylates subunit p65 of NF-kB at the position Ser536, 
which activates the transcriptional activity of NF-kB [15]. The transgenic expression of 
human IKKß mRNA was present only in E3L.LIKK mice and did not alter murine IKKß 
mRNA expression (Supplemental Fig. 2C-D). The enhanced hepatic NF-kB activation 
in E3L.LIKK mice did not result in increased IL-6 expression in whole liver, but did 
result in a tendency towards increased IL-1b expression (P=0.085) and a significant 
increase in MCP-1 expression (Supplemental Table 2).
To evaluate whether the increased hepatocyte-specific NF-kB activation in E3L.LIKK 
mice enhanced the systemic inflammatory state, we determined the plasma inflammation 
marker SAA and plasma cytokines under basal conditions. LIKK expression did not affect 
SAA before (3.1 ±0.17 vs. 3.4 ±0.15 µg/mL) and after 8 weeks (4.4 ±0.28 vs. 4.2 ±0.31 µg/
mL) and 24 weeks (4.9 ±0.51 vs. 5.4 ±0.78 µg/mL) of Western-type diet feeding (Fig. 1), 
and neither the determined plasma cytokine levels (Supplemental Fig. 3A-F). SAA levels 
increased significantly with Western-type diet feeding in E3L.LIKK mice (Fig. 1).
Since we did not observe a clear increased systemic proinflammatory state under 
basal conditions, we challenged the mice with LPS to boost the inflammatory response. 
Interestingly, after injection of LPS, proinflammatory cytokines (e.g. IL-1b, IFNg) 
showed a tendency towards increased plasma levels in E3L.LIKK mice as compared to 
E3L mice (Fig. 2A-F). The anti-inflammatory IL-10:IL-1b ratio was significantly lower 
in E3L.LIKK mice (Fig. 2G). Overall, these data indicate that E3L.LIKK mice are more 
sensitive to proinflammatory triggers compared to their E3L littermates.
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Figure 1. LIKK does not increase plasma 
SAA levels. SAA levels were determined 
in plasma from E3L.LIKK (black bars) 
and E3L (white bars) mice fed a Western-
type diet for 0, 8 and 24 weeks. Values are 
means ±SEM; n=15/group; **P<0.01.
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Figure 2. LIKK tends to enhance plasma 
cytokines after LPS stimulation. LPS was 
injected intravenously in E3L.LIKK (black 
bars) and E3L (white bars) mice. Cytokine 
levels were measured 90 minutes after LPS 
injection (A-F). The IL-10:IL-1b ratio was 
calculated (G). Values are means ±SEM; n=7/
group; *P<0.05.
To study whether this chronic low-grade inflammation in E3L.LIKK mice also 
resulted in increased inflammatory cell counts in liver and plasma, we determined the 
hepatic mRNA expression of various cell-type markers of inflammatory cells present in 
the liver, which are likely to influence atherogenesis [16], and the number of circulating 
monocytes. Hepatic mRNA expression of CD68 (Kupffer cells), CD3 ((NK)T cells), 
and Va14 (NKT cells) were not different between the genotypes (Supplemental Table 
2), neither were the total number of circulating monocytes, the proinflammatory 
Ly6C-hi  monocyte subset, the intermediate Ly6C-med monocyte subset and the less 
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inflammatory Ly6C-lo monocyte subset (Supplemental Fig. 4A-D). Together, the above 
findings indicate that the enhanced hepatocyte-specific NF-kB activation in E3L.LIKK 
mice results in a tendency towards a mildly enhanced hepatic proinflammatory state 
and an elevated sensitivity to proinflammatory stimuli as compared to E3L littermates. 
likk transiently enhances Vldl cholesterol levels
To assess the effect of hepatocyte-specific NF-kB activation on plasma lipid levels, 
TC, TG and PL concentrations were determined every 4 weeks in E3L.LIKK and E3L 
mice. LIKK expression caused a transient increase of plasma TC levels only at 8 weeks 
(+50%; P<0.0001) and 12 weeks (+28%; P<0.05) of Western-type diet feeding (Fig. 3A). 
Accordingly, the cumulative total cholesterol exposure was higher in E3L.LIKK than in 
E3L mice (+17%; P<0.05; Fig. 3B). A similar transient increase was found for plasma 
TG and PL levels (Supplemental Fig. 5A-B).
To determine which lipoproteins contribute to the transient elevated plasma TC 
levels, lipoproteins were size-fractionated by FPLC, and cholesterol was measured in the 
individual fractions. The transient increase in plasma TC levels at 8 weeks of Western-
type diet feeding in E3L.LIKK mice was confined to (V)LDL, whereas at 16 weeks the 
lipoprotein distribution in the E3L.LIKK mice was similar to that of the E3L mice, in line 
with the plasma lipid levels (Fig. 3C). In line with our previous finding that expression 
of LIKK increased the VLDL production in male mice on chow diet [14], we found that 
expression of LIKK increased, albeit not significantly, the VLDL-TG production rate 
(+24%) (Supplemental Fig. 6A), and tended to increase the VLDL-apolipoprotein B 
(apoB) production rate (+33%) (Supplemental Fig. 6B). No differences were observed in 
the liver lipid content between E3L.LIKK and E3L mice (Supplemental Fig. 7A-E). Taken 
together, these findings indicate that hepatocyte-specific NF-kB activation results in a 
modest and transient increase in plasma lipid levels in E3L mice. 
likk enhances atherosclerosis development
To investigate the effect of LIKK expression on atherosclerosis development, E3L.
LIKK and E3L mice were sacrificed after 24 weeks of Western-type diet feeding, and 
lesion size and severity were measured in the aortic root. Representative pictures of 
both groups are shown in Fig. 4A. E3L.LIKK mice developed more than 2-fold larger 
atherosclerotic lesions (+131%; P<0.05; Fig. 4B) as compared to their E3L littermates. 
This increased lesion area coincided with more advanced lesion progression, since we 
found markedly fewer segments without atherosclerotic lesions (11% vs. 42%; P<0.001) 
and more segments with mild (63% vs. 44%; P<0.001) and severe lesions (26% vs. 14%; 
P<0.001) as compared to E3L mice (Fig. 4C). Examples of mild and severe lesions are 
shown in Supplemental Figure 8. These data indicate that chronic hepatocyte-specific 
NF-kB activation severely augments atherosclerosis development in E3L mice. 
likk aggravates atherosclerotic lesion composition
We next evaluated whether LIKK expression would affect monocyte adherence and 
recruitment to the vascular wall, as well as the composition of the atherosclerotic 
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lesions with respect to the macrophage, smooth muscle cell, and collagen content of the 
lesions. Adherence of monocytes to the vessel wall and the content of the chemokine 
monocyte chemoattractant protein-1 (MCP-1) of the atherosclerotic lesions were not 
significantly enhanced in E3L.LIKK mice as compared to E3L mice (Fig. 5A-B). LIKK 
expression did not affect the relative macrophage and collagen content of the lesions 
(Fig. 5C+E), but did result in an increased smooth muscle cell content of the lesions 
(+79%, P<0.05; Fig. 5D).
aggravated atherosclerosis development in e3l.likk mice does not solely depend on  
the transient increase in plasma cholesterol levels
In E3L mice on Western-type diet, the cumulative plasma cholesterol exposure is highly 
predictive for the atherosclerotic lesion area (unpublished data, J.F.P. Berbée, P.C.N. 
Rensen). To verify if the transient increase in plasma TC levels (Fig. 3) alone could 
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Figure 3. LIKK transiently increases (V)LDL. Plasma cholesterol levels of E3L.LIKK (black 
symbols) and E3L (white symbols) mice fed a Western-type diet were assessed (A), and 
cumulative total cholesterol exposure was calculated (B). Lipoprotein profiles were determined 
at 8 (left) and 16 (right) weeks (C). Values are means ±SEM; n=15/group; *P<0.05, **P<0.01, 
****P<0.0001.
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account for the aggravation in atherosclerosis development observed in E3L.LIKK 
mice, or whether additional mechanism(s) could contribute, including the low-grade 
systemic inflammation, we assessed the correlation between the cumulative plasma 
total cholesterol exposure and the atherosclerotic lesion area of the E3L.LIKK and E3L 
mice. As expected, there was a significant positive logarithmic correlation between 
the atherosclerotic lesion area and the cumulative plasma cholesterol exposure in the 
control E3L mice (Supplemental Fig. 9A; r2=0.757, P=0.002). However, we did not 
observe such a correlation in the E3L.LIKK mice (Supplemental Fig. 9B; r2=-0.250, 
P=0.369), indicating that in addition to the transient increase in plasma TC levels in 
E3L.LIKK mice, additional mechanism(s), most likely the augmented sensitivity to 
proinflammatory stimuli, contributed to the aggravated atherosclerosis development 
in these mice.
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Figure 4. LIKK aggravates atherosclerotic lesion area and severity. After 24 weeks of Western-
type diet feeding, E3L.LIKK (black bars) and E3L (white bars) mice were sacrificed and cross-
sections of aortic roots were stained with HPS. Representative pictures are shown. Arrows 
indicate lesions (A). Total lesion area was assessed in 4 sections of the aortic root (B) and lesion 
severity was determined separately in each of the 3 segments between the aortic valves of the 
4 sections (C). Statistical analysis for lesion area was performed by Mann-Whitney U test, for 
lesion severity was determined by the x2 test. Values are means ±SEM; n=15/group; *P<0.05, 
***P<0.001.
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Figure 5. LIKK induces more advanced 
atherosclerotic lesions. In the sections 
obtained as described in Fig. 4, the number 
of adhering monocytes (A), monocyte 
chemoattractant protein-1 (MCP-1) content 
(B), macrophage content (C), smooth muscle 
content (D) and collagen content (E) was 
determined. Values are means ±SEM; n=15/
group; *P<0.05, **P<0.01.
discUssion
NF-κB is regarded as a potential therapeutic target in atherosclerosis [3, 4] and studying 
tissue- and cell-specific effects of NF-kB in atherogenesis will expand our knowledge in 
the comprehensive actions of NF-kB on atherosclerosis development. The present study 
demonstrates for the first time that chronic, hepatocyte-specific expression of IKKß 
(LIKK) and subsequent activation of NF-kB aggravates atherosclerosis development 
in E3L mice. In addition, the atherosclerotic lesion composition with respect to the 
macrophage and collagen content was not affected by LIKK, but in accordance with 
the presence of more advanced lesions, the smooth muscle cell content was increased. 
Expression of LIKK resulted in transiently increased plasma cholesterol levels and 
an enhanced sensitivity to proinflammatory triggers, which both are likely to have 
contributed to the increased atherosclerotic lesion size and severity. Since lesion size 
and severity are often correlated in atherosclerosis studies with different murine models 
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[13, 17], the increased lesion severity in E3L.LIKK mice is likely to be mainly attributed 
to the larger size of the lesions. 
Expression of LIKK in E3L mice increased the activation of the NF-kB pathway in 
the liver, in line with our previous report [14]. In addition, hepatic mRNA expression 
of inflammatory parameters was increased or tended to be increased in E3L.LIKK 
mice, indicating that inflammatory mediators at local tissue level were enhanced in 
E3L.LIKK mice. This enhanced activation of hepatocyte-specific NF-kB in E3L.LIKK 
mice, however, did not result in a significant increased systemic proinflammatory state 
under basal conditions as compared to their E3L littermates. Importantly, Cai et al. 
[12] demonstrated that in LIKK mice on a wild-type background, systemic levels of 
IL-6 were only mildly elevated, while IL-1b and TNFα levels were similar as in wild-
type mice. Our results show that LIKK expression on an E3L background resulted in 
a less pronounced hepatic inflammatory state as compared to LIKK expression on a 
wild-type background as described by Cai et al. [12], as reflected in a smaller increase 
in active NF-kB (1.4- vs. 2.2-fold) and mRNA levels of proinflammatory cytokines 
levels in the liver. Furthermore, under basal conditions E3L mice have lower levels of 
active NF-kB present in the liver as compared to wild-type mice (unpublished data, 
J.A. van Diepen, M.C. Wong, P.J. Voshol). This implies that E3L mice have a lower 
chronic inflammatory state than wild-type mice, which could interfere with the 
proinflammatory effects caused by expression of LIKK in the present study. Also, in 
comparison with other murine atherosclerosis models, e.g. the apoe-/- and ldlr-/- mice, 
E3L mice display a milder phenotype with respect to hyperlipidemia and increased 
inflammation [18, 19]. In the current study, basal circulating levels of some cytokines 
were at borderline of the detection limit of current assays (Supplemental Fig. 3) and as 
expected, the levels increased 5-3700x after LPS injection (Fig. 2). Furthermore, after 
stimulation with LPS, E3L.LIKK mice showed a tendency towards a higher systemic 
inflammatory state than E3L mice.
There is a strong interaction between inflammation and lipid metabolism [20]. 
For example, lowering inflammation using salicylate did not only reduced NF-kB 
activation, but concomitantly also reduced circulating cholesterol levels in E3L mice 
[21]. In line with this observation, in the present study we found higher plasma lipid 
levels at 8 weeks of Western-type diet feeding in female E3L.LIKK compared to E3L 
mice, which were confined to (V)LDL. We hypothesize that the increased lipid levels 
at this time point is accompanied by a maximal enhanced systemic inflammatory state. 
As mentioned above, lipid metabolism and inflammation strongly influence each other 
[20]. A possible cause for the increased plasma lipid levels at 8 weeks of diet is therefore 
a more enhanced inflammation in the liver, possibly due to an increased activation of 
the NF-kB pathway in the liver.  
We recently reported that male E3L.LIKK mice on chow diet also showed enhanced 
(V)LDL levels as a result of an increased hepatic VLDL-TG production rate [14], and 
found in the current study a trend towards an enhanced VLDL-apoB production in 
female E3L.LIKK mice on Western-type diet, with a similar effect-size. Possible reasons 
for the less apparent increase of VLDL-TG production in females compared to males 
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are differences in gender and/or diet. Although the increase in VLDL-TG production 
is more apparent in male E3L.LIKK mice, we used female mice in the present study. 
The main reason for this is that female E3L mice are more susceptible to develop 
atherosclerosis. In order for male E3L mice to become similarly atherosclerosis-prone 
they need to be fed Western-type diets not only with higher percentages of cholesterol, 
but also containing cholate. In addition, fructose was added in the drinking water to 
further raise their (V)LDL-cholesterol levels [22]. The increase in (V)LDL levels in 
females in the current study was only transient at 8 weeks of Western-type diet feeding 
and disappeared at 16 weeks. Since no differences in plasma lipid levels and hepatic 
mRNA expression of genes involved in lipid metabolism were detected between both 
groups at 24 weeks of diet, the increased VLDL-TG production at 8 weeks of diet is 
likely to be transient. At present, we cannot explain the transient nature of this increase 
in (V)LDL levels, but it may be the result of a progressive negative feedback mechanism 
to reduce the hepatic VLDL production which takes place during long-term Western-
type diet feeding. 
Dyslipidemia is regarded as the classical risk factor for atherosclerosis development. 
The transiently enhanced total cholesterol levels, resulting in a modest increase (+17%) 
in cumulative total cholesterol exposure upon LIKK expression, thus likely contributed 
to the enhanced atherosclerosis development. Previous diet-induced atherosclerosis 
studies in E3L mice have consistently demonstrated that there is a positive logarithmic 
relation between the cumulative cholesterol exposure during the study and the 
atherosclerotic lesion area (J.F.P. Berbée, P.C.N. Rensen, unpublished data). In agreement 
with these previous observations, we did observe such a significant logarithmic relation 
in E3L mice but not in E3L.LIKK mice. This suggests that the increase in atherosclerotic 
lesion area in E3L.LIKK mice can only partly be attributed to the transiently enhanced 
plasma cholesterol levels and that additional mechanisms are involved.
Inflammation is the second main risk factor for atherosclerosis. Enhanced 
extravascular or systemic inflammation, by the periodontal pathogen Porphyromonas 
gingivalis [23] or by repeated administration of LPS [24], respectively, promotes 
atherosclerosis development. In addition, in humans, low-grade systemic inflammation 
is associated with enhanced risk of coronary artery disease [25, 26]. It is thus likely 
that, as discussed above, the increased sensitivity for proinflammatory triggers, such as 
LPS, in E3L.LIKK mice also directly contributed to the enhanced atherosclerotic lesion 
formation.
We excluded higher circulating levels of proinflammatory Ly6C-hi monocytes as 
being another possible contributor to the aggravated atherosclerosis development in 
E3L.LIKK mice. Adhesion of monocytes to endothelial cells and subsequent migration 
into the vessel wall is one of the crucial steps in atherosclerotic lesion formation. 
Ly6C-hi monocytes are more prone to adhere to activated endothelium than Ly6C-lo 
monocytes and are, therefore, associated with enhanced atherosclerosis development 
[27]. We found that E3L.LIKK mice had similar levels of circulating subsets of 
monocytes as compared to their E3L controls, which is consistent with the observed 
similar number of adhering monocytes to the vascular wall. 
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In line with the enhanced atherosclerosis development that we observed in E3L.
LIKK mice, Luchtefeld et al. [11] have reported that gp130-deficient mice with defective 
IL-6 signaling specifically in hepatocytes, develop less atherosclerosis, indicating that 
modulation of hepatic inflammation can have profound effects on atherogenesis. 
These studies also underscore that enhanced inflammation in the liver, e.g. due to 
viral hepatitis or steatohepatitis, may augment atherosclerosis development. Indeed, 
in several clinical studies, such hepatic pathological conditions are associated with 
an elevated occurrence of CVD [28, 29, 30]. Even after adjustment for classical risk 
factors for CVD, such as LDL cholesterol levels, chronic hepatitis C infection was still 
significantly associated with increased atherosclerosis in a cross-sectional study [30]. 
Together, these findings suggest that there is a direct effect of hepatic inflammation 
on atherosclerosis development, independent of systemic lipid levels. Moreover, they 
suggest that in addition to the currently used lipid-targeted drugs such as statins, 
reducing NF-κB activity in the liver may be a promising additive therapeutic strategy 
against atherosclerosis development.
In conclusion, we have shown that hepatocyte-specific activation of NF-kB leads 
to larger and more advanced atherosclerotic lesions. Our studies furthermore suggest 
that both the transient elevated (V)LDL cholesterol levels as well as the increased 
sensitivity to proinflammatory stimuli are most likely responsible for this aggravating 
effect on atherosclerosis. These findings contribute to the present understanding of 
the role of the liver, and more specifically the role of hepatic NF-kB, in atherosclerosis 
development and may help to develop new innovative anti-atherosclerotic strategies.
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Supplemental Table 1. Primers used for RT-PCR.




















IKKβ, IκB kinase-β; Apob, apolipoprotein B; Cd3, marker for (NK)T cells; CD68, marker for macrophages 
(Kupffer cells); Cpt1a, carnitine palmitoyltransferase 1a; Cyclo, cyclophilin; Fas, fatty acid synthase; Gapdh, 
glyceraldehyde-3-phosphate dehydrogenase; Hmgcr, HMG-CoA reductase; Hprt, hypoxanthine-guanine 
phosphoribosyl transferase; IL-1β, interleukin-1b; IL-6, interleukin-6; MCP-1, monocyte chemoattractant 
protein-1; Mttp, microsomal triglyceride transfer protein; Srebp-1c, sterol-regulatory element binding 
protein; Vα14, marker for NKT cells.
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Supplemental Table 2. Expression of LIKK increases hepatic MCP-1 expression. 
Gene E3L E3L.LIKK Significance
Cytokines and chemokines
IL-1β 1.00 ± 0.05 1.24 ± 0.14 P = 0.085
Il-6 1.00 ± 0.13 1.24 ± 0.20 n.s.
MCP-1 1.00 ± 0.27 1.39 ± 0.32* P = 0.049
Inflammatory cells
CD68 1.00 ± 0.29 1.15 ± 0.14 n.s.
CD3 1.00 ± 0.14 0.69 ± 0.30 n.s.
Vα14 1.00 ± 0.08 0.94 ± 0.21 n.s.
VLDL secretion
Apob 1.00 ± 0.24 1.00 ± 0.33 n.s.
Mttp 1.00 ± 0.13 1.15 ± 0.28 n.s.
Lipogenesis
Srebp-1c 1.00 ± 0.19 1.46 ± 0.49 n.s.
Fas 1.00 ± 0.21 0.83 ± 0.19 n.s.
After 24 weeks of Western-type diet, E3L.LIKK and E3L mice were sacrificed, livers were isolated and 
mRNA expression of indicated targets were quantified by RT-PCR. Data are calculated as fold difference 
as compared to the control group. Values are means ± SEM (n=6-15). *P<0.05 compared to the control 
group. n.s., not significant. IKKβ, IκB kinase-β; Apob, apolipoprotein B; Cd3, marker for (NK)T cells; CD68, 
marker for macrophages (Kupffer cells); Cpt1a, carnitine palmitoyltransferase 1a; Cyclo, cyclophilin; Fas, 
fatty acid synthase; Gapdh, glyceraldehyde-3-phosphate dehydrogenase; Hmgcr, HMG-CoA reductase; 
Hprt, hypoxanthine-guanine phosphoribosyl transferase; IL-1β, interleukin-1b; IL-6, interleukin-6; MCP-1, 
monocyte chemoattractant protein-1; Mttp, microsomal triglyceride transfer protein; Srebp-1c, sterol-regu-
latory element binding protein; Vα14, marker for NKT cells.
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Supplemental Fig. 1. Expression of LIKK does not affect body weight and food intake. 
E3L.LIKK (black symbols) and E3L mice (white symbols) were fed a Western-type diet for 24 
weeks. Body weight (A) and food intake (B) were measured weekly. Values are means ±SEM; 
n=15/group.


















































































Supplemental Fig. 1. Expression of LIKK does not affect body weight and food intake. 
E3L.LIKK (black symbols) and E3L mice (white symbols) were fed a Western-type diet for 24 
weeks. Body weight (A) and food intake (B) were measured weekly. Values are means ±SEM; 
n=15/group.
Supplemental Fig. 1. Expression of LIKK does not affect body weight and food intake. E3L.
LIKK (black symbols) and E3L mice (white symbols) were fed a Western-type diet for 24 weeks. 
Body weight (A) and food intake (B) were measured weekly. Values are means ±SEM; n=15/group.




















































































































































































































































































































Supplemental Fig. 2. Expression of LIKK increases hepatic IKKβ mRNA and protein 
expression, and NF-κB protein activity. After 24 weeks of Western-type diet, E3L.LIKK (black 
bars) and E3L mice (white bars) were sacrificed, livers were isolated and hepatic mRNA 
expression of human IKKß (A) and murine IKKβ (B) was quantified by RT-PCR. Human IKKβ is 
expressed as fold difference compared to E3L.LIKK mice and murine IKKβ to E3L mice. The 
inserts show representative bands of two mice per group of the qPCR product run on a gel. 
Values are mean ±SEM; n=14-15/group; nd: not detectable, ****P<0.0001 versus E3L. Hepatic 
protein expression of IKKβ normalized to tubulin (C) and phosphorylated NF-κB p65Ser536 
normalized to total NF-κB (D) was assessed in E3L.LIKK (black bars) and E3L mice (white 
bars). Values are mean ±SEM; n=6-7/group; *P<0.05, **P<0.01 versus E3L controls.
Supplemental Fig. 2.  Expression of LIKK increases hepatic IKKb mRNA and protein 
expression, and NF-kB protein activity. After 24 weeks of Western-type diet, E3L.LIKK 
(black bars) and E3L mice (white bars) were sacrificed, livers were isolated and hepatic mRNA 
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Supplemental Fig. 3. LIKK does not affect plasma cytokines after 0 and 24 weeks of diet. 
E3L.LIKK (black bars) and E3L (white bars) were fed 24 weeks of Western-type diet. Plasma 
levels of the indicated cytokines were measured at t=0 and 24 weeks of diet. Values are means 
±SEM; n=15/group.
Supplemental Fig. 3. LIKK does not affect plasma cytokines after 0 and 24 weeks of diet. E3L.
LIKK (black bars) and E3L (white bars) were fed 24 weeks of Western-type diet. Plasma levels 
of the indicated cytokine  were measured at t=0 and 24 weeks of diet. Values are means ±SEM; 
n=15/group.
expression of human IKKß (A) and murine IKKb (B) was quantified by RT-PCR. Human IKKb 
is expressed as fold difference compared to E3L.LIKK mice and murine IKKb to E3L mice. The 
inserts show representative bands of two mice per group of the qPCR product run on a gel. 
Values are mean ±SEM; n=14-15/group; nd: not detectable, ****P<0.0001 versus E3L. Hepatic 
protein expression of IKKb normalized to tubulin (C) and phosphorylated NF-κB p65Ser536 
normalized to total NF-kB (D) was assessed in E3L.LIKK (black bars) and E3L mice (white bars). 
Values are mean ±SEM; n=6-7/group; *P<0.05, **P<0.01 versus E3L controls.
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Supplemental Fig. 4. LIKK does not affect circulating subsets of monocytes. Blood was 
drawn from E3L.LIKK (black circles) and E3L (open circles) mice fed a Western-type diet for 8 
weeks. The number of monocytes (A) and Ly6C-hi (B), Ly6C-med (C) and Ly6C-lo (D) 
expressing subsets were determined by FACS analysis. n=7-8/group.















































































Supplemental Fig. 5. LIKK transiently increases plasma triglycerides and phospholipids.
E3L.LIKK (black symbols) and E3L mice (white symbols) were fed a Western-type diet for 24 
weeks. Plasma was obtained every 4 weeks to determine triglycerides (TG) (A) and 
phospholipids (PL) (B) concentration over time. Values are means ±SEM; n=15/group; *P<0.05,
***P<0.001.
Supplemental Fig. 4. LIKK does not affect circulating subsets of monocytes. Blood was drawn 
from E3L.LIKK (black circles) and E3L (open circles) mice fed a Western-type diet for 8 weeks. 
The number of monocytes (A) and Ly6C-hi (B), Ly6C-med (C) and Ly6C-lo (D) expressing 
subsets were determined by FACS analysis. n=7-8/group.
Supplemental Fig. 5. LIKK transiently increases plasma triglycerides and phospholipids. E3L.
LIKK (black symbols) and E3L mice (white symbols) were fed a Western-type diet for 24 weeks. 
Plasma was obtained every 4 weeks to determine triglycerides (TG) (A) and phospholipids (PL) 
(B) concentration over time. Values are means ±SEM; n=15/group; *P<0.05, ***P<0.001.
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Supplemental Fig 6. Expression of LIKK tends to increase VLDL-apoB production. After 8 
weeks of Western-type diet, E3L.LIKK (black bars) and E3L mice (white bars) were fasted 4 
hours and injected with Trans35S and tyloxapol, and blood samples were drawn after tyloxapol 
injection. The rate of TG production was calculated from the slopes of the curves from the 
individual mice (A). After 120 min., the total VLDL-fraction was isolated by ultracentrifugation, 
35S-activity was counted, and the production rate of newly synthesized VLDL-35S-apoB was 
determined (B). Values are means ±SEM; n=5-11/group. 








































































































































































Supplemental Fig. 7. LIKK does not affect liver lipid content. After 24 weeks of Western-
type diet, the livers of E3L.LIKK (black bars) and E3L mice (white bars) were isolated and 
triglyceride (TG) (A), phospholipid (PL) (B), total cholesterol (TC) (C), free cholesterol (FE) (D), 
cholesteryl ester (CE) (E) content was determined. Values are means ±SEM; n=14-15/group. 
Supplemental Fig. 6. Expression of LIKK tends to increase VLDL-apoB production. After 
8 weeks of Western-type diet, E3L.LIKK (black bars) and E3L mice (white bars) were fasted 4 
hours and injected with Trans35S and tyloxapol, and blood samples were drawn after tyloxapol 
injection. The rate of TG production was calculated from the slopes of the curves from the 
individual mice (A). After 120 min., the total VLDL-fraction was isolated by ultracentrifugation, 
35S-activ ty was counted, and the production rate of newly synth ized VLDL-35S-apoB was 
determined (B). Values are means ±SEM; n=5-11/group.
Supplemental Fig. 7. LIKK does not 
affect liver lipid content. After 24 weeks 
of Western-type diet, the livers of E3L.
LIKK (black bars) and E3L mice (white 
bars) were isolated and triglyceride 
(TG) (A), phospholipid (PL) (B), total 
cholesterol (TC) (C), free cholesterol 
(FE) (D), cholesteryl ester (CE) (E) 
content was determined. Values are 
means ±SEM; n=14-15/group.
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SUPPLEMENTAL FIGURE 8
Supplemental Fig. 8. Representative pictures of HPS-stained segments classified in 
different severities. Atherosclerotic lesions are categorized into mild (type I-III) and severe 
(type IV-V) phenotypes. Magnification 200x.
(A). No lesion.
(B). Type I, early fatty streak: per section up to 10 foam cells present in the intima.
(C). Type II, regular fatty streak: more than 10 foam cells present in the intima.
(D). Type III, mild plaque: extension of foam cells into the media and covered by a fibrotic cap.
(E). Type IV, moderate plaque: a more progressive lesion infiltrating into the media, fibrosis in 
the media, without loss of architecture.
(F). Type V, severe plaque: the media is severely damaged, elastic lamina are broken, 
presence of cholesterol clefts, mineralization and/or necrosis.
Supplemental Fig. 8. Representative pictures of HPS-stained segments classified in different 
severities. Atherosclerotic lesions are categorized into mild (type I-III) and severe (type IV-V) 
phenotypes. Magnification 200x. (A) No lesion. (B) Type I, early fatty streak: per section up to 10 
foam cells present in the intima. (C) Type II, regular fatty streak: more than 10 foam cells present 
in the intima. (D) Type III, mild plaque: extension of foam cells into the media and covered 
by a fibrotic cap. (E) Type IV, moderate plaque: a more progressive lesion infiltrating into the 
media, fibrosis in the media, without loss of architecture. (F) Type V, severe plaque: the media is 
severely damaged, elastic lamina are broken, presence of cholesterol clefts, mineralization and/
or necrosis.
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Supplemental Fig. 9. Correlation between cumulative plasma TC exposure and 
atherosclerotic lesion area. The correlation between the cumulative plasma TC exposure and 
atherosclerotic lesion area, after log transformation, in E3L (open circles) (A) and the E3L.LIKK 
mice (closed circles) (B) was determined using the Pearson correlation test. n=15/group.
Supplemental Fig. 9. Correlation between cumulative plasma TC exposure and atherosclerotic 
lesion area. The correlation between the cumulative plasma TC exposure and atherosclerotic 
lesion area, after log transformation, in E3L (open circles) (A) and the E3L.LIKK mice (closed 
circles) (B) was determined using the Pearson correlation test. n=15/group.
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In preparation
absTracT
High-fat diet (HFD) feeding increases hepatic inflammation, as evidenced by increased 
Toll-like receptor 4 (TLR4)/nuclear factor κB (NF-κB) signaling in livers of HFD-fed 
mice. In lean animal models, administration of lipopolysaccharide (LPS), a well-known 
ligand for TLR4, as well as activation of hepatic NF-κB both directly increase VLDL-TG 
production, pointing towards an important link between TLR4/NF-κB signaling and 
hepatic VLDL-TG production. Furthermore, TLR4 deficiency has recently been shown 
to protect against HFD-induced hepatic inflammation. The aims of this study were to 
investigate 1) whether FA composition of HFD based on lard (HFD-L) and palm oil 
(HFD-P) differentially affect hepatic NF-κB signaling and VLDL-TG production and 
2) whether TLR4 deficiency reduces the hepatic VLDL-TG production in HFD-fed 
mice. We demonstrate that FA composition of the HFD strongly affects hepatic 
inflammation, whereby HFD-P, but not HFD-L, markedly increased hepatic NF-κB 
signaling. However, the increase in hepatic NF-κB signaling was not accompanied by 
an increased VLDL-TG production. Furthermore, in contrast to our hypothesis, TLR4 
deficiency did not affect hepatic VLDL-TG production in mice fed HFD-L and even 
increased VLDL-TG production in mice fed HFD-P. We therefore conclude that 1) FA 
composition determines the ability of HFD to induce hepatic inflammation, 2) HFD-
P-induced hepatic inflammation does not increase VLDL-TG production, and 3) TLR4 
deficiency does not reduce VLDL-TG production in HFD-fed mice.
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inTrodUcTion
Obesity and high-fat diet (HFD) feeding are associated with a chronic low-grade 
inflammation as characterized by activation of inflammatory pathways in numerous 
organs including the liver, which have been linked to metabolic disturbances such as 
insulin resistance and dyslipidemia.1,2 Activation of inflammatory pathways has shown 
to causally interact with metabolic pathways.1,3 We recently reported that hepatic 
activation of the inflammatory IKK-ß/NF-κB pathway induced hypertriglyceridemia 
by increasing hepatic VLDL-TG production 2. In addition, administration of bacterial 
lipopolysaccharide (LPS) in rodents directly increases VLDL-TG production.4 LPS is 
a major component of the cell wall of Gram-negative bacteria and is a potent inducer 
of NF-κB activity via activation of Toll-like receptor (TLR) 4,5 proposing the TLR4/
NF-κB pathway as a candidate linking inflammation and dyslipidemia. 
Interestingly, accumulating evidence exists that beside LPS, also saturated fatty 
acids (SFAs) may serve as ligands for TLR4.6, 7 Moreover, SFAs have been reported to 
increase NF-κB activity and proinflammatory cytokine expression in a TLR4 dependent 
manner in various tissues,7,8 while unsaturated fatty acids (UFAs) can have anti-
inflammatory effects.9 It has been suggested that HFD feeding, by increasing plasma 
and tissue SFA concentrations, could induce local tissue inflammation via activation 
of TLR4. Accordingly, TLR4 deficient mice are protected against hepatic inflammation 
induced by both SFA infusion or HFD feeding.7,10 
The aims of the current study were to investigate 1) whether FA composition of 
the HFD based on lard (HFD-L) and palm oil (HFD-P) differently affects NF-κB 
signaling and VLDL-TG production, and 2) whether TLR4 deficiency reduces the 
hepatic VLDL-TG production in HFD-fed mice. We show that HFD-P, but not HFD-L, 
markedly induced NF-κB signaling, which however did not increase hepatic VLDL-TG 
production. In addition, in contrast to our hypothesis, TLR4 deficiency did not affect 
hepatic VLDL-TG production in mice fed a HFD-L and even increased VLDL-TG 
production in mice fed a HFD-P.
maTerials and meThods
animals and diets
TLR4 deficient (TLR4-/-) mice on a C57Bl/6J background that have been described 
before11 were kindly provided by Dr. S. Akira and Dr. T. van der Poll, and bred in our 
animal facility. Male TLR4-/- mice and wild-type (WT) littermates were housed under 
standard conditions with a 12-hour light-dark cycle and had free access to food and 
water. At the age of 12 weeks, animals were assigned to a high fat diet (HFD), which 
provided 45% energy from lipids (D12451, Research Diet Services, Wijk bij Duurstede, 
The Netherlands). The HFDs that were used were identical, except for the source of 
fat in the diet, that was either lard (lard-based high fat diet; HFD-L) or palm oil (palm 
oil-based high fat diet; HFD-P), which have been described before.12 Macronutrient 
composition of both diets is listed in table 1. In addition, details of FA composition 
Tlr4 deficiency does noT redUce Vldl-TG prodUcTion
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of both diets are shown in table 2. All experiments were approved by the institutional 
ethical committee on animal care and experimentation of the Leiden University 
Medical Center.
western blot analysis
Liver tissue was homogenized by Ultraturrax (22,000 rpm; 2x5 sec) in an ice-cold 
buffer (pH 7.4) containing 30 mM Tris.HCl, 150 mM NaCl, 10 mM NaF, 1 mM 
EDTA, 1 mM Na3VO4, 0.5% (v/v) Triton X-100, 1% (v/v) SDS and protease inhibitors 
(Complete, Roche, Mijdrecht, The Netherlands) at a 1:10 (w/v) ratio. Homogenates 
were centrifuged (16,000 rpm; 15 min, 4°C) and the protein content of the supernatant 
was determined using the BCA protein assay kit (Pierce, Rockford, IL). Proteins (20-50 
µg) were separated by 7-10% SDS-PAGE followed by transfer to a polyvinylidene 
fluoride (PVDF) membrane. Membranes were blocked for 1 h at room temperature 
in Tris-buffered saline with Tween-20 (TBST) with 5% non-fat dry milk followed by 
an overnight incubation with the following antibodies: p-Ser536 NF-κB p65 (#3031), 
NF-κB p65 (#3034), IκBα (#9242) (all from Cell Signalling) or ß-actin (#A5441; 
Sigma). Blots were then incubated with a horseradish peroxidase (HRP)-conjugated 
Table 1. Macronutrient composition of the high fat lard diet (HFD-L) and high fat palm oil 
diet (HFD-P)
Macronutrients HFD-L (g/kg) HFD-P (g/kg)
Casein 200 200
L-cystine 3 3




Soybean oil 25 25
Palm oil 0 177.5
Lard 177.5 0
Mineral Mix 10 10
Dicalcium phosphate 13 13
Calcium carbonate 5.5 5.5
Potassium citrate 16.5 16.5
Vitamin mix 10 10
Choline bitartrate 2 2
Other 141.85 141.85
FD&C red dye 0.05 0.05
Total 858.15 858.15
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secondary antibodies for 1 h at room temperature. Bands were visualized by enhanced 
chemiluminescence (ECL) and quantified using Image J (NIH, USA).
hepatic Vldl-TG production
To measure VLDL production in vivo, mice were fasted for 4 hours and anesthetized 
by intraperitoneal injection of acepromazine (6.25 mg/kg Neurotranq, Alfasan 
International BV, Weesp, The Netherlands), midazolam (6.25 mg/kg Dormicum, 
Roche Diagnostics, Mijdrecht, The Netherlands), and fentanyl (0.31 mg/kg Janssen 
Pharmaceuticals, Tilburg, The Netherlands). At t=0 min, Triton WR-1339 (Sigma-
Aldrich, St Louis, MO) was injected intravenously (0.5 mg/g body weight, 10% solution 
in PBS) to block serum VLDL clearance. Blood samples were drawn before (t=0) and 
15, 30, 60 and 90 min after injection into chilled capillaries, centrifuged and used for 
determination of plasma TG concentration using a commercially available enzymatic 
kit from Roche Molecular Biochemicals (Indianapolis, IN).
statistical analysis
Data are presented as means ± SD. Statistical significant differences were calculated using 
a Student’s T-test (SPSS Inc, Chicago, IL). P<0.05 was regarded statistically significant.
resUlTs
a palm oil-based, but not a lard-based hfd, increases hepatic nf-κb signaling in wT mice
We first determined whether FA composition of a HFD would affect hepatic NF-κB 
signaling. Therefore, WT mice were fed a HFD based on either lard (HFD-L) or palm oil 
Table 2. Fatty acid composition of the high fat lard diet (HFD-L) and high fat palm oil diet 
(HFD-P)
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(HFD-P) or a control chow diet for 5 weeks. Hepatic NF-κB signaling was determined 
by western blot on homogenized liver tissue. Surprisingly, the HFD-L did not increase 
hepatic pNF-κB signaling compared to a chow diet (Fig 1). In contrast, the HFD-P 
strongly increased hepatic phosphorylation of NF-κB over total NF-κB compared to 
the chow diet (+175%; P<0.05; Fig 1C) and also tended to decrease total IκBα over 
ß-actin (Fig 1D). This indicates increased IκBα ubiquitination and degradation by the 
proteasome, which reflects activation of the NF-κB pathway, albeit that the reduction 
in total IκBα did not reach statistical significance (P=0.09). Taken together, these data 
show that a HFD-P, but not a HFD-L, increases hepatic NF-κB signaling in WT mice. 
Figure 1. A high fat palm oil diet (HFD-P), but not a high fat lard diet (HFD-L), increases 
hepatic NF-κB signaling in WT mice. WT mice were either fed a HFD-L, HFD-P or a control 
chow diet (chow) for 5 weeks. NF-κB signaling was measured in liver tissue by phosphorylation 
of NF-κB (A,C) and total IκBα protein (B,D). Representative Western blots are shown for 2 mice 
per group (A,B). Ratios of phosphorylated NF-κB over total NF-κB and IκBα over ß-actin were 
quantified (B,D). Values are means ± SD (n=7-8). *P<0.05.
The increased hepatic nf-κb signaling in hfd-p-fed mice does not translate into an increased 
Vldl-TG production
Since activation of hepatic NF-κB signaling has been shown to increase VLDL-TG 
production,2 we investigated whether a HFD-P increases the VLDL-TG production 
compared to a HFD-L. Therefore, WT mice were fed a HFD-P or HFD-L and the rate of 
VLDL-TG production was measured by determining plasma TG levels after intravenous 
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Figure 2. TLR4 deficiency does not affect VLDL-TG production in mice fed a high fat lard diet 
(HFD-L) and increases VLDL-TG production in mice fed a high fat palm oil diet (HFD-P). 
TLR4-/- and WT mice were fed a HFD weeks and VLDL-TG production was measured after a 
4 hour fasting period. Mice were intravenously injected with Triton WR1339 (t=0) and blood 
samples were drawn at the indicated time points. TG concentrations were determined in plasma 
of WT mice (open circles) and TLR4-/- mice (closed circles) fed a HFD-L (A) or HFD-P (B) and 
plotted as the increase in plasma TG relative to t=0 (A). Values are means ± SD (n=7-8). 
Triton WR1339 injection. Surprisingly, the increased hepatic NF-κB signaling in HFD-
P-fed mice that we had observed did not translate into an increased hepatic VLDL-TG 
production (Fig. 2A and B). The VLDL-TG production, as determined from the slope 
of the curve from all individual mice, was similar between mice fed a HFD-P and 
HFD-L (6.01 ± 1.32 vs 5.28 ± 0.95 mM/h; N.S.)
Tlr4 deficiency does not affect Vldl-TG production in mice fed a hfd-l and increases Vldl-TG 
production in mice fed a hfd-p
Previous studies reported that TLR4 deficiency reduces hepatic NF-κB signaling in HFD-fed 
mice.13 Therefore, we investigated whether TLR4 deficiency would also decrease VLDL-TG 
production in HFD-fed mice. TLR4-/- and WT mice were fed a HFD-L or HFD-P and 
the rate of VLDL-TG production was measured by determining plasma TG levels after 
intravenous Triton WR1339 injection. In HFD-L fed mice, TLR4 deficiency did not affect 
VLDL-TG production (Fig 2A). The slope of the curve from all individual mice, was similar 
between TLR4-/- and WT mice (5.53 ± 0.97 vs 5.28 ± 0.95 mM/h; N.S.). In accordance, 
basal plasma TG levels were also not affected (0.47 ± 0.12 vs 0.48 ± 0.18 mM; N.S.). 
In mice fed a HFD-P, TLR4 deficiency did not affect basal plasma TG levels (0.56 
± 0.19 vs 0.55 ± 0.17 mM; N.S.) but in contrast to our hypothesis, TLR4 deficiency 
clearly increased VLDL-TG production (Fig 2B). The rate of VLDL-TG production, 
as determined from the slope of the curve from all individual mice, was significantly 
higher in TLR4-/- compared to WT mice (7.71 ± 1.01 vs 6.01 ± 1.32 mM/h; P<0.05). 




High-fat diet (HFD) feeding induces activation of inflammatory pathways in numerous 
organs including liver.1,14 These inflammatory pathways have shown to cause metabolic 
disturbances such as insulin resistance and hypertriglyceridemia.1,2 Both administration 
of LPS, the natural ligand for TLR4, as well as direct hepatic activation of NF-κB, 
have been reported to increase hepatic VLDL-TG production,2,4 thereby contributing 
to hypertriglyceridemia. Deficiency of TLR4 protects against HFD induced hepatic 
inflammation7,13 but so far it is unknown whether TLR4 deficiency is able to reduce 
VLDL-TG production after HFD-feeding. Surprisingly, our results document that 
TLR4 deficiency did not affect hepatic VLDL-TG production in animals fed a HFD-L, 
and even increased hepatic VLDL-TG production in animals fed a HFD-P. Therefore, 
we conclude that, in opposite to expectations, TLR4 deficiency did not reduce hepatic 
VLDL-TG production in HFD-fed mice. 
Although it has previously been shown that HFD feeding induces hepatic 
inflammation 1, in the current study we reveal that the type of HFD that is used can 
highly affect the activation of hepatic NF-κB signaling; a HFD based on palm oil clearly 
induced hepatic NF-κB activity, while a HFD based on lard did not affect hepatic 
NF-κB activity. It will be interesting to elucidate which specific FAs in the HFD-P 
are responsible for the activation of hepatic inflammation, which is difficult to obtain 
from this study since the HFD-P and HFD-L differ with respect to more than one 
FA. In general, it has been shown that SFAs activate inflammatory pathways, while 
unsaturated fatty acids (UFAs) conduct anti-inflammatory effects.6,9 Therefore, it is 
most likely that the increase in one or more of the SFAs (C12:0, C16:0, C20:0 or C22:0) 
or the reduction in one of the UFAs (C16:1 or C18:1) in the HFD-P are responsible for 
the increased hepatic inflammation in mice fed this HFD.
Another intriguing observation of the current study is that the HFD-P induced 2.8-
fold increase in hepatic NF-κB activity did not translate into an increased VLDL-TG 
production. We recently showed that hepatocyte-specific overexpression of IKK-ß 
induced a 1.6-fold increase in hepatic NF-κB activity, which significantly increased 
VLDL-TG production.2 In the liver, hepatocytes are responsible for the production of 
VLDL-TG, while Kupffer cells are the resident macrophages that are responsible for 
a first line of defense against inflammatory agents.15, 16 Although in vitro, SFAs have 
shown to directly activate inflammatory pathways in hepatocytes,9,17 HFD-derived 
SFAs in vivo might primarily act on Kupffer cells rather than on hepatocytes. It is 
conceivable that Kupffer cells require a certain level of activation of inflammatory 
signaling to secondarily activate inflammatory signaling in hepatocytes via local 
cytokine production. This would explain why administration of LPS, that strongly 
increases inflammatory pathways, but not HFD-derived SFAs, that only moderately 
increases inflammatory pathways, is able to increase hepatic VLDL-TG production.4 
The second hypothesis of the current study was that TLR4 deficiency decreases 
the VLDL-TG production HFD-fed mice. From our data we conclude that, opposed 
to expectations, TLR4 deficiency did not reduce hepatic VLDL-TG production in 
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HFD-fed mice. One mechanism that could explain this unexpected observation is 
the fact we used only male mice for our experiments. A sexual dimorphism has been 
reported for TLR deficient mice, showing that TLR2 and TLR4 deficient female mice 
fed a HFD are more evidently protected against metabolic disturbances compared with 
males.7,18 In the study of Shi et al,7 although male TLR4 deficient male mice were clearly 
protected against HFD-induced hepatic inflammation, they were not protected against 
the development of insulin resistance. Since insulin resistance has been linked to an 
increased VLDL-TG production,19 this could possibly explain why TLR4 deficiency in 
male mice did not reduce the VLDL-TG production in the current study. 
It is remarkable that the type of HFD strongly influences the rate of VLDL-TG 
production in TLR4 deficient mice. A previous study from our group already revealed 
that the HFD-L and HFD-P differently affect other metabolic parameters such as tissue-
specific insulin resistance 12. One of the most intriguing findings of this study however 
is the observation that TLR4 deficiency actually increased the hepatic VLDL-TG 
production in mice fed a HFD-P, an observation that is in contrast to our hypothesis and 
rather difficult to explain. Earlier studies have reported that TLR4 deficiency decreases 
hepatic NF-κB activity and cytokine expression in HFD-fed mice.7,13 In our study we 
did not yet verify whether TLR4 deficiency indeed decreased hepatic inflammation. 
It is possible that absence of TLR4 causes compensatory upregulation of other TLRs 
such as TLR2, which has also been linked to HFD-induced hepatic inflammation.18 
Actually, both C12:0 and C16:0 that are more abundant in the HFD-P have shown 
to be able to activate TLR2 in vitro.20,21 Theoretically, upregulation of TLR2 in TLR4 
deficient mice fed a HFD-P could, therefore, increase rather than decrease hepatic 
inflammation and consequently increase the VLDL-TG production. Future studies 
should elucidate whether FA composition of the HFD affect metabolic parameters by 
activation of specific TLRs. In addition, whether counteracting upregulation of TLR2 
occurs in livers of TLR4 deficient mice remains to be determined; no change in TLR2 
expression has been observed in adipose tissue of TLR4 deficient mice.22
In general, we can conclude that TLR4 deficiency does not reduce VLDL-TG 
production in HFD-fed mice. In addition, it appears that the FA composition of 
the HFD strongly affects the VLDL-TG production in TLR4 deficient mice. Our 
observations imply that the FA composition of the HFD in experimental studies on 
metabolism and inflammation can strongly affect the conclusions to be drawn.
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absTracT
Inflammation plays a key role in the pathogenesis of obesity. Chronic overfeeding 
leads to macrophage infiltration in the adipose tissue, resulting in pro-inflammatory 
cytokine production. Both microbial and endogenous danger signals trigger assembly 
of the intracellular innate immune sensor Nlrp3 resulting in caspase-1 activation and 
production of pro-inflammatory cytokines IL-1β and IL-18. Here, we showed that mice 
deficient in Nlrp3, ASC and caspase-1 were resistant to the development of high fat 
diet-induced obesity, which correlated with protection from obesity-induced insulin 
resistance. Further, hepatic triglyceride content, adipocyte size and macrophage 
infiltration in adipose tissue were all reduced in mice deficient in inflammasome 
components. Monocyte chemoattractant protein (MCP)-1 is a key molecule that 
mediates macrophage infiltration. Indeed, defective inflammasome activation was 
associated with reduced MCP-1 production in adipose tissue. Furthermore, plasma 
leptin and resistin that affect energy use and insulin sensitivity were also changed 
by inflammasome-deficiency. Detailed metabolic and molecular phenotyping 
demonstrated that the inflammasome controls energy expenditure and adipogenic 
gene expression during chronic overfeeding. These findings reveal a critical function 
of the inflammasome in obesity and insulin resistance and suggest inhibition of the 
inflammasome as a potential therapeutic strategy.
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inTrodUcTion
The discovery of NOD-like receptors (NLRs) as essential components of the 
immune system triggered significant interest in the study of their contribution to the 
pathogenesis of inflammatory and autoimmune diseases. NLRs comprise a large family 
of intracellular proteins that are believed to be primarily involved in the innate immune 
response to microbial pathogens through the recognition of conserved pathogen-
associated molecular patterns.1-3 However, they also contribute to inflammation by 
sensing ‘danger signals’, i.e. endogenous molecules that are produced during tissue 
damage or inflammation.3-5 A prominent example of an NLR protein implicated in 
auto-inflammatory disease is Nlrp3 (also called Cryopyrin)6. Nlrp3 activation induces 
the recruitment and autocatalytic activation of the cystein protease caspase-1 in a large 
cytosolic protein complex named the ‘inflammasome.2-7 The bipartite adaptor protein 
ASC bridges the interaction between Nlrp3 and the caspase-1 by means of homotypic 
interactions involving its pyrin and CARD motifs, making it essential for activation of 
the inflammasome.7 Activated caspase-1 processes the cytosolic precursors of the related 
cytokines interleukin (IL)-1β and IL-18, thus allowing secretion of the biologically 
active cytokines. Hence, mice lacking caspase-1 are defective in the maturation and 
secretion of IL-1β and IL-18.8-10 IL-1β participates in the generation of systemic and 
local responses to infection, injury and immunological challenges by inducing the 
“acute phase response” characterized by fever, synthesis of acute phase proteins and 
leukocytosis.11 Although IL-18 lacks the pyrogenic activity of IL-1β, it is involved in 
the induction of several secondary pro-inflammatory cytokines, chemokines and cell 
adhesion molecules.12,13 
Obesity is accompanied by the development of a chronic low grade inflammation 
that is promoted by expanding adipose tissue.14,15 Expansion of fat mass characterized 
by adipocyte enlargement fuels the infiltration of macrophages into the adipose 
tissue.16,17 Altogether, the enhanced inflammatory trait of the adipose tissue instigates 
the production of cytokines that contribute to the development of insulin resistance.18-19 
IL-1β and IL-18 have also been linked to the development of obesity-induced insulin 
resistance. IL-1β has been reported to inhibit adipocyte differentiation,20 while the 
absence of IL-18 induced obesity and insulin resistance.21,22 Moreover, high fat diet 
feeding resulted in the activation of caspase-1 in adipose tissue in mice.23 Interestingly, 
absence of NLRP3 has recently been shown to prevent the development of obesity-
induced insulin resitance.24 However, the role of caspase-1 and the inflammasome 
member ASC in the development of high fat diet-induced obesity has not been 
characterized. Chronic activation of inflammasome-mediated caspase-1 activity may 
underlie the development of obesity-induced insulin resistance. To understand the 
role of the inflammasome in obesity and insulin resistance, we studied the response of 
Nlrp3-/-, ASC-/- and Casp1-/- mice to high fat diet (HFD) feeding. Our results indicate 
a major role for the inflammasome in modulating obesity and reveal its critical function 
in obesity-induced inflammation and insulin resistance. 





Nlrp3-/-, ASC-/- and Casp1-/- mice backcrossed to C57BL/6 background for at least 
10 generations have been described before.33,34 Mice were housed in a pathogen-free 
facility and the animal studies were conducted under protocols approved by St. Jude 
Children’s Research Hospital Committee on Use and Care of Animals. All mice were 
male, 8-10 weeks old at the start of the diet intervention and maintained in a SPF 
facility. All experiments were conducted under protocols approved by the St. Jude 
Children’s research Hospital Committee on Use and Care of Animals and the animal 
experimentation committee of Leiden University Medical Center.
diet intervention 
Male mice received a low fat diet (LFD) or high fat diet (HFD) for 16 weeks, providing 
10 or 45% energy percent in the form of fat (D12450B or D12451, Research Diets). 
At the end of the feeding experiment, blood was collected in EDTA-coated tubes and 
centrifuged to collect plasma. Liver and epididymal white adipose tissue were dissected, 
weighed, and immediately frozen in liquid nitrogen. All studies described below were 
performed in animals fed the HFD. 
hyperinsulinemic euglycemic clamp 
The hyperinsulinemic euglycemic clamp study was performed as published 
previously.21,35,36 Plasma glucose, insulin and free fatty acid levels were determined 
using commercially available kits (Instruchemie, crystal chem. INC. and Wako Pure 
Chemical Industries).
calculations
Turnover rates of glucose (μmol/min/kg) were calculated during the basal period and 
in steady-state clamp conditions as the rate of tracer infusion (dpm/min) divided 
by the plasma specific activity of 3H-glucose (dpm/μmol). All metabolic parameters 
were expressed per kilogram of bodyweight. The hepatic glucose production (EGP) 
is calculated from the rate of disappearance (Rd) and glucose infusion rate (GIR) by 
the following equation: Rd = EGP + GIR. The Rd is measured from Steele’s equation 
in steady state using the tracer infusion rate (Vin) and plasma specific activity (SA) of 
3Hglucose (dpm/μmol) by the following formula: Rd = Vin/SA.
indirect calorimetry 
Groups of 8 mice per genotype were subjected to individual indirect calorimetry and 
metabolic cage measurements for a period of 84 hours (Comprehensive Laboratory 
Animal Monitoring System, Columbus Instruments). A period of 24 hours prior to 
the start of the experiment allowed the acclimatization of the animals to the cages and 
single housing. Experimental analysis started at 07:00h and continued for 60 hours. 
Statistical analysis indirect calorimetry: Averages were tested for significant differences 
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between groups using student T-Test after D’Agostino and Pearson test for normality. 
The statistical significance threshold was set at 0.05. 
histology/immunohistochemistry 
Morphometry of individual fat cells was assessed using digital image analysis. 
Microscopic images were digitized in 24 bit RGB (specimen level pixel size 1.28x1.28 
um2). Recognition of fat cells was initially performed by applying a region growing 
algorithm on manually indicated seed points, and minimum Feret diameter were 
calculated. For detection of macrophages/monocytes, an F4/80+ antibody (Serotec) 
was used. Visualization of the complex was done using 3,3’-diaminobenzidene for 5 
minutes. Negative controls were used by omitting the primary antibody. Haematoxylin 
and Eosin staining of sections was done using standard protocols.
liver triglycerides 
Liver triglycerides were determined in 10% liver homogenates prepared in buffer 
containing 250 mM sucrose, 1mM EDTA and 10 mM Tris-HCl at pH 7.5.
cell culture 
Human SGBS cells were differentiated towards adipocytes using a standard protocol. 
In short, differentiation of cells was induced by treatment with transferrin, insulin, 
cortisol, T3, dexamethasone and IBMX. IL-1β (5 ng/ml), IL-18 (25 ng/ml) or IL-1ra 
(5 μg/ml) were added during differentiation. After 10 days of differentiation, RNA was 
isolated, cDNA was prepared and qPCR analysis was performed as described below.
rna isolation and qpcr analysis 
RNA from animal tissues or cultured cells was isolated using Trizol Reagent 
(Invitrogen) following manufacturer’s instructions. RNA was reverse transcribed 
(iScript cDNA Synthesis Kit, Bio-Rad Laboratories) and real-Time PCR was done with 
a Power Sybr Green PCR master mix (Applied Biosystems) using a 7300 Real-Time 
PCR System (Applied Biosystems). Melt curve analysis was included to assure a single 
PCR product was formed. Values were corrected using the housekeeping gene 36B4 or 
beta2-microglobulin (B2M).
plasma adipokines/adipose tissue-chemokines 
Plasma concentrations of insulin, leptin and resistin are determined using Luminex 
techniques following manufacturer’s instructions. Concentration of different 
chemokines in adipose tissue was determined by ELISA following manufacturer’s 
instructions (R&D systems) or radio immune assays. Values were expressed as total 
amount per milligram WAT.
microarray gene expression analysis 
RNA quality was determined by analysis on the Agilent 2100 Bioanalyzer, and all 
samples had a RIN>8. Total RNA (100ng) was labeled, and processed automatically 
The inflammasome in obesiTy and insUlin resisTance
7 
121
on an HT MG-430 PM array plate using the Affymetrix GeneTitan system in the St. 
Jude microarray core according to the manufacturer’s instructions. The probes on the 
HT MG-430 PM array were redefined according to Dai et al.37 Normalized expression 
estimates were generated from the raw intensity values using the RMA algorithm in 
the Bioconductor library AffyPLM.38 Differentially expressed probesets were identified 
using linear models, applying moderated t-statistics that implement empirical Bayes 
regularization of standard errors.39 To adjust for both the degree of independence of 
variances relative to the degree of identity and the relationship between variance and 
signal intensity, the moderated t-statistic was extended by a Bayesian hierarchical 
model to define a intensity-based moderated T-statistic (IBMT).40 P-values were 
corrected for multiple testing using a false discovery rate method.41 Probesets with 
a FDR < 10% (q-value < 0.1) were considered to be significantly regulated. Changes 
in gene expression were related to functional changes using gene set enrichment 
analysis (GSEA).42 Gene sets were derived from Gene Ontology, KEGG, NCI, PFAM 
and Biocarta pathway databases. Enrichment Map was used for interpretation of the 
GSEA results.43 Only gene sets consisting of more than 10 and less than 500 genes were 
taken into account. The enrichment map was generated with gene sets that passed the 
significance threshold of p-value < 0.005 and similarity cut-off value of 0.6, resulting 
in a network of 226 nodes (gene sets) and 670 edges (interactions). All singletons were 
removed to create the final gene set interaction network.
statistical analysis 
Statistical significant differences were calculated using a Student’s T-test. The cut-off 
for statistical significance was set at a P-value of 0.05 or below.
resUlTs
absence of the inflammasome protects from high fat diet-induced obesity
To investigate the role of the inflammasome in the adipose tissue, we first analyzed the 
expression and activation of inflammasome downstream molecule caspase-1 in adipose 
tissue. In line with our previous work,23 caspase-1 gene expression and activation in 
white adipose tissue (WAT) of HFD fed wild-type mice were increased (Fig.1a,b). We 
next assessed the functional roles of Nlrp3, ASC and Caspase-1 in the development 
and progression of HFD-induced obesity using mice lacking Nlrp3, ASC or Caspase-
1. During 16 weeks of HFD-feeding, food intake and bodyweight development were 
examined weekly. HFD-feeding of wild-type, Nlrp3-/- (Fig. 1c), ASC-/- (Fig. 1d) 
and Casp1-/- (Fig. 1e) animals demonstrated that the absence of the inflammasome 
components protects against the development of high fat diet-induced obesity. The 
observed lean phenotype in Nlrp3-/-, ASC-/-, and Casp1-/- mice was due to defective 
inflammasome activation confirmed by significantly reduced IL-1β production, but 
not IL-6, in WAT of HFD-fed mice as compared to wild-type mice (Supplementary 
Fig. 1). The daily caloric food intake of all genotypes fed the LFD or HFD was similar 
(Fig. 1f). Concurrent with the development of HFD-induced obesity, HFD-fed 
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Figure 1. Absence of the Nlrp3-inflammasome protects against the development of HFD-
induced obesity. qPCR analysis of caspase-1 gene expression levels in epididymal WAT of LFD 
and HFD fed wild-type C57/Bl6 animals after 16 weeks of diet-intervention (A). Caspase-1 
protein levels in WAT of LFD vs. HFD-fed wild-type animals (B). Comparison of bodyweight 
gain in wild-type, Nlrp3-/-(C), ASC-/- (D) and Casp1-/- (E) animals on LFD or HFD during 
16 weeks. Daily food intake of wild-type, Nlrp3-/-, ASC-/- and Casp1-/- animals fed a LFD or 
HFD (F). Plasma concentrations of insulin (G), leptin (H) and resistin (I) in LFD and HFD-fed 
wild-type, Nlrp3-/-, ASC-/- and Casp1-/- mice. **P < 0.01; **P < 0.001; n= 6-8 mice per group. 
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wild-type animals displayed hyperinsulinemia (Fig. 1g). In contrast, HFD-fed ASC-/- 
and Casp1-/- animals had significantly lower plasma insulin and leptin levels (Fig. 
1g,h). Moreover, plasma concentrations of resistin, which is known to impair glucose 
tolerance and insulin action,25 were significantly reduced in HFD-fed Nlrp3-/-, ASC-/- 
and Casp1-/- mice (Fig. 1i). However, plasma triglycerides and cholesterol levels were 
not significantly different between all genotypes (Table 1).
asc deficient mice are protected from hfd-induced insulin resistance, liver steatosis and 
adipocyte hypertrophy
To explore the effects of the key inflammasome adaptor ASC on HFD-induced insulin 
resistance, we performed insulin and glucose tolerance tests. As shown in Fig. 2a, both 
insulin sensitivity and glucose tolerance were improved in ASC-/- mice fed the HFD 
compared to wild-type mice. We next analyzed liver and adipose tissue morphology after 
16 week of HFD intervention in wild-type and ASC-/- mice. The development of liver 
steatosis was blunted in ASC-/- mice (Fig. 2b,c). However, such striking effect of reduced 
liver Triglyceride (Tg) was not observed in Nlrp3-/- mice (Supplementary Fig. 2a). In 
line with the lower body weight and plasma leptin levels, epididymal adipose tissue 
mass was reduced in HFD-fed ASC-/- mice (Fig. 2d). Further analysis of the adipose 
tissue morphology in HFD-fed ASC-/- mice (Fig. 2e) revealed a significant reduction 
in adipocyte size (Fig. 2f,g) suggestive of an improvement in adipose tissue dynamics.26 
In contrast, obesity-induced macrophage infiltration into the adipose tissue was not 
prevented by the absence of ASC as determined by an immunohistochemical localization 
of macrophages (Fig. 2h). These results were further confirmed by qPCR analysis of the 
macrophage marker CD68 in total adipose tissue (wild-type LFD: 1 ± 0.29, wild-type 
HFD: 6.86 ± 1.87, ASC-/- LFD: 1.91 ± 0.31, ASC-/- HFD: 7.17 ± 2.17). Adipose tissue 
morphology was also examined in Nlrp3-/- mice which showed a marginal reduction in 
adipocyte size compared to the wild-type (Supplementary Fig. 2b).
Table 1. Total plasma cholesterol en triglyceride concentrations were measured after 16 
weeks of low fat or high fat diet feeding. Values are means ± SEM (n=5-10).
  Triglycerides (mg/dL) Cholesterol (mg/dL)
Wt-LFD 129 ± 11 163 ± 8
Wt-HFD 143 ± 6 185 ± 7
Casp1-/- LFD 146 ± 23 125 ± 5
Casp1-/- HFD 116 ± 14 161 ± 9
ASC-/- LFD 131 ± 15 132 ± 10
ASC-/- HFD 132 ± 11 174 ± 14
NLRP3-/- LFD 104 ± 10 178 ± 7
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S  -/- 
Figure 2. ASC-/- animals are protected against HFD-induced insulin resistance, steatosis 
and adipocyte hypertrophy. Insulin tolerance test (ITT) and glucose tolerance tests (GTT) of 
HFD-fed wild-type and ASC-/- animals (A). Liver triglyceride (Tg) levels in HFD-fed wild-type 
and ASC-/- mice (B). Liver histology as determined by hematoxylin and eosin (H&E) staining 
(C). Scale bars: 100 μm. Epididymal adipose tissue weight of LFD and HFD-fed wild-type or 
ASC-/- mice (D). Adipose tissue morphology after H&E staining of HFD-fed wild-type and 
ASC-/- mice. Scale bars: 100 μm (E) Quantification of adipocyte size using software analysis 
(F,G) Localization of macrophages in WAT of HFD-fed wild-type and ASC-/- at week 16 (H). 
Arrow indicates macrophage specific immunoreaction. Scale bars: 100 μm.
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hyperinsulinemic euglycemic clamp studies reveal a critical role for inflammasome in hfd 
induced insulin resistance
We next investigated the role of inflammasome in HFD-induced insulin resistance. 
Hyperinsulinemic euglycemic clamp studies revealed that glucose infusion rates were 
higher 5 in HFD-fed Casp1-/- mice (Fig. 3a,b) in line with an improvement in insulin 
sensitivity due to the absence of caspase-1. Blood glucose concentrations during the 
clamp as well as basal and hyperinsulinemic plasma, insulin and FFA levels are shown 
in Supplementary Fig. 3 and Supplemental Table 1. The elevated glucose infusion rate 
during hyperinsulinemia was caused by an increase of peripheral glucose uptake (Fig. 
3c) while hepatic glucose production was unchanged (Fig. 3d) compared to HFD-fed 
wildtype animals. Similarly, inhibition of caspase-1 using pralnacasan in Ob/ob 




























































































Basal                         Insulin 
Figure 3 
s  -/- 
Figure 3. Absence of caspase-1 protects against the development of HFD-induced insulin 
resistance as determined by hyperinsulinemic euglycemic clamp analysis. Glucose infusion 
rates (GIR) during the euglycemic hyperinsulinemc clamp in HFD-fed wild-type and Casp1-/- 
animals (A). Average glucose infusion rate of wild-type and Casp1-/- animals fed a HFD for 16 
weeks (B). Rate of disappearance (Rd), a measure of peripheral glucose uptake in wild-type and 
Casp1-/- animals (C). Endogenous (hepatic) glucose production (EGP) during the clamp (D). 
Mice were maintained on a HFD during 16 weeks prior to the clamp experiment. **P < 0.01; **P 
< 0.001; n= 6-8 mice per group. Error bars represent s.e.m.
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adiponectin levels (Ob/ob + vehicle vs. Ob/ob + pralnacasan: 697.5 ± 40.1 vs. 797.5 ± 
24.7, p-value< 0.05). 
caspase-1 mediates macrophage influx into adipose tissue
Since caspase-1 is the core molecule of inflammasome complex, we focused on Casp1-/- 
mice to understand the role of the inflammasome in adipose tissue function after HFD-
feeding. The resistance to HFD-induced body weight-gain in Casp1-/- animals (Fig. 1e) 
was accompanied by a dramatic reduction in WAT mass as determined by DEXA-scan 
analysis (Fig. 4a). Notably, liver triglyceride storage upon HFD feeding was unchanged 
in Casp1-/- animals as compared to wild-type mice (Supplemental Fig. 4). We next 
analyzed morphological changes of the WAT induced by HFD-feeding. As shown in Fig. 
4b, histological analysis revealed the presence of smaller adipocytes in HFD-fed Casp1-
/- animals (Fig. 4b-d). Immunohistochemical localization of macrophages in WAT of 
HFD-fed animals showed a reduction in the number of macrophages in Casp1-/- mice 
(Fig. 4e). These results were confirmed by qPCR analysis of the macrophage marker 
CD68 in WAT (Fig. 4f). Additionally, as MCP-1 is responsible for macrophage influx,27 
we analyzed protein levels of MCP-1 in adipose tissue of HFD-fed animals. As shown in 
Fig. 4g, MCP-1 protein levels were significantly reduced (P < 0.01) in adipose tissue of 
Casp1-/- animals compared to wild-type mice. To test the relative contribution of IL-1β 
and IL-18 to this phenomenon, human adipocytes (SGBS cell line) were differentiated 
towards adipocytes in the presence of IL-1β or IL-18. As shown in Supplemental Figure 
5, MCP-1 gene expression levels were enhanced by treatment of the cells with IL-1β 
(fold change vs. control: 3.6, p-value < 0.001) whereas IL-18 (fold change vs. control: 
0.57, p-value: NS) had no effect. Moreover, blockade of endogenous IL-1 bioactivity 
by treatment with IL-1 receptor antagonist (IL-1ra) during differentiation of the cells, 
led to a significant reduction in MCP-1 gene expression levels (fold change vs. control: 
0.25, p-value < 0.05) suggesting that the lower levels of MCP-1 in adipose tissue of 
HFD-fed Casp-1-/- animals (Fig. 4g), can mainly be attributed to the absence of IL-1β. 
To acquire more information regarding the molecular pathways controlled by caspase-
1 in adipose tissue during HFDfeeding, we performed a microarray analysis comparing 
HFD-fed wild-type and Casp1-/- animals (Fig. 4h) that revealed a substantial overlap 
of pathways regulated in both Casp1-/- and ASC-/- animals including cell cycle and 
immunometabolism that encompasses functional gene sets both involved in immunity 
and metabolism. However, several pathways were regulated specifically in one 
genotype. For example, sphingolipid metabolism that may generate ligands including 
ceramide, is specifically regulated in the absence of caspase-1. A complete overview of 
differentially expressed genes in adipose tissue of HFD-fed animals is available online 
(http://humannutrition2.wur.nl/stienstra2011).
defects in inflammasome increase energy expenditure in hfd-fed mice
We further analyzed the role of the inflammasome in obesity by examining energy 
expenditure, fecal output and caloric content in HFD-fed wild-type and Casp1-/- 
animals. Detailed analysis of the food intake revealed that, although the absence of 
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Figure 4. HFD-fed Casp1-/- animals are protected against obesity-induced adipocyte 
hypertrophy and macrophage influx into the adipose. Total % WAT as determined by 
DEXA scan analysis of wild-type and Casp1-/- on LFD or HFD for 16 weeks (A). Histology as 
determined by hematoxylin and eosin staining of WAT. Scale bars: 100 μm (B). Software analysis 
of adipocyte size (C) and quantification (D). Macrophage influx into the WAT as determined by 
immunohistochemistry (E). Arrow indicates macrophage specific immunoreaction. Scale bars: 
100 μm. qPCR analysis of the macrophage marker CD68 in white adipose tissue (F). Concentration 
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caspase-1 protects against the development of obesity, Casp1-/- animals eat more as 
compared to wild-type mice (Fig. 5a). However, as shown in Fig. 5b, fecal output was 
significantly enhanced in Casp1-/- animals. Analysis of the fat content of the feces as 
determined by the percent of steatocrit, revealed no significant difference between 
both genotypes (Fig. 5c). Finally, caloric content of the feces did not differ between 
both genotypes on the HFD (Fig. 5d) suggesting that the net energy intake is similar in 
HFD-fed wild-type and Casp1-/- mice. However, although total daily caloric intake was 
highly similar, feeding behavior was strikingly different between wild-type and Casp1-
/- mice (Supplemental Fig. 6a). Whereas wild-type animals displayed a constant intake, 
the Casp1-/- mice were characterized by the consumption of relatively large amounts of 
food followed by periods in which the animals did not eat at all. Inasmuch gut hormones 
are known to control food intake, we measured circulating concentrations of GIP, PYY 
and ghrelin before and two hours after the administration of a lipid bolus. Circulating 
postprandial levels of the satiety signals GIP and PYY were not different between both 
phenotypes (Supplemental Fig.9b).In contrast, whereas circulating levels of ghrelin 
were reduced in wildtype animals after receiving the lipid bolus (Supplemental Fig. 
6b), this postprandial reduction was not observed in Casp1-/- mice suggesting that 
an orexigenic action of ghrelin may contribute to modulation of the feeding pattern. 
In contrast, analysis of the energy expenditure in HFD-fed caspase-1-deficient mice 
unveiled significantly higher energy expenditure (Fig. 5e,f). These results indicate 
that although total energy intake does not differ, energy expenditure is enhanced in 
Casp1-/- animals.
discUssion
The prevalence of obesity has reached epidemic proportions worldwide. During the 
development of obesity, the morphology and functional properties of adipose tissue 
change dramatically. In addition to adipocyte hypertrophy, adipose tissue turns into 
an inflamed tissue characterized by macrophage infiltration and altered secretion of 
adipokines.14,17 Whereas the secretion of proinflammatory cytokines is enhanced, the 
production of insulin-sensitizing adipokines such as adiponectin is reduced. To date, 
several pro-inflammatory cytokines have been linked to the development of insulin 
resistance including IL-1β and IL-18.14 These cytokines are both produced as inactive 
precursors in the cytosol, and are released following their maturation by the cysteine 
protease caspase-1. The cytosolic zymogen form of caspase-1 consists of an N-terminal 
Enrichment map for gene expression in WAT of Casp-1-/- (n=3) (inner node area) and ASC-/- 
(n=3) (node borders) compared to WT (n=4) at 16 weeks after HFD intervention (H). Nodes 
represent functional gene sets, and edges between nodes their similarity. Color intensity of node 
area or border is proportional to enrichment significance in Casp-1-/- or ASC-/- mice compared 
to WT; red indicates increased and blue suppressed gene sets in null mice compared to WT. 
Node size represents the gene set size, and edge thickness represent degree of overlap between 
two connected gene sets. Clusters were manually circled and labeled to highlight the prevalent 
biological functions among related gene sets.
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prodomain that is processed and activated within the inflammasomes, which are 
assembled on NLR protein scaffolds. Because of the metabolic effects described for 
IL-1β and IL-18, and due to the crucial role of the inflammasome in the activation of 
these cytokines, we set out to test the role of the inflammasome in obesity. Our studies 
demonstrate that the mice deficient in inflammasome components are protected from 
HFD-associated body weight gain, adipocyte hypertrophy, hyperinsulinemia and 
hyperresistinemia. Importantly, HFD-induced production of the protein resistin was 
significantly reduced in inflammasome-deficient animals implying its critical role 
in driving the inflammatory potential of adipocytes. Further, chronic overfeeding 
resulted in pheno- and genotypical differences in WAT of inflammasome-deficient 
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Figure 5. Increased energy expenditure without 
any changes in net energy intake in HFD-fed 
Casp1-/- mice 16 weeks. Cumulative food intake 
of HFD-fed animals (A). Fecal output in HFD-fed 
wild-type and Casp1-/- animals (B). Fat content 
of faeces from HFD-fed wild-type and Casp1-/- 
animals as determined by steatocrit measurement 
(C). Caloric content of faeces from wild-type and 
Casp1-/- animals determined by bomb calorimetry 
(D). Energy expenditure of HFD-fed wild-type and 
Casp1-/- mice (E,F). * P < 0.05; **P < 0.01; n= 6-8 
mice per group. Error bars represent s.e.m.
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Deficiency in caspase-1 or ASC results in the same phenotype, which strongly 
suggests a role for the inflammasome in obesity. However, there are slight differences 
between ASC- and caspase-1-deficient mice. Although changes in adipogenic gene 
expression in caspase-1 and ASC-deficient animals show a considerable overlap, subtle 
differences exist. Whereas ASC may mediate effects on adipocyte hypertrophy as 
observed in Casp-1-/- animals, macrophage influx in the ASC-/- animals may partly 
be regulated independently of caspase-1. In this regard, recent studies reported that 
ASC directly mediates gene expression28 and has a critical role in the development 
of experimental autoimmune encephalomyelitis and arthritis independently of the 
inflammasome.29,30 However, in obesity, several of the parameters tested suggest that 
ASC and caspase-1 work in the same pathway. Indeed, caspase-1 appears to have a 
central role in adipose tissue functioning during chronic overfeeding by regulating 
macrophage influx and systemic insulin sensitivity. Although part of the protective 
effects in HFD-fed Casp1-/- animals are explained by the absence or lower levels 
of IL-1β, caspase-1 may also control alternative pathways. The wide range of genes 
differentially regulated between HFD-fed wild-type and Casp1-/- animals support the 
hypothesis of novel functions of caspase-1 in adipose tissue. In addition, the increase 
in energy expenditure observed in Casp1-/- animals identifies caspase-1 as a metabolic 
regulator. Finally, caspase-1 appears to drive the production of different chemokines 
in adipose tissue that regulated inflammatory cell influx. We postulate that caspase-
1 downstream signaling contributes to the enhanced energy expenditure observed 
in HFD-fed Casp1-/- animals. Indeed, using the diagonal gel proteomic approach, 
several proteins that are involved in energy metabolism were identified as caspase-1 
substrates.31 Additional substrates of caspase-1 in adipose tissue may be identified by in 
silico analysis and may help to explain its contribution to the development of adipose 
tissue dysfunction during HFD-induced obesity. 
One of the future challenges is to delineate the exact role of adipose-tissue specific 
caspase-1 to the development of HFD-induced obesity and insulin resistance. Moreover, 
future studies in animals that have adipocyte-specific overexpression of caspase-1 will 
be helpful to identify the differential contribution of macrophage- or adipocyte-derived 
caspase-1 to adipose tissue dysfunction and obesity. It will also be important to identify 
metabolic signals activating the inflammasome during the development of obesity. 
Interestingly, ceramide, a lipid molecule, has been described as a potent danger signal 
for inflammasome activation.24 However, these results were generated in vitro and do not 
rule out alternative pathways that mediate activation of caspase-1. Indeed, high levels 
of glucose have also been shown to activate caspase-1 within adipose tissue.32 Possibly, 
multiple danger signals exist that may use specificinflammasome pathways all leading 
to caspase-1 activation.  Although we have clearly established the importance of the 
inflammasome during the development of obesity in animal models, additional studies 
focused on unraveling the importance of the inflammasome activation in human 
adipose tissue are needed. In conclusion, our study shows that the inflammasome, in 
addition to its role in the innate immune response, contributes to the development 
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of obesity-induced insulin resistance. Therefore, the inflammasome represent a useful 
therapeutic target in the treatment of obesity and insulin resistance.
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Suppl. Fig. S1: Cytokine analysis in WAT from HFD-fed wild-type, Nlrp3-/-, ASC-/-, and 
Casp1-/- mice. Total adipose of HFD-fed animals (16 weeks of diet intervention) was used to 
analyze concentrations of IL-1β and IL-6. * p-value < 0.05 vs. WT, ** p-value <0.01 vs. WT
Suppl. Table S1. Plasma FFA and insulin levels during the euglycemic hyperinsulinemic 
clamp analysis. 
 
FFA (mM) Insuline (ng/mL)
Basal Hyperinsulinemic Basal Hyperinsulinemic
Wildtype 0.74 ± 0.07 0.58 ± 0.04 1.38 ± 0.40 4.74 ± 0.40
Casp1-/- 0.71 ± 0.04 0.42 ± 0.06* 0.64 ± 0.15 3.30 ± 0.30*
Euglycemic hyperinsuliemic clamp was performed after an overnight fast in caspase1 deficient and wild-




















Supplementary Figure 2 
NLRP3-/- 
Suppl. Fig. S2: Liver triglyceride content (A) 
and H&E staining of white adipose tissue (B) 
in HFD-fed wild-type and Nlrp3-/- animals.
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Suppl. Fig. S4: Liver histology as determined by H&E staining and liver triglyceride content 
in HFD-fed wild-type and Casp1-/- animals.
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Suppl. Fig. S5: Monocyte chemotactic protein 1 (MCP-1) gene expression results in human 
SGBS adipocytes treated with IL-1β, IL-18 or IL-1 receptor antagonist during differentiation. 
MCP-1 gene expression results were analyzed in SGBS cells after 10 days of differentiation in 
the absence or presence of recombinant IL-1β (5 ng/ml), IL-18 (25 ng/ml) or IL-1ra (5 μg/ml). 
** p-value < 0.001 * p-value < 0.05 vs. control
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Suppl. Fig. S6: Feeding behaviour (a) and gut hormones levels after a postprandial response 
(b) in wild-type and Casp1-/- animals.
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absTracT
Inflammasome-mediated caspase-1 activates the pro-inflammatory cytokines 
interleukin (IL)-1ß and IL-18. Recently, we showed that caspase-1 deficiency strongly 
reduces high fat diet (HFD)-induced weight gain, but the mechanism is still unclear. 
We now aimed to elucidate the mechanism by which caspase-1 deficiency modulates 
resistance to HFD-feeding by focusing on the role of caspase-1 in the regulation of 
triglyceride (TG)-rich lipoprotein metabolism. Postprandial TG kinetics, intestinal 
TG absorption, very low-density lipoprotein (VLDL)-TG production as well as TG 
clearance, all of which strongly contribute to the supply of TG for storage in adipose 
tissue, were measured in caspase-1 deficient and compared to results obtained in wild-
type mice (both C57Bl/6 background). Microarray and qPCR analysis were used to 
identify intestinal and hepatic metabolic pathways involved. Caspase-1 deficiency 
reduced the postprandial response to an oral lipid load. The tissue-specific clearance 
of TG-rich lipoproteins was not changed, evidenced by unaltered kinetics of i.v. 
administered VLDL-like emulsion particles. An oral gavage of [3H]TG-containing 
olive oil revealed that caspase-1 deficient mice had decreased intestinal chylomicron-
TG production and reduced uptake of [3H]TG-derived fatty acids (FA) in liver, muscle, 
and adipose tissue. Similarly, despite an elevated hepatic TG content, caspase-1 
deficiency reduced the hepatic VLDL-TG production without reducing VLDL-apoB 
production. Pathway analysis of microarray data revealed that caspase-1 deficiency 
reduces intestinal and hepatic expression of genes involved in lipogenesis. The reduced 
adiposity of caspase-1 deficient mice is caused by a hampered assembly and secretion 
of TG-rich lipoproteins, which decreases the availability of TG-derived FA for uptake 
by peripheral organs including adipose tissue. We anticipate that caspase-1 represents 




Obesity is accompanied by low-grade chronic systemic inflammation, characterized 
by increased circulating levels of proinflammatory cytokines including interleukin 
(IL)-1β, tumor necrosis factor-α (TNF-α) and IL-6.1 Activation of inflammatory 
pathways induces metabolic disturbances, leading to insulin resistance, dyslipidemia 
and cardiovascular diseases. Caspase-1 is a cysteine protease that is crucial for the 
activation of the pro-inflammatory cytokines IL-18 and IL-1β. Caspase-1 activation 
is in turn controlled by the inflammasome, a multiprotein complex consisting of a 
member of the Nod-like receptor family (e.g. NLRP3), and the inflammasome adaptor 
molecule ASC.2 A close interaction has been described between the innate immune 
system and lipoprotein metabolism in general, and triglyceride (TG) metabolism 
in particular.3 This interaction has largely been derived from studies that evaluated 
the effects of lipopolysaccharide (LPS), a major component of the cell wall of Gram-
negative bacteria, and individual cytokines on lipoprotein metabolism.4-6 
Although inflammasome-mediated caspase-1 activity has recently been linked 
to metabolic disturbances such as steatohepatitis7 and cardiovascular diseases,8 the 
role of caspase-1 in lipoprotein metabolism has never been elucidated. We recently 
showed that absence of caspase-1 in mice is accompanied by a profound decrease in 
both adipocyte size and total adipose tissue mass upon high-fat diet (HFD)-induced 
obesity9. Remarkably, inhibition of caspase-1 in adipocytes in vitro actually increases 
adipocyte differentiation,9 suggesting that the decrease in adipose tissue mass in vivo is 
not due to a primary defect in adipogenesis, yet may be the result of a lack of sufficient 
lipid supply.
Dietary intake and subsequent intestinal absorption of fat strongly contribute to 
the supply of lipids for storage in adipose tissue. Dietary fat is extremely efficiently 
absorbed in the small intestine and incorporated into chylomicrons for distribution to 
other tissues. Interestingly, caspase-1 deficient (caspase-1-/-) mice fed a HFD display an 
increased feces weight,10 suggesting a decreased intestinal capacity for the absorption 
of dietary fat. We therefore hypothesized that caspase-1 might play a direct role in the 
regulation of (postprandial) TG-rich lipoprotein metabolism that could underlie the 
reduction in adipose tissue mass in caspase-1-/- mice. 
In the current study, we investigate the role of caspase-1 in TG metabolism and 
show that caspase-1 deficiency markedly reduces intestinal TG absorption as well as 
hepatic very low-density lipoprotein (VLDL)-TG production, thereby limiting the 
availability of lipids for peripheral storage.
maTerials and meThods
animals
Caspase-1-/- mice9 were backcrossed ten generations to C57Bl/6 mice and age-matched 
wild-type C57Bl/6J mice were used as control mice. Mice were housed under standard 
conditions with a 12-hour light-dark cycle and were fed a standard mouse chow diet 
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with free access to water. Experiments were performed in 14 to 16-week old animals. 
When indicated, mice were fasted overnight (from 18.00-8.00 h) or for 4 h (from 8.00-
12.00 h). All experiments were approved by the institutional ethical committee on 
animal care and experimentation of the Leiden University Medical Center.
fatty acid composition of feces
Mice were individually housed for 4 days to collect feces quantitatively. Feces were 
weighed, freeze-dried, grounded and fecal fatty acids (FA) were subsequently derivatized 
by methyl esterification. Therefore, 2 mL methanol/hexane (4:1 v/v) containing 80 µg 
pentadecanoic acid (C15:0) as an internal standard (Fluka) was added to 15 mg feces. 
Then, 200 µL acetyl chloride (Merck) was added and samples were incubated at 95°C. 
After subsequent cooling to 4°C, 5 mL 6% K2CO3 (Sigma) was added and samples were 
centrifuged (10 min, 4000 rpm, 4°C). The upper hexane layer was isolated and used for 
GC analysis of FA methyl esters (FAME). FAME were separated on a 50 m x 0.25 mm 
capillary GC column (CP Sil 88, Agilent technologies) in a 3800 GC gas chromatograph 
(Varian) equipped with a flame ionization detector. The injector and flame ionization 
detector were kept at 270°C. The column temperature was programmed from 170°C to 
210°C. FAME were introduced by split injection (split ratio 20:1). Quantification was 
based on the area ratio of the individual FA to the internal standard.
postprandial TG response
To measure the postprandial response, overnight fasted mice received an intragastric 
load of 200 µL olive oil (Carbonell, Cordoba, Spain). Blood samples were drawn before 
(t=0) and 1, 2, 4 and 8 h after the bolus into chilled capillaries coated with paraoxon 
(Sigma, St Louis, MO) to prevent ongoing lipolysis.11 Plasma was assayed for TG 
with the commercially available enzymatic kit from Roche Molecular Biochemicals 
(Indianapolis, IN) and for free FA (FFA) using NEFA-C kit from Wako Diagnostics 
(Instruchemie, Delfzijl, The Netherlands).
In vivo clearance of TG-rich emulsion particles
VLDL-like TG-rich emulsion particles (80 nm) labeled with glycerol tri[3H]oleate 
[triolein (TO)] and [14C]cholesteryl oleate (CO) were prepared and characterized 
as described previously.12 To study the in vivo clearance of the VLDL-like TG-rich 
particles, mice were fasted for 4 h and injected (t=0) via the tail vein with 200 µL of 
emulsion particles (1.0 mg TG per mouse). Blood samples were taken from the tail 
vein at 2, 5, 10 and 15 min after injection to determine the serum decay of [3H]TO and 
[14C]CO. Plasma volumes were calculated as 0.04706 x body weight (g) as determined 
from 125I-BSA clearance studies as described previously.13 After taking the last blood 
sample, the liver, hindlimb muscle, brown adipose tissue (BAT) and gonadal (gWAT), 
subcutaneous (sWAT) and visceral (vWAT) white adipose tissues were collected. 
Organs were dissolved overnight at 60°C in Tissue Solubilizer (Amersham Biosciences, 
Rosendaal, The Netherlands) and 3H- and 14C-activity was counted. Uptake of [3H]
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TO- and [14C]CO-derived radioactivity by the organs was corrected for plasma 
radioactivity present in the respective tissues and expressed per mg wet tissue weight.
intestinal TG absorption
To measure intestinal lipid absorption, overnight fasted mice received an intragastric 
load of [3H]triolein ([3H]TO) (5 µCi; GE Healthcare, Little Chalfont, UK) in 200 µL 
olive oil (Carbonell, Cordoba, Spain). Blood samples were drawn before gavage (t=0) 
and at 1 and 2 h after gavage and serum 3H-activity was counted. Plasma volumes (mL) 
were calculated as 0.04706 x body weight (g).13 Two hours after the oral lipid load, 
liver, muscle, BAT and gWAT, sWAT and vWAT were collected. Organs were dissolved 
overnight at 60°C in Tissue Solubilizer (Amersham Biosciences, Rosendaal, The 
Netherlands) and counted to determine 3H uptake. In addition, the intestinal tract (i.e. 
duodenum, proximal jejunum, distal jenunum and ileum) were isolated and washed 
2 times in 10 mL phosphate-buffered saline (PBS). Both the intestinal tissue and the 
non-absorbed luminal content (in PBS) were counted for 3H-activity to determine the 
amount of absorbed versus non-absorbed olive oil present in the intestinal tract.
In vivo hepatic Vldl-TG and Vldl-apob production
To measure VLDL production in vivo, mice were fasted for 4 h and anesthetized by 
intraperitoneal injection of acepromazine (6.25 mg/kg Neurotranq, Alfasan International 
BV, Weesp, The Netherlands), midazolam (6.25 mg/kg Dormicum, Roche Diagnostics, 
Mijdrecht, The Netherlands), and fentanyl (0.31 mg/kg Janssen Pharmaceuticals, 
Tilburg, The Netherlands). Mice were injected intravenously with Tran[35S] label (150 
µCi/mouse; MP Biomedicals, Eindhoven, The Netherlands) to label newly produced 
apolipoprotein B (apoB). After 30 min at t=0 min, Triton WR-1339 (Sigma-Aldrich) 
was injected intravenously (0.5 mg/g body weight, 10% solution in PBS) to block serum 
VLDL clearance. Blood samples were drawn before (t=0) and at 15, 30, 60 and 90 min 
after injection and used for determination of plasma TG concentration as described 
above. After 120 min, mice were exsanguinated via the retro-orbital plexus. VLDL 
was isolated from serum after density gradient ultracentrifugation at d<1.006 g/mL by 
aspiration14 and counted for incorporated 35S-activity. 
liver lipids
Lipids were extracted from livers of mice that were in a fed state and after 4h-fasting 
according to a modified protocol from Bligh and Dyer.15 Briefly, a small piece of liver 
was homogenized in ice-cold methanol. After centrifugation, lipids were extracted by 
addition of 1800 µL CH3OH:CHCl3 (3:1 v/v) to 45 µL homogenate. The CHCl3 phase 
was dried and dissolved in 2% Triton X-100. Hepatic TG, total cholesterol (TC) and 
phospholipid (PL) concentrations were measured using commercial kits from Roche 
Molecular Biochemicals (Indianapolis, IN). Liver lipids were expressed per mg protein, 
which was determined using the BCA protein assay kit.
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rna isolation and qpcr analysis.
Total RNA was obtained from the epithelial layer of the duodenum, jejunum and 
ileum 2 h after an oral lipid bolus as well as from 4 h-fasted livers. RNA was extracted 
using TRIzol reagent (Invitrogen, Carlsbad, CA), followed by DNAse treatment and 
column purification using the RNeasy mini kit (Qiagen, Hilden, Germany). The RNA 
concentration was determined using a Nanodrop ND-1000 spectrophotometer and 
subsequent cDNA analysis was done using iScript reagent (Biorad). qPCR analysis was 
carried out on a Bio-Rad MyIQ. 36B4 was used as housekeeping genes and PCR primer 
sequences were taken from the PrimerBank and ordered from Eurogentec (Seraing, 
Belgium). Sequences of the primers used are available upon request. 
microarray analysis
RNA quality was assessed with 6000 Nano chips (Bioanalyzer 2100; Agilent, Amstelveen, 
The Netherlands). RNA was judged as being suitable when RIN (RNA integrity 
number) was above 8.0. Total RNA (100 ng) was labelled and processed automatically 
on Affymetrix GeneChip Mouse Gene 1.1 ST arrays using an Affymetrix GeneTitan 
Instrument, according to the manufacturer’s recommendations. Quality control of 
the datasets was performed using Bioconductor16 packages integrated in an on-line 
pipeline.17 Various advanced quality metrics, diagnostic plots, pseudo-images and 
classification methods were applied to ascertain only excellent quality arrays were used 
in the subsequent analyses.18 The probes on the array were redefined according to Dai et 
al.19 utilizing current genome information. In this study probes were reorganized based 
on the Entrez Gene database, build 37, version 2 (remapped CDF v14). Normalized 
expression estimates were obtained from the raw intensity values using the robust 
multiarray analysis (RMA) preprocessing algorithm.20 To determine the intestinal 
expression level for each gene, expression data of all three segments (duodenum, 
jejunum, ileum) were combined and averaged per mouse. Changes in gene expression 
were related to functional changes using gene set enrichment analysis (GSEA). Gene 
sets were derived from Gene Ontology, KEGG, National Cancer Institute, PFAM, 
Biocarta, Reactome, and WikiPathway curated pathway databases. Enrichment Map 
was used for interpretation of the GSEA results. Only gene sets consisting of more 
than 15 and fewer than 500 genes were taken into account. The enrichment map was 
generated with gene sets that passed the combined significance threshold of P value < 
0.01 and FDR q-value < 0.5, and similarity (Jaccard index) cut-off value of 0.375. All 
singletons were removed to create the final gene set interaction network.
statistical analysis
Data are presented as means ± SD. Statistical significant differences were calculated 




absence of caspase-1 reduces white adipose tissue mass 
Caspase-1-/- and wild-type (WT) mice were evaluated for body weight and adipose 
tissue mass. In line with results from our previous study,9 caspase-1 deficiency markedly 
reduced white adipose tissue (WAT) mass, while body weight was similar between 
caspase-1-/- vs WT mice (30.0 ± 3.2 vs 30.8 ± 2.5). The reduction in WAT was reflected 
by a reduction in the amount of gWAT (-69%; P<0.001) and sWAT (-34%; P<0.01), and 
a trend toward reduction in the amount of vWAT (-17%; P=0.16).
absence of caspase-1 reduces the postprandial response to an oral lipid load
As intestinal absorption of fat strongly contributes to the supply of lipids for storage 
in adipose tissue, we investigated whether the reduction in adipose tissue mass and 
the resistance to obesity upon high fat feeding in caspase-1-/- mice9, 10 reflects impaired 
postprandial lipid handling. Hereto, overnight fasted WT and caspase-1-/- mice received 
an intragastric olive oil bolus (200 µL) and the appearance of TG and FFA in plasma 
were determined (Fig 1). In caspase-1-/- mice, the postprandial increase in TG levels 
was completely abolished (peak TG level -59% at t=2 h; P<0.01; Fig 1A), which was 
paralleled by a postprandial drop in serum FFA (peak FFA level -38% at t=4 h; P<0.05; 
Fig 1B) levels.
caspase-1 deficiency does not affect TG-rich particle clearance
The postprandial TG response is determined by the balance between intestinal TG 
production and the rate of plasma TG clearance. To determine whether the decreased 
postprandial response in caspase-1-/- mice was caused by an increased clearance of 
Figure 1. Caspase-1 deficiency reduces the postprandial lipid response. Overnight fasted WT 
and caspase-1-/- mice received an intragastric olive oil gavage and blood samples were drawn at the 
indicated time points. Plasma TG (A) and FFA (B) concentrations were determined in WT mice 
(open circles) and caspase-1-/- mice (closed circles). Values are means ± SD (n=8). *P<0.05 and 
**P<0.01.
caspase-1 deficiency redUces TG-rich lipoproTein secreTion
8
145
TG-rich particles, we evaluated plasma clearance and organ distribution of [3H]TO 
and [14C]CO-double-labeled TG-rich emulsion particles in WT and caspase-1-/- mice 
(Fig 2). Caspase-1 deficiency slightly delayed clearance of [3H]TG from plasma (Fig 2A). 
However, at 15 min after the injection, both WT and caspase-1-/- mice had equally cleared 
the [3H]TG from the circulation. Caspase-1 deficiency did not affect 3H uptake per g of 
tissue by the liver, muscle, BAT and vWAT, while 3H uptake in gWAT and sWAT was even 
increased in caspase-1-/- mice (Fig 2B). This observation implies that the reduction in 
adiposity observed in caspase-1-/- mice can not be explained by a defect in clearance and/
or uptake of TG-derived [3H]FA by WAT. Similarly, caspase-1 deficiency did not affect 
[14C]CO clearance (Fig 2C) or [14C]CO uptake by the various organs (Fig 2D), indicating 
that TG-rich particle turnover was similar in caspase-1-/- and WT mice. 
absence of caspase-1 reduces intestinal TG absorption and increases fecal fa content
Since the markedly decreased postprandial TG response in caspase-1-/- mice was not 
explained by increased plasma TG clearance, we then evaluated intestinal lipid absorption 
Figure 2. Caspase-1 deficiency does not affect clearance of VLDL-like TG-rich particles. 
WT and caspase-1-/- mice were fasted for 4 h and received an i.v. bolus of [3H]TO and [14C]
CO-double labeled TG-rich emulsion particles (1 mg TG per mouse) (n=7-8). Blood was 
collected at the indicated time points and 3H (A) and 14C (C) activities were counted in plasma 
of WT mice (open circles) and caspase-1-/- mice (closed circles). At 15 min after injection, organs 
were isolated and uptake of 3H (B) and 14C (D) activity by the organs was measured. Values are 
means ± SD. *P<0.05.
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in caspase-1-/- and WT mice after an overnight fast. Mice were challenged with an oral 
lipid load containing 5 µCi of glycerol tri[3H]oleate in 200 µL olive oil, followed by 
assessment of the appearance of 3H-activity in plasma and uptake of 3H-activity by tissues 
(Fig 3). Two hours after the gavage, the appearance of 3H activity in plasma of caspase-
1-/- mice was significantly reduced (-37%; P<0.001; Fig 3A), suggesting a reduction in 
chylomicron-TG production. In line with this finding, a decreased amount of 3H-activity 
was retrieved in the liver (-44%), muscle (-45%), BAT (-72%) and gWAT (-65%) of 
caspase-1-/- mice (Fig 3B). Since we observed that caspase-1 deficiency does not affect 
clearance of TG-rich particles per se, these data confirm that caspase-1 deficiency reduces 
the intestinal TG production after an oral lipid load, and as a consequence reduces uptake 
and incorporation of intestinally derived TG into peripheral lipid stores. 
To determine whether the reduced intestinal TG production was secondary to 
a decreased FA retention by the enterocytes from the luminal tract, we isolated the 
intestinal tract 2 h after the gavage and determined both the amount of 3H that was 
present in the intestinal tissue and the non-absorbed amount of 3H that was still present 
in the lumen of the intestinal tract. Caspase-1 deficiency did not affect the presence 
of [3H]TG-derived tissue 3H-activity in the different parts of the intestinal tract (Fig 
3C), suggesting that the reduction in intestinal TG production in absence of caspase-
1 was not caused by a reduced postprandial intracellular TG-derived FA availability, 
which was confirmed by Oil red O staining (not shown). Instead, caspase-1 deficiency 
resulted in the accumulation of non-absorbed [3H]TG in the lumen of the distal part of 
the intestinal tract (Fig 3D), indicating reduced TG absorption. 
To investigate whether the decrease in postprandial intestinal TG production 
results in long-term reduction of intestinal lipid absorption, feces was collected from 
individually housed mice over a 4-day period and the fecal FA content was evaluated. 
Indeed, the feces of caspase-1-/- mice displayed an increased amount of C14:0, C16:0, 
C18:1, C18:2 and C18:3 compared to wild-type mice (Fig 3E), resulting in an increase 
of the total fecal FA content (85.7 ± 9.4 vs 69.4 ± 7.3 µmol/g feces; P<0.01; Fig 3F).
caspase-1 deficiency decreases Vldl-TG production, without affecting Vldl-apob production, 
despite increased hepatic lipid content.  
In fasting conditions, the availability of lipids for peripheral organs is determined by 
the production of VLDL-TG by the liver through mechanisms similar to intestinal 
chylomicron synthesis. Since caspase-1 deficiency reduces postprandial chylomicron-
TG production, we hypothesized that caspase-1 deficiency could similarly affect 
hepatic VLDL-TG production. VLDL-TG production was measured in 4 h fasted 
mice by determining plasma TG levels after Triton WR1339 injection (Fig 4). 
Caspase-1-/- mice indeed showed a strong reduction of TG accumulation in plasma 
compared to WT mice (Fig 4A). The VLDL-TG production rate, as determined from 
the slope of the curve from all individual mice, was decreased by -42% (3.6 ± 0.5 
vs 6.3 ± 0.7 mM/h; P<0.001), whereas the rate of VLDL-apoB production did not 
change significantly (Fig 4B). As the reduced rate of VLDL-TG production could be 
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Figure 3. Caspase-1 deficiency reduces intestinal TG production. Overnight fasted WT 
and caspase-1-/- mice received an intragastric load of 200 µL olive oil containing [3H]triolein 
([3H]TO) (n=6-7). Blood samples were drawn at the indicated timepoints and 3H activity was 
counted in plasma of WT mice (open circles) and caspase-1-/- mice (closed circles) (A). At 2 
h after the oral lipid load, organs were collected and uptake of 3H activity was measured (B). 
Intestine was isolated and washed twice to remove intestinal luminal non-absorbed olive oil. 
Both the 3H activity in the intestinal tissue (C) and the non-absorbed 3H activity in the lumen 
(D) were determined. Feces was collected from individual housed WT and caspase-1-/- mice 
(n=8) and fecal fatty acids were derivatized and extracted followed by fatty acid separaton and 
quantification using gas chromatography. Individual fatty acids were determined (E) and total 
fatty acid content (µmol/g feces) was calculated from the sum of all individual fatty acids (F). 
Values are means ± SD. *P<0.05 and ***P<0.001.
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caused by a decreased hepatic lipid substrate availability in the liver, we evaluated the 
hepatic TG (Fig 4C) and TC (Fig 4D) content in livers from both fed and 4 h-fasted 
WT and caspase-1-/- mice. In the fed state, hepatic lipid content was not affected 
by caspase-1 deficiency. Surprisingly, 4 h of fasting strongly increased hepatic TG 
content in caspase-1-/- compared to WT mice (+64%; P<0.05), which was confirmed 
by Oil Red O staining (data not shown). These data show that caspase-1 deficiency 
reduces VLDL-TG production despite an increased availability of lipids. This suggests 
that caspase-1 deficiency reduces secretion of TG from the liver thereby causing the 
increased hepatic TG content.
Caspase-1 deficiency is thus associated with a reduction of both intestinal 
chylomicron-TG- and hepatic VLDL-TG production, suggesting a general role of 
caspase-1 in the assembly and/or secretion of TG-rich lipoprotein particles.
reduced hepatic and intestinal expression of genes involved in fa metabolism and lipogenesis 
in caspase-1 deficient mice.  
To investigate whether caspase-1 deficiency influences intestinal molecular pathways 
involved in postprandial lipid handling, we performed microarray analysis on 
postprandial intestinal samples of WT and caspase-1-/- mice. Comparison of expression 
of function gene sets revealed that caspase-1 deficiency downregulated metabolic 
clusters of genes involved in FA metabolism and oxidation (Fig 5). 
The secretion of intestinal chylomicron-TG in the postprandial state and hepatic 
VLDL-TG in the fasted state are regulated by similar pathways.21 We, therefore, further 
analyzed a selection of genes that are directly involved in the hepatic and intestinal 
secretion of TG (FA uptake, lipogenesis and VLDL/chylomicron secretion) in caspase-
1-/- and WT mice by qPCR (Table 1). Mice deficient for caspase-1 had normal expression 
of hepatic- and intestinal apoB (Apob) and microsomal TG transfer protein (Mttp), 
both involved in the assembly and secretion of chylomicrons and VLDL. Likewise, 
genes involved in FA uptake and transport, apart from increasing expression of Cd36, 
were largely unaffected in these mice. Rather, caspase-1 deficiency reduced expression 
of the main regulator of lipogenesis, Srebf1, in liver (-80%; P<0.05) and intestine (-50%; 
P<0.05). Furthermore, caspase-1-/- mice showed reduced expression of other genes 
involved in lipogenesis in liver (Scd1) and intestine (Srebf2 and Fasn). 
discUssion
Inflammasome-mediated caspase-1 activity has recently been established as an 
important mediator of obesity and obesity-related insulin resistance, as caspase-1-/- 
mice are protected against HFD-induced obesity and associated insulin resistance 9, 10. 
We have now established a role for caspase-1, either direct or indirect, in the regulation 
of the production of chylomicron-TG by the intestine and VLDL-TG by the liver. 
Animals lacking caspase-1 showed reduced postprandial chylomicron-TG secretion 
as well as fasting VLDL-TG secretion, leading to a reduced availability of TG-derived 
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FA for uptake by peripheral organs and increased fat excretion in the feces. These data 
provide a mechanistic explanation for the reduced adipose tissue mass observed in 
caspase-1-/- mice upon HFD-feeding and suggest that caspase-1 represents a novel link 
between innate immunity and the regulation of TG-rich lipoprotein production.
Our observations demonstrate that caspase-1 deficiency does not affect the uptake 
of TG-derived FA by adipose tissue per se, by showing that adipose tissue is fully capable 
of taking up [3H]FA derived from TG-rich particles that are administered directly 
into the circulation. This, together with our observation that in vitro adipogenesis is 
enhanced rather than reduced in adipocytes in the absence of caspase-1,9 suggests 
that adipose tissue mass in caspase-1-/- mice is not reduced as a result of an impaired 
adipose tissue functioning by means of FA uptake and adipogenesis. Data from the 
current study show that caspase-1 deficiency rather reduces TG-derived FA delivery to 
the adipose tissue secondary to a reduction in TG-rich lipoprotein secretion.
Figure 4. Caspase-1 deficiency decreases VLDL-TG production without affecting VLDL-apoB 
production, and increases hepatic steatosis. WT and caspase-1-/- mice were fasted for 4 hours 
and received injections of Tran35S to label newly synthesized protein and Triton WR1339 to block 
lipolysis (n=8). Blood samples were drawn at the indicated timepoints and TG concentrations 
were determined in plasma of WT mice (open circles) and caspase-1-/- mice (closed circles) and 
plotted as the increase in plasma TG relative to t=0 (A). TG production rates were determined 
by linear regression analysis. At 120 min, mice were exsanguinated and VLDL was isolated and 
assayed for 35S-apoB (B). Livers were obtained from fed and 4 h-fasted WT and caspase-1-/- mice 
and lipids were extracted (n=3). Triglycerides (TG) (C) and total cholesterol (TC) (D) were 
measured and expressed per mg protein. Values are means ± SD. *P<0.05 and ***P<0.001.
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 It is interesting to speculate how caspase-1 deficiency reduces hepatic and intestinal 
TG secretion. The secretion of TG-rich lipoproteins is dependent on TG availability, 
which can be derived from FA supply from the diet (intestine), plasma (liver) or from 
de novo lipogenesis. The reduction in intestinal TG secretion in caspase-1-/- mice can 
probably not be explained by a reduction of FA uptake per se by enterocytes from the 
diet, since both tracer studies and Oil Red O staining of intestinal sections revealed 
that enterocytes of both caspase-1-/- and WT mice were capable of FA uptake. Also, 
caspase-1 deficiency did not reduce intestinal or hepatic expression of Cd36, Slc27a4 
and Fabp, proteins involved in FA transport and activation, implying that the intestine 
and liver of caspase-1-/- mice were able to take up FA. Actually, intestinal expression 
of Cd36 was increased in caspase-1-/- mice, which may be a compensatory reaction 
to the reduced chylomicron secretion, since Cd36 has shown to be essential for the 
production of chylomicrons.22
Up regulated in wild-type vs. casp-1-/- 
Down regulated in wild-type vs. casp-1-/- 
Fatty acid metabolism/oxidation 
Steroid biosynthesis 
Nucleic acid metabolism 
Translation Immune response 







Figure 5. Caspase-1 deficiency reduces intestinal signaling pathways involved in FA 
metabolism. Overnight fasted WT and caspase-1-/- mice received an intragastric olive oil gavage. 
After 2 h, duodenum, jejunum and ileum were isolated and mRNA from the epithelial layer was 
used for micro-array analysis (n=3). Expression data of all three segments (duodenum, jejunum 
and ileum) were combined and averaged for each gene. Nodes represent functional gene sets, 
for which red indicates increased and green suppressed gene sets in caspase-1-/- mice. Node size 
represents the size of the gene set. Clusters were manually circled and labeled to highlight the 
prevalent biological functions among related gene sets.














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































It appears that caspase-1 deficiency is associated with reduced expression of the 
intestinal- and hepatic lipogenic genes such as Srebf1, Srebf2 and Fasn, which are 
involved in FA synthesis and intracellular resynthesis of TG for the secretion of lipid-
rich lipoproteins. However, the reduced expression of lipogenic genes in liver and 
intestine was not paralleled by reduced lipid content. Actually, hepatic TG secretion is 
lower in caspase-1-/- animals despite an increased TG availability in the liver, suggesting 
that the reduced expression of lipogenic genes that we observe is a consequence rather 
than cause of the reduced TG secretion. Other studies indeed observed a reduction in 
expression of Srebf1 as a response to steatosis.23 These data implicate that a reduction in 
lipogenesis is not the predominant mediator of the reduced TG secretion, as caspase-
1 deficiency is associated with reduced intestinal TG secretion despite adequate 
availability of lipids. The fact that TG secretion is reduced without changes in hepatic 
apoB secretion or intestinal and hepatic expression of Apob, suggests that caspase-1 
deficiency mainly affects apoB lipidation and secretion of the lipoprotein particle.  
As caspase-1 processes a number of cytokines, including pro-IL-1ß and pro-IL-
18 into the active form, absence of caspase-1 is associated with reduced levels of 
bioactive IL-1ß and IL-18. To what extent these differences are involved in the reduced 
production of TG-rich lipoprotein secretion in caspase-1-/- animals remains to be 
determined. Injection of pro-inflammatory IL-1ß in rats has since long been known to 
increase lipogenesis and hepatic secretion of TG-containing lipoproteins,6 suggesting 
that absence of bioactive IL-1ß in caspase-1-/- mice could well be responsible for the 
reduction in secretion of TG-containing lipoproteins. Accordingly, a recent report 
revealed that IL-1ß gene polymorphisms affect the postprandial TG response in 
humans.24 Subjects with the polymorphism that conveys higher IL-1ß activity displayed 
an increased postprandial TG response. Our data suggest that these observations may 
thus be explained by an increased intestinal and/or hepatic TG production, rather 
than by reduced LPL activity, which has been suggested as a possible mechanism for 
their observation.25 An IL-1ß-mediated increase in intestinal TG secretion may also 
contribute to the tendency towards higher abdominal obesity previously observed in 
these subjects.26 Similar to IL-1ß, genetic variation in IL-18 has been associated with 
postprandial TG levels,27 suggesting that absence of caspase-1 may reduce TG-rich 
lipoprotein production indirectly via these cytokines. However, in addition to IL-1ß 
and IL-18, caspase-1 has recently been shown to be able to directly cleave additional 
substrates.28, 29 Future studies will need to identify new potential cleavage sites in 
proteins involved in lipoprotein assembly that may contribute to the reduction in TG 
secretion in caspase-1-/- mice.
In conclusion, we show that mice deficient for caspase-1 show an attenuated 
intestinal chylomicron-TG production and hepatic VLDL-TG production, both 
of which limit the availability of FA for uptake by adipose tissue. The current study 
reveals a novel function for caspase-1, or caspase-1 derived substrates, in controlling 
intestinal and hepatic TG-rich lipoprotein assembly and secretion and thus reveals a 
new link between innate immunity and lipoprotein metabolism. We anticipate that 
caspase-1 deficiency redUces TG-rich lipoproTein secreTion
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caspase-1 may be a novel therapeutic target for the treatment of obesity and obesity-
related disorders such as cardiovascular disease.
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9General discUssion and fUTUre perspecTiVes

An overload of nutrients in the diet is known to cause so called diet-induced 
inflammation or “metabolic inflammation”, a low-grade systemic inflammation 
characterized by elevated levels of inflammatory cytokines and other markers of 
inflammation in the circulation. The development of metabolic inflammation may 
depend on the composition of nutrients in the diet, the overall exposure to the nutrients 
and the type of tissue involved. White adipose tissue (WAT) and liver appear to be largely 
involved in the onset and development of metabolic inflammation, although the exact 
contribution of these tissues and the inflammatory pathways involved are still under 
investigation. The studies described in this thesis evaluated the role of inflammation 
in WAT and liver in the development of insulin resistance, hypertriglyceridemia and 
atherosclerosis.  
whiTe adipose TissUe inflammaTion and insUlin resisTance
Obesity induces expansion of adipose tissue that coincides with the influx of macrophages 
and secretion of pro-inflammatory cytokines.1,2 The cytokines IL-1β and IL-18 are 
secreted by the adipose tissue upon expansion and have been linked to the development 
of obesity and insulin resistance, although both cytokines appear to have opposite 
effects. Whereas IL-1β induces insulin resistance, IL-18 protects against obesity and 
insulin resistance.3-7 In chapter 7, we revealed that absence of their common activator, 
caspase-1, strongly reduces high fat diet (HFD)-induced obesity and insulin resistance. 
Caspase-1 becomes active as part of a multiprotein complex called ‘the inflammasome’. 
Interestingly, absence of the other components of the inflammasome (i.e. NLRP3 and 
ASC) similarly protected against HFD-induced obesity, and absence of ASC additionally 
protected against HFD-induced insulin sensitivity. This suggests that the inflammasome 
is an important mediator in the development of obesity and insulin resistance. Our 
findings were confirmed by others, showing that mice deficient for NLRP3 or ASC are 
protected from both palmitate- and HFD-induced insulin resistance8,9 
The NLRP3 inflammasome is the most well known inflammasome, although other 
inflammasomes exist that can activate ASC and caspase-1 (i.e. NLRP1, NLRC4 or 
AIM2).10 Processes that are known to induce insulin resistance (i.e. mitochondrial 
dysfunction, endoplasmatic reticulum stress and ceramide production) have recently 
been shown to activate the NLRP3 inflammasome,9,11,12 suggesting that the NLRP3 
inflammasome may be an important mediator in the induction of insulin resistance 
by these processes. However, we show that NLRP3 deficiency reduced plasma markers 
of obesity and insulin resistance to a more mild extent compared to deficiency of 
the other inflammasome components ASC and caspase-1 (chapter 7). Additionally, 
another study showed that the loss of NLRP3 reduced, but not eliminated, caspase-1 
function in obesity,9 suggesting that other inflammasomes such as NLRP1, NLRC4 or 
AIM2 may contribute to the pathophysiology of obesity and insulin resistance, which 
needs to be evaluated by future research.
We and others showed that obesity in mice increases expression of components of 




In line with these data, weight loss clearly reduces expression of components of the 
inflammasome in adipose tissue of obese subjects.9 The exact contribution of adipocytes 
and macrophages to the expression and function of components of the inflammasome 
is so far not fully understood. A recent study showed that, in adipose tissue of obese 
subjects, caspase-1 was highly expressed in adipocytes, while ASC expression mainly 
originated from the stromavascular fraction.13 This dissociation suggests that caspase-
1 and ASC may function separately in both cell types. In line with this, we show 
that deficiency of caspase-1 and ASC in mice differently affects metabolic pathways 
in adipose tissue (chapter 7). Caspase-1 deficiency reduces macrophage infiltration 
and ASC deficiency reduces adipocyte size; both components influence another cell 
type than where they are highest expressed in human adipose tissue. The underlying 
mechanism for this is so far unknown and may be caused by species differences. Future 
studies need to unravel how components of the inflammasome become activated in 
adipocytes and macrophages, and how they exert their metabolic effects in these, or 
other, cell types.
role of meTabolic inflammaTion in TG-rich lipoproTein meTabolism
A close interaction has been described between the immune system and lipoprotein 
metabolism in general and triglyceride (TG) metabolism in particular. Observations in 
patients with acute inflammation reveal that bacterial and viral infection is accompanied 
by hypertriglyceridemia.14, 15 Most of the current knowledge on the mechanistic relation 
between inflammation and TG metabolism has largely been derived from studies that 
evaluated the effects of lipopolysaccharide (LPS), a major component of the cell wall 
of Gram-negative bacteria, and individual cytokines on lipoprotein metabolism.16 In 
this thesis we investigated the effects of various inflammatory pathways on TG-rich 
lipoprotein metabolism (i.e. VLDL and chylomicron), in order to gain more insight 
into the effects of metabolic inflammation on the development of hypertriglyceridemia.
hepatic inflammation and Vldl-TG secretion
HFD feeding and obesity not only induce inflammation in WAT, but also in liver, as 
reflected by increased markers of hepatic inflammation in obese subjects (SAA and 
CRP)17,18 and increased hepatic NF-κB activity in mice fed a HFD.19,20 Hepatic lipid 
accumulation has long been thought to induce inflammation. However, not all steatotic 
livers display increased inflammation,21 suggesting that other factors may be involved. 
We show that the type of HFD that is consumed can strongly affect the activation of 
hepatic inflammation (chapter 6). A HFD based on palm oil (HFD-P) clearly induced 
hepatic NF-κB activity, while a HFD based on lard (HFD-L) did not affect hepatic NF-κB 
activity. In addition to FA composition of the diet, other studies show that addition 
of cholesterol to a HFD strongly increases hepatic inflammation22,23 and seems more 
important for the induction of inflammatory pathways than hepatic TG accumulation.22 
The liver consists of multiple cell types including Kupffer cells (the resident 
macrophages) and hepatocytes. It is known that inflammatory stimuli such as cytokines 
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or LPS induce hypertriglyceridemia by increasing hepatic VLDL-TG secretion,24 
although the role of Kupffer cells and hepatocytes in this process is not fully clear. 
This is because LPS associates with macrophages rather than with hepatocytes,25 but 
the secretion of VLDL-TG is a metabolic process that is executed by hepatocytes in 
the liver, suggesting cross-talk between both cell types. In chapter 4, we revealed that 
chronic activation of the inflammatory transcription factor NF-κB specifically in the 
hepatocyte increased hepatic VLDL-TG production, both in vivo and in vitro, thereby 
inducing hypertriglyceridemia. These findings demonstrate a direct intracellular effect 
of NF-κB activity on the secretion VLDL-TG. In addition, this suggests that hepatocytes 
are the cells ultimately responsible for the metabolic disturbances that are associated 
with hepatic inflammation.
The relative contribution of Kupffer cells and hepatocytes to the development of 
HFD-induced hepatic inflammation is still under investigation. Dietary cholesterol 
can induce hepatic inflammation by Kupffer cell-mediated internalization of modified 
lipoproteins, suggesting that Kupffer cells play a major role in the cholesterol-induced 
hepatic inflammation26 FAs on the other hand have been suggested to induce hepatic 
inflammation by acting as endogeneous ligands for Toll-like receptors (TLR) 2 and 
TLR4, two receptors that can activate NF-κB signaling. TLR2 and TLR4 are expressed 
on both Kupffer cells as well as hepatocytes,45 suggesting that FA may activate both 
cell types. Indeed, addition of palmitic acid to hepatocytes and macrophages in vitro 
at equal concentrations similarly induces inflammatory signaling in both cell types.27 
It remained to be established, however, whether FA similarly induces inflammation in 
both cell types in a more physiological situation such as HFD feeding in vivo. In chapter 
6 we show that a HFD- increased total hepatic NF-κB activity, which however did not 
translate towards an increased VLDL-TG production. Since we showed that a similar 
activation of NF-κB within the hepatocyte directly increased VLDL-TG production 
(chapter 4), this implies that the increased hepatic NF-κB activity upon HFD-P feeding 
reflects an increased NF-κB activity in Kupffer cells rather than hepatocytes. 
As summarized in Figure 1, we hypothesize that not only cholesterol derived 
from (ox)LDL26 and LPS,25 but also FA (chapter 6), activate inflammation, primarily 
in Kupffer cells. Activated Kupffer cells can subsequently secrete pro-inflammatory 
mediators including the cytokines TNFα and IL-1ß that increase NF-κB activity in 
adjacent hepatocytes,28 which increases the secretion of VLDL-TG (chapter 4). 
Following this hypothesis, data from chapter 6 suggest that activation of NF-κB 
activity in hepatocytes occurs only when inflammation within Kupffer cells reaches a 
certain threshold to secrete a sufficient amount of cytokines. This threshold would be 
consistent with the exponential rather than linear interrelationship between dietary 
cholesterol and hepatic inflammation.23
inhibition of hepatic inflammation and Vldl-TG secretion
The causal link between hepatocyte-specific NF-κB activity and VLDL-TG 
production suggests that inhibition of NF-κB activity in the hepatocyte may reduce 




whether aspirin primary acts on Kupffer cells or hepatocytes, we show that high-
dose aspirin that decreases total hepatic NF-κB activity,19,29 also decreases hepatic 
VLDL-TG production in HFD-fed mice, thereby reducing hypertriglyceridemia in a 
hypertriglyceridemic mouse model (chapter 3). 
High-dose aspirin may therefore be an interesting anti-inflammatory therapy to 
reduce hypertriglyceridemia, but aspirin dose is associated with side effects,30 urging 
the need to search for additional therapies that may reduce NF-κB activity within the 
hepatocyte. TLR4 deficiency reduces HFD-induced hepatic NF-κB activity,31 which 
would suggest that TLR4 deficiency also reduces hepatic VLDL-TG production. 
To our surprise, TLR4 deficiency did not reduce hepatic VLDL-TG production in 
HFD-fed mice (chapter 6). According to our hypothesis presented in Figure 1, these 
data would suggest that TLR4 deficiency reduced NF-κB activity in the macrophage 
rather than hepatocyte, therefore not affecting VLDL-TG secretion. TLR4 may indeed 
be predominantly present on Kupffer cells, based on the fact that LPS, the primary 
ligand for TLR4, associates with Kupffer cells rather than hepatocytes.25 Even more 
surprising was that TLR4 deficiency increased VLDL-TG in mice fed a HFD-P, by a 
mechanism that is still unknown. We did not measure hepatic NF-κB activity in our 
study, but it may be speculated that deficiency of TLR4 induces upregulation of other 
TLRs involved in inflammatory signaling that may counteract any effects of TLR4 
deficiency on NF-κB activity. 
Figure 1. Schematic model showing how hepatic inflammation, originating in macrophages, 
may affect VLDL-TG secretion in hepatocytes. See text for explanation.
General Discussion
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VLDL-TG production (chapter 4), this implies that the increased hepatic NF-κB activity upon 
HFD-P feeding reflects an increased NF-κB activity in Kupffer cells rather than hepatocytes.
As summarized in Figure 1, we hypothesize that not only cholesterol derived from 
(ox)LDL26 and LPS,25 but also FA (chapter 6), activate inflammation, primarily in Kupffer cells.
Activated Kupffer cells can subsequently secrete pro-inflammatory mediators including the
cytokines TNFα and IL-1ß that increase NF-κB activity in adjacent hepatocytes,28 which 
increases the secretion of VLDL-TG (chapter 4). Following this hypothesis, data from
chapter 6 suggest that activation of NF-κB activity in hepatocytes occurs only when 
inflammation within Kupffer cells reaches a certain threshold to secrete a sufficient amount of 
cytokines. This threshold would be consistent with the exponential rather than linear 
interrelationship between dietary cholesterol and hepatic inflammation.23
Figure 1. Schematic model showing how hepatic inflammation, originating in 
macrophages, may affect VLDL-TG secretion in hepatocytes. See text for explanation.
Inhibition of hepatic inflammation and VLDL-TG secretion
The ca sal li k between h patocyt -specific NF-κB activity and VLDL-TG production 
suggests that inhibition of NF-κB activity in the hepatocyte may reduce hypertriglyceridemia 
by reducing VLDL-TG production. Although it is not known whether aspirin primary acts on 
Kupffer cells or hepatocytes, we show that high-dose aspirin that decreases total hepatic NF-
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It must be noted that in humans, general inhibition of inflammation (e.g. with 
aspirin) is associated with a reduction in hypertriglyceridemia. On the other hand, 
inhibition of  specific cytokines, such as TNFα or IL-1ß, does not reduce or even 
increases hypertriglyceridemia (discussed in chapter 2), implying that counter 
regulatory mechanisms may be involved. This suggests that general inhibition of 
inflammation may be more useful to reduce hypertriglyceridemia, rather than targeting 
a single receptor or cytokine involved in inflammation. Future research should thus 
further delineate the exact contribution of (combinations of) specific components of 
inflammatory pathways on VLDL-TG production and hypertriglyceridemia. 
In chapter 8 we identified caspase-1 as a potential new therapeutic target to 
reduce hypertriglyceridemia. Deficiency of caspase-1 highly reduced both VLDL-TG 
production as well as chylomicron-TG production, suggesting that it generally 
reduces assembly and secretion of TG-rich lipoproteins. Theoretically, this may reduce 
hypertriglyceridemia and atherosclerosis, which needs to be further evaluated in 
hypertriglyceridemic mouse models. Interestingly, a recent report showed that absence 
of the activator of caspase-1, the NLRP3 inflammasome, in bone marrow-derived 
cells reduces atherosclerosis development in hyperlipidemic LDLr-deficient mice.32 
This, however, occurred independently of plasma lipid levels that were unchanged. 
In scope of our findings, we could hypothesize that (additional) caspase-1 deficiency 
in hepatocytes would further reduce atherosclerosis by lowering circulation of 
TG-rich lipoproteins. The effect of total caspase-1 deficiency on atherosclerosis has 
so far only been evaluated in hyperlipidemic apoE-deficient mice, where it did not 
reduce atherosclerosis.33 However, it should be realized that the apoE-deficient mouse 
model already has a markedly impaired VLDL-TG secretion34 which may not be 
further reduced by caspase-1 deficiency. This makes the apoE-deficient mouse a less 
suitable model to verify whether caspase-1 deficiency reduces hypertriglyceridemia 
and subsequent atherosclerosis. It would be rather interesting to investigate the 
contribution of caspase-1 deficiency to hyperlipidemia and atherosclerosis in other 
hyperlipidemic mouse models such as the LDLr deficient mouse or the APOE*3 Leiden 
mouse model with unaltered VLDL production. Bone marrow transplantation studies 
using these models may reveal the exact contribution of caspase-1 in hepatocytes 
versus macrophages in the development and/or regression of atherosclerosis. 
hepatic inflammation and atherosclerosis
Inflammatory processes in one organ may activate and aggravate inflammatory 
processes in other organs via secretion of pro-inflammatory cytokines. In line with this 
idea, we showed that specific activation of NF-κB signaling in hepatocytes increases 
the macrophage content in plaques in the vasculature (chapter 5), implying crosstalk 
between inflammatory processes in liver and vasculature. It remains to be elucidated 
whether pro-inflammatory cytokines play a prominent role in this crosstalk. We showed 
that specific activation of NF-κB in hepatocytes did not increase fasted serum cytokines, 




We rather observed an elevated plasma cytokine response to LPS stimulation. LPS levels 
are known to increase after consumption of a fat-rich meal.35,36 Therefore, the hepatocyte-
specific activation of NF-κB signaling may aggravate the postprandial circulation of 
cytokines that could activate vascular inflammatory processes such as macrophage 
infiltration. Alternatively, hepatocyte-specific activation of NF-κB may induce vascular 
inflammation by (temporarily) increased secretion of VLDL-TG (chapter 4 and 5), 
thereby increasing circulating levels of lipoproteins and lipoprotein remnants that are 
prone to modification and can activate macrophages elsewhere. 
metabolic inflammation and intestinal chylomicron production
By assembly and secretion of TG-rich chylomicrons via the lymph into the circulation, 
the intestine regulates transport of dietary lipids to peripheral tissues. We showed that 
deficiency of caspase-1, an important regulator of the innate immune response, markedly 
reduces intestinal chylomicron-TG secretion (chapter 8), suggesting an important 
role for inflammatory pathways in the regulation of intestinal lipid metabolism. The 
role of inflammation in intestinal lipid metabolism is strengthened by a recent report 
revealing that IL-1β gene polymorphisms affect the postprandial response in humans. 
Subjects with higher IL-1β activity displayed an increased postprandial TG response,37 
sustaining our observation that caspase-1 deficiency reduces intestinal TG secretion. 
It remains to be established why components of the immune system such as 
caspase-1 would affect the secretion of intestinal chylomicron-TG. It has been shown 
that increased circulation of TG-rich lipoproteins can protect against bacterial 
infections.38 The involvement of caspase-1 in the regulation of TG-rich lipoprotein 
production may therefore be beneficial for protection or even survival during 
infections. It is interesting to note that the intestinal tract contains an immense amount 
of bacteria, called the intestinal microbiota, that play an important role in the defense 
against invading pathogens. Intestinal epithelial cells, including enterocytes, sense 
microbial products that are able to activate inflammasome-mediated caspase-139-41 
that may further initiate activation of immune cells. Our data suggest that caspase-1 
activation may simultaneously increase secretion of chylomicrons to increase defense 
mechanisms. Interestingly, gut microbiota have lately received a lot of attention as 
they have been suggested to regulate energy homeostasis and lipid metabolism and 
modulate obesity.42 Germ-free mice are resistant to obesity43 and supplementation of 
probiotics that modulate microbiota, reduce intestinal lipid absorption in rats.44 The 
mechanisms explaining the effects of (changes in) microbiota on lipid metabolism are 
so far unknown. Future studies may evaluate whether caspase-1 is a mediator in the 
relation between gut microbiota and postprandial lipid metabolism.
conclUdinG remarks
Obesity and high-fat diets (HFD) that trigger obesity coincide with the presence 
of chronic inflammation that is causally involved in the pathology of metabolic 
disturbances such as hypertriglyceridemia, atherosclerosis and insulin resistance. 
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Therefore, reducing inflammation may provide new therapeutic strategies in the 
treatment of related diseases such as cardiovascular disease (CVD) and type 2 diabetes 
mellitus (T2D). For the development of new drugs that reduce inflammation, it is 
however essential to evaluate the contribution of individual inflammatory pathways 
to specific metabolic disturbances. In this thesis we showed that augmenting 
hepatocyte-specific NF-κB activity directly increases the VLDL-TG production, 
thereby inducing hypertriglyceridemia. This, in addition to an increased sensitivity 
for inflammatory stimuli, increases atherosclerosis. Inhibition of NF-κB activity in the 
hepatocyte (e.g. with aspirin) may therefore represent an interesting therapy to treat 
hypertriglyceridemia and atherosclerosis.  Furthermore, we identified caspase-1 a new 
link between innate immunity and triglyceride metabolism. Inflammasome-mediated 
caspase-1 appeared involved in the development of obesity, adipose tissue inflammation 
and insulin resistance. Our data suggest that caspase-1 represents a novel target to treat 
obesity and insulin resistance.
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Obesity is frequently accompanied by the development of metabolic disturbances such 
as insulin resistance that ultimately results in the onset of type 2 diabetes mellitus, 
and hyperlipidemia, an important risk factor for the development of atherosclerosis. 
Obesity is accompanied by low-grade systemic inflammation that is secondary to the 
onset and development of metabolic inflammation in peripheral tissues such as adipose 
tissue and liver. In fact, metabolic inflammation appears to be causally involved in 
the onset and development of metabolic disturbances such as insulin resistance and 
atherosclerosis.
Both hyperlipidemia and inflammation are well known risk factors for the 
development of atherosclerosis and have been shown to play a causal role in the 
progression of atherosclerotic plaques. In chapter 2, we discussed the interplay between 
lipid metabolism and inflammatory pathways, which may explain why lipid-lowering 
drugs and anti-inflammatory drugs reduce atherosclerosis beyond expectations 
as solely based on their primary mode of action. We therefore discussed the direct 
and indirect effects of lipid-lowering drugs (i.e. statin, fibrates, niacin, ezetimibe) on 
inflammatory processes, as well as the effect of inflammation-lowering drugs (i.e. 
salicylate, anti-TNF, IL-1ra) on lipid metabolism, both of which may be of additive 
value in the treatment of atherosclerosis.
Systemic inflammation induces an increase in plasma triglyceride (TG) levels, also 
called hypertriglyceridemia. Aspirin treatment lowers inflammation via inhibition of 
nuclear factor κB (NF-κB) activity, but also reduces hypertriglyceridemia in humans. 
The aim of chapter 3 was to investigate the mechanism by which aspirin improves 
hypertriglyceridemia. Therefore, human APOC1 mice, an animal model with elevated 
plasma TG levels, as well as normolipidemic wild-type (WT) mice were fed a high-fat 
diet (HFD) and treated with aspirin. Aspirin treatment reduced hepatic NF-κB activity 
in HFD-fed APOC1 and WT mice and in addition, aspirin decreased plasma TG levels 
in hypertriglyceridemic APOC1 mice. This TG-lowering effect could not be explained 
by enhanced VLDL-TG clearance, but aspirin selectively reduced hepatic production 
of VLDL-TG in both APOC1 and WT mice without affecting VLDL-apoB production. 
Aspirin did not alter hepatic expression of genes involved in fatty acid (FA) oxidation, 
lipogenesis and VLDL production, but decreased the incorporation of plasma-derived 
FA by the liver into VLDL-TG, which was independent of hepatic expression of genes 
involved in FA uptake and transport. These data led us to conclude that aspirin improves 
hypertriglyceridemia by decreasing VLDL-TG production without affecting VLDL 
particle production. Our findings suggest that the inhibition of inflammatory pathways 
by aspirin could be an interesting target for the treatment of hypertriglyceridemia. 
The liver is an organ that is involved in both inflammation and lipid metabolism. 
However, it is not known whether the liver plays a direct role in the interaction 
between inflammation and hypertriglyceridemia. Since NF-κB is a central regulator of 
inflammatory processes, in chapter 4 we investigated the relation between chronically 
enhanced hepatic NF-κB activation and hypertriglyceridemia. To this end, we evaluated 
whether hepatocyte-specific overexpression of IκB kinase (IKK-β) would affect 
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VLDL-TG metabolism directly in hyperlipidemic APOE*3-Leiden (E3L) mice, a well-
established model for human-like lipoprotein metabolism. We found that hepatocyte-
specific IKK-β overexpression induced hypertriglyceridemia. With mechanistic in 
vivo studies we revealed that this that was caused by increased hepatic VLDL-TG 
production, rather than by reduced VLDL-TG clearance from plasma. Studies in 
primary hepatocytes showed that IKK-β overexpression also enhances TG secretion 
in vitro, indicating a direct relation between IKK-β activation and TG production 
within the hepatocyte. Hepatic lipid analysis and hepatic gene expression analysis of 
pathways involved in lipid metabolism suggested that the increased VLDL production 
was not caused by increased steatosis or decreased FA oxidation, but most likely by 
ChREBP-mediated upregulation of Fas expression. These findings implicate that 
specific activation of inflammatory pathways exclusively within hepatocytes induces 
hypertriglyceridemia. Furthermore, we identified the hepatocytic IKK-β pathway as 
another possible target to treat hypertriglyceridemia.
Inflammation is a causal factor in the development of atherosclerosis and, as 
mentioned above, the liver is a key organ involved in inflammation. The relation 
between hepatic inflammation and atherogenesis is however poorly understood. In 
chapter 5 we investigated whether hepatocyte-specific IKK-β overexpression aggravates 
atherosclerosis development in E3L mice fed a Western-type diet for 24 weeks. We 
showed that hepatocyte-specific IKK-β overexpression increased the atherosclerotic 
lesion area in the aortic root and increased lesion severity. Hepatocyte-specific IKK-β 
overexpression did not affect basal levels of inflammatory parameters, but tended 
to increase plasma cytokine levels after administration of an inflammatory stimulus 
(lipopolysaccharide, LPS). In addition, hepatocyte-specific IKK-β overexpression 
transiently increased plasma cholesterol levels, confined to (V)LDL, which resulted in 
a mild increased cumulative plasma cholesterol exposure. Taken together, we showed 
that selective activation of IKK-β in hepatocytes considerably promotes atherosclerosis 
development which is (at least partly) explained by an increased sensitivity to 
proinflammatory triggers as well as transiently increased plasma cholesterol levels. 
HFD feeding increases hepatic inflammation, as evidenced by increased hepatic 
Toll-like receptor 4 (TLR4)/NF-κB signaling. In lean animal models, administration of 
LPS, a well-known ligand for TLR4, as well as activation of hepatic NF-κB both directly 
increase VLDL-TG production, pointing towards an important link between TLR4/
NF-κB signaling and hepatic VLDL-TG production. Furthermore, TLR4 deficiency 
has been shown to protect against HFD-induced hepatic inflammation. In chapter 6, 
we therefore aimed to investigate 1) whether FA composition of HFD based on lard 
(HFD-L) and palm oil (HFD-P) differentially affect hepatic NF-κB signaling and 
VLDL-TG production and 2) whether TLR4 deficiency reduces the hepatic VLDL-TG 
production in HFD-fed mice. We demonstrated that FA composition of the HFD 
strongly affects hepatic inflammation, whereby HFD-P, but not HFD-L, markedly 
increased hepatic NF-κB signaling. However, the increase in hepatic NF-κB signaling 
was not accompanied by an increased VLDL-TG production. Furthermore, in contrast 
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to our hypothesis, TLR4 deficiency did not reduce hepatic VLDL-TG production in 
mice fed HFD-L and even increased VLDL-TG production in mice fed HFD-P. Based 
on these data, we therefore concluded that 1) FA composition determines the ability of 
HFD to induce hepatic inflammation, 2) HFD-P-induced hepatic inflammation does 
not increase VLDL-TG production, and 3) TLR4 deficiency does not reduce VLDL-TG 
production in HFD-fed mice. 
 
Besides hepatic inflammation, HFD feeding induces adipose tissue inflammation, 
characterized by macrophage infiltration and production of proinflammatory 
cytokines that play a causal role in the development of insulin resistance and 
type 2 diabetes mellitus. The proinflammatory cytokines interleukin (IL)-1β and 
IL-18 require cleavage by caspase-1 to become activated. This enzyme is part of an 
intracellular multi-protein complex called “the inflammasome” that besides caspase-1 
consists of NLRP3 and adaptor protein ASC. In chapter 7, we aimed to investigated 
the role of these components of the inflammasome in HFD-induced obesity, adipose 
tissue inflammation and insulin resistance. We showed that mice deficient for NLRP3, 
ASC or caspase-1 were resistant to the development of HFD-induced obesity and had 
lower plasma leptin and resistin levels. Furthermore, absence of components of the 
inflammasome reduced hepatic TG content, adipocyte size, and macrophage infiltration 
in adipose tissue, as well as adipose tissue expression of monocyte chemoattractant 
protein (MCP)-1, a key molecule that mediates macrophage infiltration. The reduction 
in HFD-induced obesity and adipose tissue inflammation in mice deficient for ASC 
and caspase-1 was paralleled by increased insulin sensitivity. Detailed metabolic and 
molecular phenotyping demonstrated that the inflammasome is involved in energy 
expenditure and adipogenic gene expression during chronic overfeeding, although the 
exact mechanisms are still unclear. These findings revealed a critical function of the 
inflammasome in HFD-induced obesity and insulin resistance. 
Since the mechanism underlying the observation that absence of caspase-1 strongly 
reduced HFD-induced weight gain remained unclear, we aimed in chapter 8 to 
elucidate the mechanism by which caspase-1 deficiency modulates resistance to HFD-
feeding by focusing on the role of caspase-1 in the regulation of TG-rich lipoprotein 
metabolism. To this end, we used caspase-1 deficient and wild-type control mice to 
determine postprandial TG kinetics, intestinal TG absorption, VLDL-TG production 
as well as TG clearance, all of which strongly contribute to the supply of TG for storage 
in adipose tissue. We showed that caspase-1 deficiency reduced the postprandial 
response to an oral lipid load. The tissue-specific clearance of TG-rich lipoproteins 
was not changed, evidenced by unaltered kinetics of i.v. administered VLDL-like 
emulsion particles. An oral gavage of radiolabeled TG-containing olive oil revealed 
that caspase-1 deficient mice had decreased intestinal chylomicron-TG production 
and reduced uptake of TG-derived FA in liver, muscle, and adipose tissue. Similarly, 
despite an elevated hepatic TG content, caspase-1 deficiency reduced the hepatic 
VLDL-TG production without reducing VLDL-apoB production. Pathway analysis 
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of microarray data revealed that caspase-1 deficiency reduces intestinal and hepatic 
expression of genes involved in lipogenesis. From these data we concluded that the 
resistance to HFD-induced obesity in caspase-1 deficient mice is caused by a hampered 
assembly and secretion of TG-rich lipoproteins, which decreases the availability of 
TG-derived FA for uptake by peripheral organs including adipose tissue. These studies 
revealed that that caspase-1 represents a novel link between innate immunity and the 
regulation of TG-rich lipoprotein metabolism. Based on chapter 7 and chapter 8, we 
thus anticipated that inhibition of the inflammasome could be a potential therapeutic 
strategy in the treatment of obesity and insulin resistance. 
Taken together, the studies described in this thesis show that inflammation plays 
an important role in TG-rich lipoprotein metabolism both in the intestine, liver 
and adipose tissue. We show that inhibition of inflammation by aspirin reduces the 
hepatic VLDL-TG production, while hepatocyte-specific NF-κB activation enhances 
the hepatic VLDL-TG production. Our studies reveal a central role of the liver in 
the inflammation-induced hypertriglyceridemia and atherosclerosis. In addition, we 
identified caspase-1 as a novel link between the innate immune system and TG-rich 
lipoprotein assembly and secretion and as a new therapeutic target in the treatment of 
obesity and insulin resistance.
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De belangrijkste vetten in ons dieet zijn triglyceriden (TG) en cholesterol, beide 
essentieel voor het menselijk lichaam. Omdat vetten slecht oplosbaar zijn in bloed, 
worden ze in het lichaam getransporteerd in zogenaamde lipoproteïnen. Deze deeltjes 
lossen wel op in bloed en brengen de vetten van en naar verschillende organen. 
Chylomicronen zijn lipoproteïnen die vetten na een maaltijd vanuit de darm naar 
overige organen zoals vet, spier, hart en lever transporteren. Als men een tijdje niet 
heeft gegeten zorgt de lever voor voldoende beschikbaarheid van vetten door productie 
van zogenaamde zeer lage dichtheids lipoproteïnen (VLDL). Zowel chylomicronen als 
VLDL bevatten voornamelijk TG en daarom noemen we deze deeltjes ook wel TG-
rijke lipoproteïnen. In het bloed worden de TG vanuit het VLDL en chylomicronen na 
lipolyse opgenomen in diverse organen zoals wit vetweefsel (voor opslag), spier en hart 
(voor leveren van energie) of bruin vetweefsel (voor warmteproductie). Als de energie-
inname het energieverbruik overstijgt (d.w.z. een positieve energiebalans), worden de 
TG opgeslagen in het vetweefsel. Op lange termijn zal een postitieve energiebalans 
daarom leiden tot overgewicht en obesitas. 
Obesitas gaat vaak gepaard met de ontwikkeling van metabole stoornissen. Een 
voorbeeld hiervan is insulineresistentie dat uiteindelijk leidt tot het ontstaan van 
type 2 diabetes mellitus. Een ander voorbeeld is hyperlipidemie, een belangrijke 
risicofactor voor de ontwikkeling van atherosclerose (aderverkalking). Obesitas gaat 
ook gepaard met een milde systemische ontsteking in het lichaam. Deze ontsteking 
wordt veroorzaakt door de ontwikkeling van metabole ontsteking in perifere organen 
zoals vetweefsel en de lever. Metabole ontsteking lijkt bovendien causaal gerelateerd te 
zijn aan de ontwikkeling van insulineresistentie en atherosclerose.
Zowel hyperlipidemie als ontsteking zijn bekende risicofactoren voor de 
ontwikkeling van atherosclerose en beide spelen een causale rol bij de initiatie en 
progressie van atherosclerotische lesies. In hoofdstuk 2 beschrijven we de interactie 
tussen vetmetabolisme en ontstekingsprocessen. Deze interactie kan mogelijkerwijs 
verklaren waarom zowel lipidenverlagende als anti-inflammatoire geneesmiddelen de 
mate van atherosclerose meer verminderen dan verwacht op basis van hun primaire 
werkingsmechanisme. We bespreken daarom de directe en indirecte effecten van 
lipidenverlagende middelen waaronder statines, fibraten, niacine en ezetimibe 
op ontstekingsprocessen, alsook de effecten van ontstekingsverlagende middelen 
waaronder salicylaat, anti-TNF en IL-1ra op het lipidenmetabolisme.
Systemische ontsteking veroorzaakt een stijging van het plasma TG niveau, wat 
ook wel hypertriglyceridemie wordt genoemd. Behandeling met aspirine verlaagt 
ontsteking via remming van de nucleaire factor kB (NF-κB) activiteit, en vermindert 
ook hypertriglyceridemie bij mensen. In hoofdstuk 3 wilden we het mechanisme 
onderzoeken waardoor aspirine hypertriglyceridemie verlaagt. Hiervoor gebruikten 
we APOC1 muizen, een diermodel met verhoogde plasma TG concentraties, evenals 
controle muizen met normale plasma TG concentraties. Deze muismodellen voerden 
we een vetrijk dieet, met of zonder toegevoegd aspirine in het drinkwater. Behandeling 
met aspirine verminderde zoals verwacht de NF-κB activiteit in de lever. Bovendien 
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zorgde aspirine voor een daling in het plasma TG niveau in de hypertriglyceridemische 
APOC1 muizen. Een daling in plasma TG kan worden veroorzaakt door een verhoogde 
klaring en/of verlaagde productie van VLDL-TG. Mechanistische studies toonden 
aan dat aspirine selectief de productie van VLDL-TG door de lever verlaagde in zowel 
APOC1 als controle muizen, terwijl de productie van VLDL-apoB, het belangrijkste 
eiwit van VLDL, niet veranderde. Dit geeft aan dat de productie van het aantal VLDL 
deeltjes hetzelfde was, maar dat elk VLDL deeltje minder TG bevatte. Vervolgens 
hebben we geanalyseerd op welke manier aspirine de productie van VLDL-TG 
verlaagde. Onze bevindingen lieten zien dat aspirine geen invloed had op expressie 
van genen in de lever die betrokken zijn bij vetzuuroxidatie, lipogenese en VLDL 
productie, maar zorgde voor een daling in de omzetting van vetzuren vanuit het 
plasma in VLDL-TG door de lever. Dit was onafhankelijk van hepatische expressie 
van genen betrokken bij FA opname en transport. Samengevat concludeerden wij dat 
aspirine hypertriglyceridemie verbetert door het verlagen van de productie van VLDL-
TG. Onze bevindingen suggereren dat de remming van ontsteking door aspirine een 
interessante therapie kan zijn voor de behandeling van hypertriglyceridemie.
De lever is een orgaan dat betrokken is bij zowel ontsteking als vetmetabolisme. Het 
is echter niet bekend of de lever een directe rol speelt in de interactie tussen ontsteking 
en hypertriglyceridemie. Aangezien NF-κB een centrale rol speelt in inflammatoire 
processen, hebben we in hoofdstuk 4 gekeken naar het verband tussen chronisch 
verhoogde NF-κB activatie in the lever en hypertriglyceridemie. Daarvoor bestudeerden 
we of levercel (hepatocyt)-specifieke overexpressie van IκB kinase (IKK-β), dat leidt 
tot verhoogde NF-κB activatie, het metabolisme van VLDL-TG rechtstreeks beïnvloedt 
in hyperlipidemische APOE*3-Leiden (E3L) muizen. De E3L muis is een muismodel 
dat bekend staat om zijn menselijke lipoproteïnenmetabolisme. We observeerden dat 
de hepatocyt-specifieke IKK-β overexpressie leidde tot hypertriglyceridemie. Met in 
vivo studies hebben we aangetoond dat dit werd veroorzaakt door een toegenomen 
VLDL-TG productie door de lever, en niet door een verminderde VLDL-TG klaring 
uit het plasma. Studies in geïsoleerde primaire hepatocyten toonden aan dat IKK-β 
overexpressie ook in vitro de secretie van TG verhoogde, wat wijst op een directe 
relatie tussen de IKK-β activatie en TG productie binnen de hepatocyt. Analyse van 
leverlipiden en expressie van genen die betrokken zijn bij het vetmetabolisme in 
de lever suggereerden dat de toegenomen VLDL productie niet werd veroorzaakt 
door een verhoogde vetstapeling of afgenomen FA oxidatie. We vonden echter een 
verhoging van de ChREBP-gemedieerde inductie van Fas expressie. Aangezien Fas 
codeert voor het eiwit vetzuursynthase dat een belangrijke rol speelt bij de aanmaak 
van nieuwe vetzuren, zou een verhoging van Fas expressie het aanbod van vetten in de 
hepatocyt voor de VLDL-TG productie mogelijk kunnen verhogen. Onze bevindingen 
impliceren dat specifieke activatie van inflammatoire pathways in de hepatocyt leidt tot 
hypertriglyceridemie. Verder zou IKK-β in de hepatocyt een mogelijk doelwit kunnen 
zijn voor de behandeling van hypertriglyceridemie.
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Ontsteking is een causale factor in de ontwikkeling van atherosclerose (atherogenese) 
en de lever is dus een belangrijk orgaan betrokken bij ontstekingsprocessen. De relatie 
tussen leverontsteking en atherogenese is echter nog onduidelijk. In hoofdstuk 5 
hebben we onderzocht of hepatocytspecifieke IKK-β overexpressie de ontwikkeling 
van atherosclerose verergert in E3L muizen die een vetrijk westers dieet kregen 
gedurende 24 weken. We toonden aan dat hepatocytspecifieke IKK-β overexpressie 
leidde tot grotere en ernstigere atherosclerotische lesies in de aorta. We onderzochten 
vervolgens waarom de leverontsteking leidde tot meer atherosclerose ontwikkeling. 
Hepatocytspecifieke IKK-β overexpressie had geen invloed op basale plasmaniveaus 
van inflammatoire parameters, maar vertoonde een tendens tot verhoogde plasma 
cytokine concentraties na een inflammatoire stimulus (lipopolysaccharide, LPS). 
Daarnaast verhoogde hepatocytspecifieke IKK-β overexpressie tijdelijk het plasma 
cholesterol niveau, beperkt tot (V)LDL, wat resulteerde in een licht toegenomen 
cumulatieve blootstelling aan plasma cholesterol. Samenvattend hebben we hebben 
aangetoond dat selectieve activatie van IKK-β in hepatocyten atherosclerose 
ontwikkeling aanzienlijk bevordert, wat tenminste deels verklaard kan worden door 
zowel een verhoogde gevoeligheid voor pro-inflammatoire stimuli als een tijdelijk 
verhoogd plasma cholesterolniveau.
Een vetrijke voeding (hoog-vet dieet; HFD) verhoogt leverontsteking, zoals blijkt uit 
toegenomen hepatische Toll-like receptor 4 (TLR4)/NF-κB signalering. Het is bekend 
dat activatie van TLR4 door toediening van LPS, een bekend ligand voor TLR4, evenals 
activatie van NF-κB in de lever, beide direct de VLDL-TG productie verhogen. Dit wijst 
op een belangrijke schakel tussen TLR4/NF-κB signalering en VLDL-TG productie 
door de lever. Verder is aangetoond dat deficiëntie van TLR4 beschermt tegen HFD-
geïnduceerde lever ontsteking. In hoofdstuk 6 hebben we ons daarom gericht op 
het onderzoeken of 1) de FA samenstelling van HFD gebaseerd op reuzel (HFD-L) 
en palmolie (HFD-P) verschillend van invloed zijn op de lever NF-κB activatie en 
VLDL-TG productie en 2) TLR4 deficiëntie leidt tot een verlaging van de VLDL-TG 
productie in HFD-gevoede muizen. Onze resultaten lieten zien dat de samenstelling van 
het HFD sterk van invloed is op de leverontsteking, waarbij HFD-P, maar niet HFD-L, 
de NF-κB activiteit in de lever sterk verhoogde. Echter, de toename van de NF-κB 
signalering in de lever door HFD-L ging niet gepaard met een verhoogde VLDL-TG 
productie. In tegenstelling tot onze hypothese, verlaagde TLR4 deficiëntie bovendien 
de VLDL-TG productie in HFD-L gevoede muizen niet en verhoogde TLR4 deficiëntie 
zelfs de VLDL-TG productie in HFD-P gevoede muizen. Op basis van deze gegevens 
hebben we dan ook geconcludeerd dat 1) de samenstelling van een HFD van invloed 
is op het ontstaan van leverontsteking, 2) HFD-P-geïnduceerde lever ontsteking niet 
leidt tot een verhoogde VLDL-TG productie, en 3) TLR4 deficientie niet leidt tot een 
verlaging van de VLDL-TG productie in HFD-gevoede muizen.
Naast leverontsteking induceert vetrijke voeding ook ontsteking in het vetweefsel. 
Deze ontsteking wordt gekenmerkt door infiltratie van macrofagen in het vetweefsel 
samenVaTTinG
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en de productie van pro-inflammatoire cytokinen, waarvan is aangetoond dat deze 
een causale rol spelen in de ontwikkeling van insuline resistentie en type 2 diabetes 
mellitus. De pro-inflammatoire cytokinen interleukine (IL)-1β en IL-18 hebben worden 
geactiveerd door caspase-1. Dit enzym maakt deel uit van een groot eiwitcomplex, 
het “inflammasoom”, dat naast caspase-1 bestaat uit NLRP3 en ASC. In hoofdstuk 7 
hebben we onderzoek gedaan naar de rol van deze componenten van het inflammasoom 
bij HFD-geïnduceerde obesitas, vetweefselontsteking en insulineresistentie. We zagen 
dat muizen met een deficiëntie voor NLRP3, ASC of caspase-1 alle beschermd waren 
tegen de ontwikkeling van HFD-geïnduceerde obesitas. Bovendien bleek dat de 
afwezigheid van componenten van het inflammasoom leidde tot minder vetstapeling in 
de lever, kleinere vetcellen en minder macrofaaginfiltratie in het vetweefsel. Daarnaast 
zagen we een lagere expressie van het monocyte chemoattractant proteïne (MCP)-1 
in het vetweefsel, een eiwit dat een belangrijke rol speelt bij de macrofaaginfiltratie. 
De verminderde obesitas en ontsteking van het vetweefsel in muizen met een 
deficiëntie voor ASC en caspase-1 ging gepaard met verhoogde gevoeligheid voor 
insuline. Een gedetailleerde analyse van metabole en moleculaire processen toonde 
aan dat het inflammasoom betrokken is bij het energieverbruik evenals expressie van 
genen betrokken bij adipogenese tijdens chronische overvoeding, hoewel de exacte 
mechanismen nog onduidelijk zijn. Deze bevindingen onthulden een cruciale rol van 
het inflammasoom in HFD-geïnduceerde obesitas en insulineresistentie. 
Omdat onduidelijk was op welke manier caspase-1 deficiëntie beschermde 
tegen  HFD-geïnduceerde obesitas, hebben we in hoofdstuk 8 uitgezocht wat het 
mechanisme is dat hieraan ten grondslag ligt, door de rol van caspase-1 in de regulatie 
van het TG-rijke lipoproteïnenmetabolisme te bestuderen. Hiervoor gebruikten 
we caspase-1 deficiënte muizen en controle muizen en bestudeerden we processen 
die allemaal sterk bijdragen aan de levering van TG voor opslag in het vetweefsel, 
te weten postprandiale TG kinetiek, intestinale TG absorptie, VLDL-TG productie 
en TG klaring. Onze resultaten lieten zien dat caspase-1-deficiëntie leidde tot een 
sterk verminderde postprandiale TG respons na een orale bolus van olijfolie. Een 
verminderde postprandiale respons kan veroorzaakt worden door verminderde TG 
absorptie vanuit de darm of door een toename van TG klaring uit het plasma. We lieten 
echter zien dat de weefselspecifieke klaring van TG-rijke lipoproteïnen niet veranderd 
was, zoals bleek uit de ongewijzigde kinetiek van VLDL-achtige emulsiedeeltjes die 
direct in het bloed waren toegediend. Een oraal toegediende bolus van olijfolie met 
radioactief gemerkt TG toonde aan dat caspase-1 deficiënte muizen een verminderde 
productie hadden van chylomicron-TG vanuit de darm wat leidde tot een verminderde 
opname van vetzuren afkomstig van TG in de lever, de spier en vetweefsel. Op dezelfde 
manier bleek ook dat, ondanks een verhoogde TG voorraad in de lever, caspase-1-
deficiëntie leidde tot een verminderde productie van VLDL-TG. We lieten verder zien 
dat caspase-1-deficiëntie de expressie van genen die betrokken zijn bij de vetsynthese 
vermindert in de darm en in de lever. Op basis van onze studies concludeerden we 
dat de bescherming tegen HFD-geïnduceerde obesitas in caspase-1 deficiënte muizen 
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wordt veroorzaakt door een verminderde secretie van TG-rijke lipoproteïnen (zowel 
chylomicronen als VLDL), wat leidt tot een verminderde beschikbaarheid van TG 
voor opname door perifere organen, inclusief het vetweefsel. Deze studies laten zien 
dat caspase-1 een nieuwe link is tussen ontstekingsprocessen en de regulatie van het 
TG-rijke lipoproteïnenmetabolisme. We voorzien dat op basis van hoofdstuk 7 en 
hoofdstuk 8 de remming van het inflammasoom, waaronder caspase-1, een nieuwe 
therapeutische mogelijkheid zou kunnen zijn voor de behandeling van obesitas en 
insulineresistentie.
Samengevat laten de studies in dit proefschrift zien dat ontsteking een belangrijke 
rol speelt in het metabolisme van TG-rijke lipoproteïnen, in zowel de darm, de 
lever en het vetweefsel. We tonen aan dat remming van ontsteking door aspirine de 
productie van VLDL-TG in de lever vermindert, terwijl hepatocytspecifieke NF-κB 
activatie de productie van VLDL-TG in de lever verhoogt. Onze studies onthullen 
een centrale rol van de lever in ontstekingsafhankelijke hypertriglyceridemie en 
atherosclerose. Daarnaast identificeerden we caspase-1 als een nieuwe schakel tussen 
ontstekingsprocessen en de productie van TG-rijke lipoproteïnen, en als een nieuw 
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